Uncovering Molecular Biomarkers That Correlate Cognitive Decline with the Changes of Hippocampus' Gene Expression Profiles in Alzheimer's Disease Authors: Martín Gómez Ravetti, Osvaldo A. Rosso, Regina Berretta, Pablo Moscato Published: 2010, PLOS ONE DOI: 10.1371/journal.pone.0010153 ABSTRACT Alzheimer's disease (AD) is characterized by a neurodegenerative progression that alters cognition. On a phenotypical level, cognition is evaluated by means of the MiniMental State Examination (MMSE) and the post-morten examination of Neurofibrillary Tangle count (NFT) helps to confirm an AD diagnostic. The MMSE evaluates different aspects of cognition including orientation, short-term memory (retention and recall), attention and language. As there is a normal cognitive decline with aging, and death is the final state on which NFT can be counted, the identification of brain gene expression biomarkers from these phenotypical measures has been elusive. We have reanalysed a microarray dataset contributed in 2004 by Blalock et al. of 31 samples corresponding to hippocampus gene expression from 22 AD subjects of varying degree of severity and 9 controls. Instead of only relying on correlations of gene expression with the associated MMSE and NFT measures, and by using modern bioinformatics methods based on information theory and combinatorial optimization, we uncovered a 1,372-probe gene expression signature that presents a high-consensus with established markers of progression in AD. The signature reveals alterations in calcium, insulin, phosphatidylinositol and wnt-signalling. Among the most correlated gene probes with AD severity we found those linked to synaptic function, neurofilament bundle assembly and neuronal plasticity. A transcription factors analysis of 1,372-probe signature reveals significant associations with the EGR/KROX family of proteins, MAZ, and E2F1. The gene homologous of EGR1, zif268, Egr-1 or Zenk, together with other members of the EGR family, are consolidating a key role in the neuronal plasticity in the brain. These results indicate a degree of commonality between putative genes involved in AD and prion-induced neurodegenerative processes that warrants further investigation. INTRODUCTION Gomez Ravetti and Moscato have recently shown that the abundance of five proteins, within a panel that also measured other 115 cytokines and growth factors, can be used to predict the development of clinical Alzheimer's Disease (AD) [1] . The biomarker molecular signature is composed of IL-1a, TNF-a, IL-3, EGF and G-CSF and has the same level of specificity and sensitivity as the original 18-protein signature proposed by Ray et al. [2] in late 2007, who introduced this important dataset in the literature. In the original work, Ray et al. had employed the abundance of 120 signalling proteins in plasma to obtain their 18-protein signature set. They used a training set of 83 samples to identify patients that progressed to AD in two to six years. The proposed 5-protein signature has an average of 96% accuracy in predicting clinical AD but it is still linked to the joint measurement of 120 protein abundances. In this paper, we are revisiting the quest of finding biomarkers of AD. However, this time we aim at finding biomarkers in hippocampus tissue samples which would complement the results of the previous studies on plasma biomarkers. This study will now give a different perspective on the progression of the disease, keeping a systems biology and functional genomics approach. Towards this end, we have chosen to rely on an informative experimental design and dataset contributed by Blalock et al. [3] . We believe that their dataset may help us to locate, either directly or indirectly, other biomarkers of interest that could eventually be detectable in plasma. Blalock et al. analysed samples from 35 patients with four different levels of AD severity: control, incipient, moderate and severe; for this paper we used only 31 samples for which information is available online. The label assigned to each sample (its “level of severity”) was decided after considering two important scores, those provided by the MiniMental State Examination (MMSE) and the Neurofibrillary Tangle count (NFT). The MMSE score is based on a questionnaire that aims at measuring the level of cognitive impairment of a patient. The questions are aimed at evaluating different aspects of cognition, such as orientation, short-term memory (retention and recall), attention and language. A normal score can range from 24 to 30, mild cognitive impairment on the interval 20 to 23, moderate AD between 10 to 19, and the rest (from 0 to 9) are all considered severe AD cases. As previously mentioned, Blalock et al. [3] also used the NFT score to assign a severity label to each sample. The NFT score is a well established method for the neuropathological diagnosis of AD [4] . The score is usually based on the average counts of neurofibrilary tangles considering different regions of the brain. A NFT score is a recognised indicator of AD, nevertheless, it is not completely effective as there is evidence that NFTs were also identified in healthy aging brains [5] , [6] , [7] , [8] . The analysis by Blalock et al. [3] focused on the identification of AD-related genes (ADG) and incipient ADG (IADG) using a methodology based on the correlation of the genes with NFT and MMSE scores. In turn, they identified putative biological processes and signalling pathways that are significantly present in those gene lists. Our analysis takes a different direction. While still based on the same dataset, we are attempting to map the progression of the disease, finding biomarkers linked to disease severity, by identifying the genes associated with the divergence of the gene expression profile of a sample with the gene expression average profile of the “Control” group . Analogously, we are interested in identifying the genes that seem to best correlate with the “convergence” to the average profile of the “AD Severe” group of samples. The difference between Blalock et al. 's [3] methodological approach to data analysis and ours is very important. We aim to uncover genes that correlate with the divergence of the gene expression profiles, instead of relying only on correlations with the NFT and MMSE values. Our objective is to uncover genes which are highly correlated to the progression of the disease. With this objective in mind, we will concentrate the first part of our analysis on the two most extremely separated classes, the sets of samples that have been labelled as “Control” and those labelled “AD Severe”. This important initial decision was made based on the fact that the four classes are, in some sense, arbitrarily defined as specific thresholds for the MMSE and NFT scores that were decided ad hoc . Therefore, we decided to first focus on the transitional patterns that can be identified from a “normally aging” to an “AD-severe” gene expression profile in hippocampus. With this approach, we also avoid selecting genes that diverge from the normal-aged profile by causes other than AD, as we expect that the severity scale in AD has a higher probability of being correct in the “Severe AD” cases (since they have high values of NFT and low MMSE scores, clearly a joint combination highly appreciated as a disease hallmark). This approach has an additional advantage. Using this particular dataset and with focus on the effects of incorrect diagnoses, two publications indentify four possible misdiagnoses between control and incipient AD [9] , [10] . In our case, the samples that have been labelled either “Incipient AD” or “Moderate AD” play the role of a “Test set”, as they are not used to select probes for establishing a molecular signature, thus avoiding misdiagnoses problems. RESULTS The results have been obtained using four steps in tandem: 1) abundance quantization of gene expression values and filtering of probes (this step is supervised by using the samples labelled either “Control” or “Severe AD”); 2) a feature selection algorithm to refine the probe selection based on numerical solution of a combinatorial optimization problem (the (alpha,beta)- k-Feature Set methodology); 3) a correlation analysis (that requires the computation of Jensen-Shannon divergences). Finally, a fourth step involves the pathway and Gene Ontology analysis of the results. The first two steps only used the samples labelled either “Control” or “Severe AD”. The third step requires several procedures and uses all of the samples. We first compute an average gene expression profile for the classes “Control” and “Severe AD”. This step is followed by the computation of the square root of the Jensen-Shannon divergence [11] of the gene expression profile of each sample with the average profiles of the classes “Control” and “Severe AD”. Finally, we perform a correlation analysis of each gene expression profile (now across all samples) with the results of the square root of the Jensen-Shannon divergence (we do it twice, one for the “Control” and the other for the “Severe AD” case). With this information, and using state-of-the-art pathway analysis and text mining tools, as a result of our final analysis step, we provide a comprehensive list of results of the differentially regulated genes, patterns of up (down)-regulation and the pathways that seem to be implicated in the progression of AD. We refer to the Methods section for a completely reproducible and in-depth explanation of our methodology. We start our analysis with a baseline comparison, which we have chosen to include for illustrative purposes. Figure 1 provides an example of the importance of performing an initial probe/gene selection step. The example serves as an argument for the necessity of the first two steps of our method. We have normalized each individual gene expression profile, and we have computed the average gene expression profile for classes “Control” and “Severe AD” (following the same procedure we will use in the third step of our method, but in this case using all probes in the array). For this graph, all 22,215 genes were considered in the calculation of the average profile of the samples in the “Control” and “Severe AD” classes. The square root of the Jensen-Shannon divergences to the “Control” and “Severe AD” average profile are computed, respectively giving, for each sample, its x and y coordinates in this plot. Observe that most of the “Control” samples have values lower than 0.12, with two exceptions. This result is expected, as the probability distribution function of the “Control” class was used. However, most of the samples from AD patients (having either “Incipient AD”, “Moderate” or “Severe” labels), show a divergence with the Control average gene expression profile. Figure 2 shows the important contribution provided by the feature selection step. We have used the square root of the Jensen-Shannon divergence of a pair of samples (a pair of gene expression profiles) as our measure of “dissimilarity” between them. The square root of the Jensen-Shannon divergence quantifies the difference between two probability distribution functions (PDFs) and it is a metric (we refer the reader to the Methods section for a mathematical definition and a discussion of its properties). Figure 1 plots the divergence of each sample with the average expression profile of the classes ‘Control’ and ‘Severe AD’; sqrtJSD(P, ) denotes the square root of the Jensen-Shannon divergence between sample P and the average profile on the ‘Control’ class . Analogously, sqrtJSD(P , ) denotes the square root of the Jensen-Shannon divergence between sample P and the average profile on the ‘Severe AD’ class . The advantage of using the probe/gene selection steps, which reduces the number of genes to the most informative ones, will be evident when we later compare Figure 1 with Figure 2 . However, Figure 1 already shows some interesting patterns. For instance, we can observe that a high percentage of the samples from AD patients (having either ‘Incipient AD’, ‘Moderate’ or ‘Severe’ labels) show sqrtJSD(P, ) values greater than 0.115, which indicates measurable divergence with the Control average gene expression profile. Here, all “Control” samples have the square root of the Jensen-Shannon divergences to the average gene expression of the “Control” samples (x-coordinate) smaller than 0.12 (almost all severe AD have x-coordinates greater than 0.15). In addition to that, most samples labelled “Severe AD” are located on the same region. Both results are expected. However, it is interesting that in this (x,y)-plot most samples that are labelled “Incipient AD” or “Moderate AD” seem to “bridge” between the regions that have most of the “Control” samples and the region that have most of the “Severe AD” group. This result is interesting as no samples from “Incipient AD” nor “Moderate AD” have been used in the first three steps of our methodology. In essence, the work is a “test set” indicating that it is reasonable to expect that some genes in the genetic signature of 1,372 probes have information about a putative “progression” trend of the disease, from the “Control” to the “Severe AD” profile. In what follows, correlations across all the samples with these divergences are used as a method to try to identify those gene profiles that are most correlated with the progression from “Control” to “Severe AD”. Figure 2 presents the same procedure, but only after the feature selection step has significantly reduced the number of probes fom 22,215 to 1,372. We refer to the Methods section for details. In Figure 2 , an arguably more coherent arrangement can be observed. As expected, the group of control samples (in green) have lower values of sqrtJSD(P, ) and higher values of sqrtJSD(P, ) . Obviously, the opposite behaviour is observed for the samples belonging to the severe cases. What cannot be expected, however, is a layout of the samples that could provide evidence of a continuous “progression” of the disease. The Figure shows that the samples of ‘Incipient AD’ are close to the control group and the ‘Moderate AD’ samples are closer to them and also link to severe AD. A priori, since those samples had not been used for probe selection, they could have been in any position in the (sqrtJSD(P , ), sqrtJSD(P, ) plane. Finally, Figure 3 presents the results of the MMSE score as a function of the sqrtJSD(P , ) , showing an inverse correlation between them. A similar situation happens between MMSE and sqrtJSD(P, ) , but in this case low MMSE scores correspond to low values of sqrtJSD(P,Ps) , giving a positive correlation. It is this interplay between positive and negative correlations that has enabled us to find interesting biomarkers. In the next subsection, we explain how these correlations were used to identify probes that “diverge from” their values in the “Control” group and “converge to” the values in the “Severe AD” group. ‘Incipient AD’ samples, although having a lower value for their MMSE score, still do not show a dramatic change in their x-coordinates compared to the ‘Control’ samples. ‘Moderate AD’ samples appear to be more scattered, with some of them already having a significant divergence from the ‘Control’ average profile. GENE CORRELATION ANALYSIS The third step employs a correlation analysis to select the group of probes that are the most strongly correlated. Intuitively, the idea is fairly straightforward as illustrated in the following “Gedankenexperiment” (a thought experiment). Assume, for argument's sake, that the MMSE of each patient P is not actually phenotypical information assigned to each sample. Instead, assume that the MMSE values are the microarray probe expression of some gene. In this “thought experiment”, let MMSE(P) be the expression of this hypothetical gene probe on sample P , and fDataset be the set of values it has for each sample. The correlation of the sample-ordered set of values {MMSE(P)} with the set of sample-ordered values {sqrtJSD(P, )} is negative, indicating that, in general, this hypothetical MMSE probe reduces its values as the whole gene expression profile of sample P diverges from the average “Control” profile ( Figure 3 ). Analogously, there exists a positive correlation of the set of values {MMSE(P)} with the values of the set {sqrtJSD(P, )} . This indicates that the values of MMSE tend to be reduced as the profile of sample P “converges to” the average profile of samples in the “Severe AD” group. We have computed these correlations for all probes in the signature, which are given in the supplementary material ( File S2 sheet ‘correlation Analysis’) and are the basis for our analysis. We also refer the reader to Figure 4 , which presents the computed correlations. Tables 1 and 2 present the one hundred most correlated probes (in absolute values). In the supplementary material ( File S2 sheet ‘correlation Analysis’), the correlation of each of the 1,372 probes that were selected by our method is given (and annotated, including Affymetrix and Stanford's Source outputs) to facilitate further analyses. The 50 probes in red are those most distant from the origin of this system of coordinates. Those probes have expression-value variations that are correlated with the divergences of the average “Control” profile and at the same time with the “Severe AD”. These values are then correlated with the individual expression profiles of each probe across the set of samples samples. We list here the 100 probes that have the highest Spearman correlation (absolute value, computed over all samples) between the expression of the probe and the square root of the Jensen-Shannon divergence of the sample with the average Control gene expression profile. Rows in boldface indicate the cases for which a putative relationship exist in the published literature between the gene and AD. A probe that has a positive correlation with the square root of the Jensen-Shannon divergence with the average Control gene expression profile roughly indicates, in this case, a probe that, over all samples in the set, tends to increase its expression from their values in the “Control” group to the “Severe AD”. We listed the top fifty probes with positive and negative correlation. Rows in boldface indicate the cases for which a putative relationship exist in the published literature between the gene and AD. A probe that has a positive correlation with the square root of the Jensen-Shannon divergence with the average Control gene expression profile roughly indicates a probe that, over all samples in the set, tends to increase its expression from their values in the “Control” group to the “Severe AD”. As the objective is to detect the probes correlated with the progression of AD, we will select those probes with high absolute correlations values with both groups, an indication of a divergence of the average control profile together with a convergence to the severe AD profile; these correlations computed over all sample types. We need to check both groups according to their correlations to the average profile. The first group of probes we are interested in are those that have a positive correlation with the sqrtJSD(P, ) and a negative correlation with sqrtJSD(P, ) . The probes in this group are those probes with under-expression in the non-disease sample but are over-expressed in the severe AD cases. The second group has the opposite behaviour, the probes' expression values have a negative correlation with sqrtJSD(P, ) and a positive correlation with sqrtJSD(P, ) . This pattern can be visualised in Figure 4 , where the elliptical shape of the dispersion of the probes in this scatter plot indicates that our methodology has preserved all the significant probes for both classes and that there are no probes (after the filter) presenting a high correlation simultaneously with the control and severe AD profiles. On these values a new selection criterion is applied, as we wanted to identify the group of probes that have strong correlations to both groups in absolute value. This symmetry of our argument stems from the interest in understanding the biology of the progression of the disease. For identifying disease biomarkers we may just concentrate in finding the probes that present an upregulation trend when progressing from “Control” to “Disease”. However, here we would also like to identify those probes that become increasingly downregulated, which, in turn, would help us to identify significantly dysregulated biological pathways (as members of the pathway will be either up or downregulated). Towards this end, we rank the probes in the order given by their Euclidean distance from the origin of coordinates in Figure 4 . We selected an arbitrary cut-off value of fifty probes (the selected probes are marked in red). These fifty probes are also identified by their Gene Symbols in Figures 5 and 6 . Calculating the distance of each probe to the origin, on the sqrtJSD system of coordinates, we further selected the 50 most distant probes and analysed their behaviour. Table 3 presents the 50 probes (corresponding to 48 genes), their correlation to each group and their distance to the origin of coordinates. File S2 sheet ‘correlation Analysis’ column ‘E - Distance’ of the supplementary material presents the distance to the origin of the 1,372 probes analysed. In Table 3 , it can be seen which genes have some putative annotation that links them to AD (17 genes out of 48). The column “Dist O” shows the Euclidean distance from the origin for each gene. If the gene has a known relation with AD (ADG), the reference's codes are display in column “Ref ADG”. Figure 7 shows the heat map of the 50-probe signature, where the probes and patient samples are ordered by considering the similarity of their gene-expression values only. It can be observed that the Memetic Algorithm (MA), a high performance combinatorial optimization ordering method [12] for microarray datasets introduced in 2007, ordered most of the patients with or without an incipient level of AD on the left and the more severe cases on the right. When ordering the probes' gene expression, the MA perfectly sorted the groups previously described. We refer to [12] , [13] for details of the MA. The supplementary material ( File S2 ‘1372 norm. +heat map+GO’) presents the heat map of the 1,372 gene-probes, with samples and probes sorted by the MA. The samples and probes were sorted using the memetic algorithm given in [12] , using the Euclidean distance. The transcription factors were obtained using Chang and Nevins' GATHER system to interpret genomic signatures [634] . The coloured cell and the number 1 indicate that the transcription factor has a binding motif with the gene for that row. The levels of severity as defined by Blalock et al. [635] are indicated in the first line: (0) Control, (1) Incipient AD, (2) Moderate AD and (3) Severe AD. TABLE: For each sample, we have calculated the sample's Jensen-Shannon divergence with the average Control gene expression profile. Gene symbol Probe Spearman rank correlation 1 CSF1 211839_s_at 0.79388 2 MCL1 214057_at 0.75484 3 PSMC3IP 205956_x_at 0.74816 4 ZHX3 217367_s_at 0.74416 5 C10orf76 55662_at 0.74093 6 FCAR 211307_s_at 0.72002 7 TUBD1 210389_x_at 0.71835 8 AW974666 222365_at 0.71835 9 LRP10 201412_at 0.71079 10 SERTAD2 202656_s_at 0.70679 11 ITGB5 201125_s_at 0.7059 12 CDC2L6 212899_at 0.70412 13 RNF19A 220483_s_at 0.70367 14 TTN 208195_at 0.70278 15 DHFR 202534_x_at 0.69844 16 FYCO1 218204_s_at 0.69655 17 HBEGF 38037_at 0.69388 18 ZBTB20 205383_s_at 0.69121 19 KCNK5 219615_s_at 0.69121 20 KLHL20 204177_s_at 0.68988 21 DLG5 201681_s_at 0.68899 22 CHD2 203461_at 0.68821 23 TUG1 222244_s_at 0.68721 24 ZNF500 213641_at 0.68454 25 N58524 222332_at 0.68276 26 KIR2DL5A 211410_x_at 0.68165 27 CYBRD1 217889_s_at 0.67964 28 DLG1 217208_s_at 0.67831 29 IL15 205992_s_at 0.67731 30 RND2 214393_at 0.67508 31 TNS1 221748_s_at 0.67253 32 CTBP2 210835_s_at 0.6703 33 AL050204 213929_at 0.66852 34 YES1 202933_s_at 0.66763 35 MYBL1 213906_at 0.66719 36 No gene associated 213256_at 0.66363 37 C5orf4 48031_r_at 0.66363 38 FOXO1 202724_s_at 0.66318 39 UPF1 211168_s_at 0.66096 40 STAG3L1 221191_at 0.66007 41 SLC12A7 218066_at 0.65784 42 CYP3A4 205999_x_at 0.65695 43 KRCC1 218303_x_at 0.65562 44 P53AIP1 220402_at 0.65462 45 TLE3 212769_at 0.6535 46 ZNF669 220215_at 0.65206 47 CFLAR 214486_x_at 0.65206 48 PAK4 203154_s_at 0.65028 49 M78162 217536_x_at 0.6485 50 MMP11 203876_s_at 0.6485 51 RGS7 206290_s_at −0.67475 52 ASTN1 213197_at −0.67653 53 TMSB10 217733_s_at −0.67653 54 SUPT4H1 201484_at −0.67731 55 COX6B1 201441_at −0.67742 56 WASF1 204165_at −0.67742 57 RALYL 213967_at −0.67786 58 BBS7 219688_at −0.67875 59 SEC31A 200945_s_at −0.68009 60 DDX1 201241_at −0.68009 61 RP11-336K24.9 218291_at −0.68098 62 GABBR2 209990_s_at −0.68231 63 SLC25A12 203340_s_at −0.68454 64 ATP5C1 205711_x_at −0.68587 65 NEFL 221805_at −0.68632 66 NDUFB8 201226_at −0.68854 67 OPA1 212214_at −0.69255 68 KPNA2 201088_at −0.69522 69 PPIA 211765_x_at −0.69566 70 CYP26B1 219825_at −0.69566 71 COX7AP2 217249_x_at −0.69878 72 VSNL1 203798_s_at −0.69878 73 ATP6V1D 208898_at −0.70145 74 ATP5C1 213366_x_at −0.70234 75 NRXN1 209915_s_at −0.7059 76 PCSK2 204870_s_at −0.70901 77 AI708767 211978_x_at −0.71034 78 UGCGL2 218801_at −0.71257 79 KIAA0528 212943_at −0.7139 80 SERPINI1 205352_at −0.71657 81 LZTS1 219042_at −0.71835 82 NEFM 205113_at −0.71835 83 FRY 204072_s_at −0.71924 84 CSPG5 205344_at −0.72291 85 COX6A1 200925_at −0.7277 86 COX4I1 202698_x_at −0.73037 87 KIAA0368 212428_at −0.73126 88 MYT1L 210016_at −0.73304 89 PPP3CA 202457_s_at −0.74194 90 LOC100131599 213222_at −0.74549 91 CACNG3 206384_at −0.75484 92 PPP3R1 204506_at −0.75573 93 MAN1A1 221760_at −0.75929 94 NETO2 218888_s_at −0.76819 95 LPHN1 219145_at −0.76852 96 CAPRIN2 218456_at −0.76997 97 CAMK1G 215161_at −0.77041 98 LDB2 206481_s_at −0.7802 99 TRIM36 219736_at −0.79622 100 LDHA 200650_s_at −0.80245 TABLE: List of the 100 probes with the highest Spearman correlation (absolute value, computed over all samples) between the expression of the probe and the square root of the Jensen-Shannon divergence of all samples with the average Severe AD gene expression profile. Gene symbol Probe Spearman rank correlation 1 NEFM 205113_at 0.84472 2 NRG1 206343_s_at 0.83003 3 VSNL1 203798_s_at 0.80156 4 NEFL 221805_at 0.79889 5 SLC25A12 203340_s_at 0.79666 6 BCL11A 219497_s_at 0.79266 7 RALYL 213967_at 0.78776 8 SERPINI1 205352_at 0.78242 9 ATP2B2 204685_s_at 0.78154 10 LDB2 206481_s_at 0.7802 11 ENSA 202596_at 0.77931 12 NDUFV2 202941_at 0.77753 13 KIAA0319 206017_at 0.76418 14 ATP5C1 213366_x_at 0.7584 15 TAGLN3 204743_at 0.75617 16 SV2B 205551_at 0.75484 17 DOPEY1 213271_s_at 0.75439 18 FAR2 220615_s_at 0.75395 19 SNRK 209481_at 0.7535 20 TRIM36 219736_at 0.74994 21 NRXN1 209915_s_at 0.74772 22 PKP4 214874_at 0.74461 23 CALM3 200622_x_at 0.74149 24 PIP4K2C 218942_at 0.73971 25 CRYM 205489_at 0.73437 26 SCFD1 215548_s_at 0.73037 27 COX6A1 200925_at 0.72992 28 OPA1 212214_at 0.7277 29 ATP5C1 205711_x_at 0.72414 30 LETMD1 207170_s_at 0.71969 31 PPP2R2B 213849_s_at 0.71657 32 UQCRQ 201568_at 0.71301 33 FKBP3 218003_s_at 0.71268 34 PBX1 212148_at 0.71123 35 CACNG3 206384_at 0.71079 36 TMSB10 217733_s_at 0.70812 37 KIAA1467 213234_at 0.70812 38 INA 204465_s_at 0.7059 39 ARF5 201526_at 0.70545 40 CD200 209582_s_at 0.70456 41 CAMK1G 215161_at 0.70367 42 TUBG2 203894_at 0.70234 43 LDHA 200650_s_at 0.70189 44 LOC100131599 213222_at 0.70056 45 DIMT1L 210802_s_at 0.697 46 RGS4 204339_s_at 0.69655 47 CAMKK2 212252_at 0.69611 48 BE731738 212661_x_at 0.69477 49 PPP2CA 208652_at 0.69388 50 SRD5A1 211056_s_at 0.69388 51 DMN 212730_at −0.68409 52 AW974666 222365_at −0.68721 53 SLC33A1 203164_at −0.68899 54 SYNC1 221276_s_at −0.68954 55 ITGB5 201125_s_at −0.69299 56 CNOT6 217970_s_at −0.69655 57 DYNLT1 201999_s_at −0.697 58 ZMYND8 214795_at −0.697 59 TBL1X 213400_s_at −0.69967 60 RND2 214393_a −0.70378 61 LRP10 201412_at −0.70545 62 GMPR 204187_at −0.70768 63 LTF 202018_s_at −0.70812 64 CSNK1A1 208865_at −0.70812 65 NBPF12 213612_x_at −0.70901 66 ZFP36L2 201368_at −0.70945 67 AV712577 201305_x_at −0.71212 68 FDFT1 208647_at −0.71257 69 ADARB2 220648_at −0.71301 70 CPT2 204264_at −0.7139 71 ADD3 201753_s_at −0.71524 72 37681 213256_at −0.71613 73 ITGB8 205816_at −0.71924 74 RBM19 205115_s_at −0.71969 75 HIST1H1C 209398_at −0.72058 76 NM_018612 220882_at −0.73037 77 CD68 203507_at −0.73259 78 GTF2A1L 213413_at −0.73348 79 FAM114A1 213455_at −0.73571 80 FOXO1 202724_s_at −0.73749 81 C6orf145 212923_s_at −0.73882 82 KRCC1 218303_x_at −0.74149 83 TGFBR3 204731_at −0.74372 84 ZHX3 217367_s_at −0.74594 85 TSPO 202096_s_at −0.74816 86 STAT5A 203010_at −0.74994 87 AFF1 201924_at −0.75039 88 RASL12 219167_at −0.75217 89 AL359052 214927_at −0.75528 90 ALDH3A2 202054_s_at −0.75706 91 C1S 208747_s_at −0.76062 92 AV700298 217523_at −0.76062 93 HBEGF 38037_at −0.76819 94 BG251521 213156_at −0.77086 95 ZBTB20 205383_s_at −0.77353 96 AL049443 215306_at −0.78109 97 PTTG1IP 200677_at −0.78154 98 FYCO1 218204_s_at −0.78598 99 ATP6V0E1 214150_x_at −0.802 100 SERTAD2 202656_s_at −0.84338 TABLE: The 50 genes most distant to the origin of the coordinates space × . Probe Set ID Gene Symbol Gene Title δ(sqrtJSD (P,Pc)) δ(sqrtJSD (P,Ps)) Dist O Ref (ADG) 206481_s_at LDB2 LIM domain binding 2 −0.7988 0.7427 1.0907 219736_at TRIM36 tripartite motif-containing 36 −0.8077 0.7242 1.0848 200650_s_at LDHA lactate dehydrogenase A −0.8210 0.6984 1.0778 205113_at NEFM neurofilament, medium polypeptide 150kDa −0.7448 0.7742 1.0743 [379] , [649] , [672] , [673] , [674] , [675] , [676] , [677] , [678] , [679] , [680] , [681] , [682] , [683] , [684] , [685] , [686] , [687] , [688] , [689] , [690] , [691] , [692] , [693] , [694] , [695] , [696] , [697] , [698] , [699] , [700] , [701] , [702] 202656_s_at SERTAD2 SERTA domain containing 2 0.7343 −0.7827 1.0732 203798_s_at VSNL1 visinin-like 1 −0.7093 0.7923 1.0634 [565] , [566] , [638] , [641] , [642] , [703] , [704] , [705] 205352_at SERPINI1 serpin peptidase inhibitor, clade I (neuroserpin), member 1 −0.7432 0.7496 1.0555 [706] , [707] , [708] , [709] , [710] , [711] , [712] , [713] , [714] 217367_s_at ZHX3 zinc fingers and homeoboxes 3 0.7677 −0.7129 1.0477 209915_s_at NRXN1 neurexin 1 −0.7282 0.7496 1.0451 221805_at NEFL neurofilament, light polypeptide 68kDa −0.7153 0.7552 1.0402 [715] , [716] , [717] 213366_x_at ATP5C1 ATP synthase, H+ transporting, mitochondrial F1 complex, gamma polypeptide 1 −0.7302 0.7327 1.0344 203340_s_at SLC25A12 solute carrier family 25 (mitochondrial carrier, Aralar), member 12 −0.7141 0.7444 1.0315 [718] 213967_at RALYL RALY RNA binding protein-like −0.6786 0.7758 1.0307 215161_at CAMK1G calcium/calmodulin-dependent protein kinase IG −0.7819 0.6682 1.0285 218204_s_at FYCO1 FYVE and coiled-coil domain containing 1 0.7250 −0.7222 1.0233 213222_at PLCB1 phospholipase C, beta 1 (phosphoinositide-specific) −0.7694 0.6738 1.0227 [719] , [720] , [721] , [722] , [723] , [724] 200925_at COX6A1 cytochrome c oxidase subunit VIa polypeptide 1 −0.7532 0.6883 1.0204 38037_at HBEGF heparin-binding EGF-like growth factor 0.7222 −0.7194 1.0193 [725] 209481_at SNRK SNF related kinase −0.7048 0.7331 1.0169 201412_at LRP10 low density lipoprotein receptor-related protein 10 0.6964 −0.7399 1.0161 202941_at NDUFV2 NADH dehydrogenase (ubiquinone) flavoprotein 2, 24kDa −0.6984 0.7379 1.0160 205383_s_at ZBTB20 zinc finger and BTB domain containing 20 0.6774 −0.7569 1.0157 [726] , [727] 206384_at CACNG3 calcium channel, voltage-dependent, gamma subunit 3 −0.7778 0.6516 1.0147 218888_s_at NETO2 neuropilin (NRP) and tolloid (TLL)-like 2 −0.7899 0.6246 1.0070 212214_at OPA1 optic atrophy 1 (autosomal dominant) −0.7194 0.7024 1.0054 [728] , [729] , [730] , [731] , [732] , [733] , [734] , [735] , [736] , [737] , [738] , [739] , [740] , [741] , [742] 218456_at CAPRIN2 caprin family member 2 −0.7915 0.6186 1.0046 211307_s_at FCAR Fc fragment of IgA, receptor for 0.7297 −0.6886 1.0033 202724_s_at FOXO1 forkhead box O1 0.6875 −0.7270 1.0006 [743] , [744] , [745] 219145_at LPHN1 latrophilin 1 −0.7293 0.6826 0.9989 [746] 205711_x_at ATP5C1 ATP synthase, H+ transporting, mitochondrial F1 complex, gamma polypeptide 1 −0.7153 0.6968 0.9986 55662_at C10orf76 chromosome 10 open reading frame 76 0.7632 −0.6420 0.9973 211978_x_at PPIA peptidylprolyl isomerase A (cyclophilin A) −0.7363 0.6726 0.9972 [747] , [748] , [749] , [750] 210016_at MYT1L myelin transcription factor 1-like /// hypothetical protein LOC100134306 −0.7577 0.6395 0.9915 204072_s_at FRY furry homolog (Drosophila) −0.7456 0.6512 0.9899 219497_s_at BCL11A B-cell CLL/lymphoma 11A (zinc finger protein) −0.6843 0.7117 0.9873 201125_s_at ITGB5 integrin, beta 5 0.7323 −0.6613 0.9867 211765_x_at PPIA peptidylprolyl isomerase A (cyclophilin A) −0.7230 0.6714 0.9866 [747] , [748] , [749] , [750] 214057_at MCL1 Myeloid cell leukemia sequence 1 (BCL2-related) 0.7722 −0.6137 0.9864 [751] 211839_s_at CSF1 colony stimulating factor 1 (macrophage) 0.8120 −0.5590 0.9858 [752] , [753] , [754] , [755] , [756] , [757] , [758] , [759] , [760] , [761] , [762] , [763] , [764] , [765] , [766] , [767] , [768] , [769] , [770] , [771] , [772] , [773] , [774] , [775] , [776] , [777] , [778] , [779] , [780] , [781] , [782] 205551_at SV2B synaptic vesicle glycoprotein 2B −0.6915 0.7008 0.9846 [66] 219167_at RASL12 RAS-like, family 12 0.6226 −0.7605 0.9828 214393_at RND2 Rho family GTPase 2 0.7051 −0.6799 0.9796 212899_at CDC2L6 cell division cycle 2-like 6 (CDK8-like) 0.7319 −0.6504 0.9791 220615_s_at MLSTD1 male sterility domain containing 1 −0.6665 0.7149 0.9774 201681_s_at DLG5 discs, large homolog 5 (Drosophila) 0.7093 −0.6706 0.9761 208195_at TTN titin 0.7173 −0.6617 0.9759 [783] 202457_s_at PPP3CA protein phosphatase 3 (formerly 2B), catalytic subunit, alpha isoform −0.7661 0.6016 0.9741 214150_x_at ATP6V0E1 ATPase, H+ transporting, lysosomal 9kDa, V0 subunit e1 0.6230 −0.7488 0.9741 204743_at TAGLN3 transgelin 3 −0.6952 0.6802 0.9726 213197_at ASTN1 astrotactin 1 −0.7069 0.6673 0.9721 TRANSCRIPTION FACTORS ANALYSIS OF MOST CORRELATED PROBES The signature of 50 probes we present in Figure 7 has 48 different genes (some probes are related to the same gene). The two repeated genes in this 50-probe list are ATP5C1 (ATP synthase, H+ transporting, mitochondrial F1 complex, gamma polypeptide 1) and PPIA (peptidylprolyl isomerase A (cyclophilin A)) [14] , [15] , [16] , [17] , a calcineurin regulatory protein. A recent study that used RT-PCR to examine tissue from 90 AD and 81 control human brains reports that cyclophilin is reduced in AD (both for females and males as compared with their gender-matched groups) [18] . We note here that the cutoff of 50 probes circumscribes the initial description a little, but most of the later discussion uses information from the whole signature to identify dysregulated pathways. Figure 8 presents the heat map of the 1,372-probe signature. The probes were sorted with the MA but the samples remain in the same position as obtained previously with the 50-probe signature. The probes were sorted using the memetic algorithm but the samples remain in the same order than the 50-probe signature. We analysed this list of genes using GATHER [19] , an online tool for annotating signatures. Forty-one genes out of fifty have a motif for EVI1 (ecotropic viral integration site 1) and thirty-nine of them have a binding motif with V$TCF1P_Q6 (TCF1: transcription factor 1, hepatic; LF-B1, hepatic nuclear factor (HNF1), albumin proximal factor). The same analysis can be done if we divide the set of genes in two groups. The first group has positive correlation with the control profile and are overexpressed in AD; the second group has a positive correlation with the severe profile, and tend towards being underexpressed in AD (see Table 3 ). Table 4 presents the overrepresented motifs. We note, however, that we believe that the best results to identify putative overrepresented regulatory motifs can be obtained using the whole signature of 1,372 probes, and we will present the results of this investigation after presenting the case of the most correlated probes. The second group has the opposite behaviour, that is, positive correlation with the severe profile. The first group has positive correlation with the control profile. Another interesting pattern emerged when analysing the KEGG Pathways of the 50-probe signature using GATHER and PATHWAY Studio [20] . Using GATHER, three KEGG Pathways appear significantly represented, Amyotrophic lateral sclerosis (ALS), Oxidative phosphorylation and ATP synthesis. Using PATHWAY Studio, we automatically built the “common-regulators” diagram by selecting a filter that only considers protein interactions and binding. The resulting diagram is presented in Figure 9 . As can be seen from the figure, we have chosen a circular membrane layout and our previously uncovered 5-protein signature [1] (IL1-a, TNF-a, IL-3, EGF and G-CSF) in plasma (plus IL-6) appears to have a strong relationship with CSF1 (colony stimulating factor 1 (macrophage)), the most positive correlated gene with the control profile (see Table 1 ). It is also worth mentioning, that CSF1 was found differentially expressed in blood of AD and Control subjects and belongs to the 18-protein signature uncovered by Ray et al. [2] in 2007. The figure was obtained using Pathway Studio [569] . The program received as input the 50-probes displayed in Fig. 7 and automatically searched all the known putative common regulators relationships. The highlighted proteins are the 5-protein signature (IL1- α, TNF-α, IL-3, EGF and GCSF) of [1] . We have also highlighted IL-6 (discussed in [1] in the context of results of classifiers that also use it) and CSF1, Colony-stimulating factor 1, (macrophage). TABLE: Binding factors related to two groups of genes. Transcription Factors Description P value First group V$EVI1_04 Ectopic viral integration site 1 encoded factor 0.00069 V$SMAD4_Q6 SMAD family member 4 0.0033 Second Group V$HNF1_C Hepatic nuclear factor 1 0.0022 V$ACAAT_B Avian C-type CCAAT box 0.0015 FIVE OF THE 50 MOST CORRELATED PROBES CORRESPOND TO GENES ALREADY MAPPED TO KEGGS ALZHEIMER'S DISEASE PATHWAY KEGG:05010 AND TOGETHER WITH LDHA THEY LINK TO IMPAIRED METABOLISM AND THE “NOVEL GLUCOCORTICOID HYPOTHESIS” We have observed that five genes, which are the most correlated probes with our putative signature for disease severity, can be mapped to the AD pathway of the Kyoto Encyclopaedia of Genes KEGG:05010. They are ATP5C1, COX6A1 [21] , [22] , NDUFV2 [23] , [24] , [25] , [26] , [27] , [28] , [29] , [30] , PLCB1 [31] , [32] , [33] , [34] , and PPP3CA (protein phosphatase 3 (formerly 2B), catalytic subunit, alpha isoform), the last one also known as Calmodulin-dependent calcineurin A subunit alpha isoform. In all cases, the probes showed a reduction of expression with AD severity, which may indicate a sign of impaired mitochondrial functions and energy uptake [35] , [36] . In addition to these five, we observed the reduced expression of the glycolytic enzyme LDHA, which may also indicate another challenge for energy metabolism in these neurons. Although glucose is generally considered to be the only substrate for brain energy metabolism, moncarboxylates have also been hypotheised as alternative substrates [37] . Laughton et al. report segregation in the hippocampus, with LDHA present in astrocytes and not in neurons. Instead, it is pyruvate dehydrogenase that is present in neurons but not in astrocytes and as a consequence of this study they support the argument that a metabolic compartmentalization exists in the human cortex and hippocampus where lactate produced by astrocytes could be oxidized by neurons [37] . We have also observed a reduction in expression of a probe that corresponds to PDHA1 (Pyruvate dehydrogenase (lipoamide) alpha 1, 200980_s_at) with increasing AD severity. The reduction of PDH expression, and the concurrent increase in pyruvate carboxylase gene expression, was discussed by Landfield et al. [38] , who argue that: “These changes suggest that reduced pyruvate flux through PDH and decreased oxidative metabolism of glucose may develop early in AD. Interestingly, the inactivation of PDH is also a major pathway through which glucocorticoid activity acts to conserve glucose, and apparently, to induce insulin resistance [ 65 ] , [ 66 ] . Thus, our data are consistent with the possibility that GC effects on this and other important target pathways in brain are enhanced in both aging and AD. If so, such alterations in glucocorticoid efficacy may have implications for AD pathogenesis as well as for the increased risk of AD associated with normal aging.” Our results seem to indicate that LDHA might also be discussed within the extended metabolic pathways that serve as the basic framework of this novel, more complex hypothesis [38] , [39] , [40] , [41] , [42] , [43] , [44] , [45] , [46] , [47] , [48] , [49] , [50] , [51] , [52] , [53] , [54] , [55] . FOUR OF THE 50 MOST CORRELATED GENE PROBES ARE LINKED TO SYNAPTIC FUNCTION AND NEUROFILAMENT BUNDLE ASSEMBLY AND ALSO HAVE REDUCED EXPRESSIONS WITH AD SEVERITY NEFM, NRXN1, SV2B, and NEFL all have a similar pattern of reduced gene expression with AD severity. Experiments with mice depleted of the NEFL have been previously reported in the literature. Dubois et al state that this procedure: “mimics the reduced NFL mRNA levels seen in amyotrophic lateral sclerosis and causes perikaryal accumulation of neurofilament proteins and axonal hypotrophy in motoneurons. NFL−/− mice was evaluated for regional brain metabolism by means of quantitative histochemical estimation of cytochrome oxidase activity.” [56] . Mutations in the NEFL gene [56] , [57] , [58] , [59] , [60] , [61] , [62] and in the NEFM [63] have been linked to Charcot-Marie-Tooth disease. We will discuss the loss of expression of NRXN1 (Neurexin 1) later, when we comment on its presence in a panel of putative genes linked to prion-induced neurodegeneration [64] . However, we note here that both NRXN1 and NEFL appeared to be downregulated on a transcriptional profiling study of prion infection in mice [65] . The loss of expression of SV2B is also interesting. In 2001, Heese et al. [66] reported “a new transcript of SV2B (SV2Bb) mRNA that is up-regulated at mRNA level in neurons by amyloid beta peptide (Abeta) fragment (1–42). In comparison to SV2B this new mRNA encodes for the same protein but it has an elongated 3′-untranslated region (3′UTR) that contains several AU-rich (AUR) cis-acting elements which are probably involved in posttranscriptional regulating of SV2Bb translation. In conclusion, alteration of SV2B(b) expression appears to be involved in processes of neuronal degeneration” (see also [67] ). We note that SV2B is only expressed in vesicles that undergo calcium-regulated exocytosis [68] and is a regulator of synaptotagmin 1 [69] , which is a synaptic calcium sensor with a role in neurotransmitter release previously studied in AD [70] , [71] , [72] , [73] , [74] , [75] . We present a number of genes related to synaptic function and neuronal plasticity which are increasingly down/up regulated later on the manuscript and on the supplementary material ( File S3 Sheet ‘Synapse’). ANALYSIS OF THE 1,372-PROBE SIGNATURE REVEALS ALTERATIONS IN CALCIUM AND INSULIN SIGNALLING Using GATHER, we have identified 32 genes in the Calcium signalling pathway http://www.genome.jp/dbget-bin/show_pathway?hsa04020 ( p -value<0.009). They are ADCY2, ADORA2B , AGTR1 , ATP2A3, ATP2B1, ATP2B2, ATP2B4, AVPR1A , CALM1, CALM3, CREBBP , GNA14, GNAS, GRM5 , HTR2A , ITPR1, ITPR2, LHCGR , NFATC1 , PHKA2, PLCB1 , PLCE1, PPP3CA , PPP3R1 , PRKCB1 , PTAFR , SLC25A6, SLC8A2, SYK, TBXA2R , TNNC2, and TTN. We cannot do enough justice in this manuscript to the several different hypotheses that point at imbalances/deregulation in calcium signalling and AD pathology. Instead, we contribute to these interesting discussions with our findings of genes related to this pathway within this group of 32 genes. The gene symbols in boldface can be mapped to the KEGG Pathway hsa04080, Neuroactive ligand-receptor interaction ; those in italics can be mapped to KEGG Pathway hsa04310, Wnt Signalling . Being aware of the existing interest on Wnt Signalling and AD, we went back to the list of genes present in our (alpha,beta)-k -feature set signature and we identified others that can also be linked to Wnt signalling, like CSNK1G3, CSNK2A2, FRAT1 [76] , [77] , [78] , [79] , [80] , [81] , [82] , [83] , [84] , [85] , [86] , [87] , [88] , [89] , FZD5 [89] , [90] , [91] , MDFIC, PIAS4, SOX2 [92] , [93] , [94] , [95] , [96] , TCF7L1/TCF3 [89] , [97] , [98] , TCF7L2/TCF4 [99] , [100] , [101] , [102] , [103] , [104] , [105] , [106] , and TLE3 [106] , [107] , [108] , [109] . In addition, most of the remaining 32 genes in the Calcium signalling pathway can be mapped to KEGG Pathway hsa04070, Phosphatidylinositol signalling system (CALM1, CALM3, ITPR1, ITPR2, PLCB1, PLCE1, PRKCB1), and Gap Junction (ADCY2, GNA14, GNAS, GRM5, HTR2A, ITPR1, ITPR2, PLCB1, PRKCB1). This fact suggested that we should check how many genes were mapped to these pathways. We found that Phosphatidylinositol signalling system was indeed the third pathway with most “hits” in our signature, and also with other 12 genes (CDIPT, CSNK1G3 PIK3C3, PIK3R1, PIK3R4, PI4KB, PIP5K1A, PIP5K1C, PIP4K2C, PTEN, SKIP and TTK) which brings the total number to 19. We have also found (CCND3, CSNK1A1, CSNK2A2, CTBP1, CTBP2, FRAT1, FZD5, PPARD, PPP2CA, PPP2R2B, RBX1, SMAD3, TBL1X, TCF7L1, TCF7L2, VANGL1) bringing the total to 22 genes. We refer the reader to the supplementary material ( File S3 Sheet ‘Phosphatidylinositol signalling’) for inspection of the individual pattern of expression of all these genes. Together with the 20 genes mapped to the Insulin signalling pathway KEGG hsa04910 (ACACA, CALM1, CALM3, EIF4E2, FOXO1A, INSR [110] , [111] , [112] , [113] , [114] , [115] , [116] , [117] , MAPK1, PDE3A, PHKA2, PIK3R1, PIK3R4, PPP1CC, PRKAR2A, PRKAR2B, PRKCI, RHEB, RHOQ, RPS6KB2, SKIP, and TSC2), our results seem to give some support to the hypothesis of altered calcium dynamics [35] , [118] , [119] , [120] , [121] , [122] , [123] , [124] , [125] , [126] , [127] , deregulation of insulin signalling [36] , [41] , [113] , [114] , [115] , [116] , [128] , [129] , [130] , [131] , [132] , [133] , [134] , [135] , [136] , [137] , [138] , [139] , [140] , [141] , [142] , [143] , [144] , [145] , [146] , [147] , [148] , [149] , [150] , [151] , [152] , [153] , [154] , [155] , [156] , [157] , [158] , [159] , [160] , [161] , [162] , [163] , [164] , [165] and the implication of the Wnt pathway [166] , [167] , [168] , [169] , [170] , [171] , [172] , [173] , [174] , [175] , [176] , [177] , [178] , [179] , [180] , [181] , [182] , [183] , [184] , [185] , [186] , [187] , [188] , [189] , [190] , [191] , [192] , [193] , [194] , [195] , [196] , [197] , [198] , [199] in AD pathogenesis. Figures 10 , 11 , 12 , 13 , and 14 illustrate down(up)-regulation of genes in these signalling pathways (Calcium signalling, Neuroactive ligand receptor pathway, WNT, Phosphatidylinositol and Insulin signalling, respectively). Figure 15 shows the expression of probes corresponding to genes for which there are known associations to synaptic function and neuronal plasticity. We refer the reader to the supplementary material ( File S3 ) for more searchable information. The upper graph presents the stacked normalized expression values of all the probes involved in the Calcium signaling with an upregulation trend. The lower graph analyses the genes involved in the pathway with a downregulation tendency. In the supplementary material ( File S3 sheet ‘Calcium signalling pathway’), the reader will find all the individual gene expression values, normalised and not normalised. The upper graph presents the stacked normalized expression values of all the probes involved in the pathway with an upregulation trend. The lower graph analyses the genes involved in the pathway with a downregulation tendency. In the supplementary material ( File S3 sheet ‘Neuroactive ligand-receptor’), the reader will find all the individual gene expression values, normalised and not normalised. The upper graph presents the stacked normalized expression values of all the probes involved in the pathway with an upregulation trend. The lower graph analyses the genes involved in the pathway with a downregulation tendency. In the supplementary material ( File S3 sheet ‘Wnt Signalling’), the reader will find all the individual gene expression values, normalised and not normalised. The upper graph presents the stacked normalized expression values of all the probes involved in the pathway with an upregulation trend. The lower graph analyses the genes involved in the pathway with a downregulation tendency. In the supplementary material ( File S3 sheet ‘Phosphatidylinositol signalling’), the reader will find all the individual gene expression values, normalised and not normalised. The upper graph presents the stacked normalized expression values of all the probes involved in the pathway with an upregulation trend. The lower graph analyses the genes involved in the pathway with a downregulation tendency. In the supplementary material ( File S3 sheet ‘Insulin signalling’), the reader will find all the individual gene expression values, normalised and not normalised. The upper graph presents the stacked normalized expression values of all the related probes with an upregulation trend. The lower graph analyses the genes involved with a downregulation inclination. In the supplementary material ( File S3 , Sheet ‘Synapse’), the reader will find all the individual gene expression values, normalised and not normalised. TRANSCRIPTION FACTORS ANALYSIS OF 1,372-PROBE SIGNATURE REVEALS SIGNIFICANT ASSOCIATIONS WITH THE EGR/KROX FAMILY OF PROTEINS, MAZ, AND E2F1 The analysis of the 1,372-probe signature indicates that they can be linked to putative transcription factors that have been previously implicated in AD and other neurodegenerative diseases. Using GATHER, we have observed that there is a strong association with motif V$KROX_Q6 ( p -value<0.0004) with 719 out of 1294 genes in our signature; V$MAZ_Q6 ( p -value<0.001, with 1003 genes); and V$E2F1_Q6_01 and V$E2F1_Q3_01 (with p -values which are smaller than 0.002 and 0.009 respectively). Of the 1294 genes associated with the 1,372 probes (by GATHER), more than half of them (656) have a motif for V$E2F1_Q6_01 and 603 have a motif for V$E2F1_Q3_01. MAZ (MYC-associated zinc finger protein (purine-binding transcription factor)) , also known as ZF87 and Cys2His2-type zinc finger transcription factor serum amyloid A activating factor 1 [200] , has been previously implicated in Alzheimer's disease [201] and as a blood biomarker in schizophrenia [202] . MAZ interacts with DCC, the receptor for netrin-1, a neuronal survival factor [203] . Deregulation of cyclin-dependent kinases and abnormal patterns of E2F1 regulation have also been linked with Alzheimer's disease [204] , [205] , [206] , [207] , [208] , neurodegeneration [205] , [207] , [209] , [210] , [211] , [212] , [213] , [214] , [215] , and neuronal apoptosis [216] , [217] , [218] , [219] , [220] . The involvement of the EGR/KROX (immediate early genes) family of proteins in the pathogenesis of Alzheimer's disease was first suggested in [221] . Studies of the behavioural consequences of stress have shown a link between the activation of the glucocorticoid receptor mediated response and EGR1, one of the members of this family [222] . It has been recently proposed that different members of the EGR/KROX family have different roles in learning and memory and cognitive functions [223] , [224] , [225] , [226] , [227] , [228] . Mutant mice experiments showed that EGR1/KROX24 is required for the consolidation of long-term memory, while it is EGR3 the one linked to short-term memory [229] , with EGR2 having perhaps other type of phenotypic characteristics not yet mapped [230] . In rat hippocampus, EGR1 decreases with aging [231] . In a recent study, it has been shown that initial playbacks of novel songs transiently increase EGR1 but that the observed response selectively habituates after repetition of the stimulus, with a different expression profile after one day [232] (see [233] and also [234] in which the homolog of NEFM, one of our biomarkers of reduced expression with increasing ‘AD severity’ called NF-M, is showed to be involved in the development and/or maturation of the oscine song control system). We found the following connection between EGR/KROX, E2F1 and MAZ transcription factors that makes their concurrent finding notable. A recent study of microRNA signature of prion-induced neurodegeneration [64] has shown that EGR1, E2F1 and MAZ might be also implicated in the putative deregulation of immune response related genes by miRNAs via modulation of transcriptional regulators in scrapie-infected mice. We leave these findings for the next section of the manuscript where we will discuss them and present a list of common differentially expressed genes in these two neurodegenerative processes. THE 1,372-PROBE SIGNATURE CONTAINS A SIGNIFICANT NUMBER OF GENES DIFFERENTIALLY EXPRESSED THAT ARE LINKED TO SYNAPTIC FUNCTION AND NEURONAL PLASTICITY The existence of several genes among the most correlated ones (NRXN1, SV2B, NEFM, etc.,) motivated us to try to identify which genes were present in the 1,372-probe signature that are also related to synaptic function and neuronal plasticity. We have identified 42 probes that can be divided into two groups, those that seem to be increasingly downregulated with AD severity (CABP1 [235] , [236] , [237] , [238] , [239] , [240] , [241] , [242] , [243] , CADPS2 [244] , [245] , [246] , [247] , [248] , [249] , COLQ [250] , DMD [251] , [252] , [253] , [254] , [255] , [256] , ELOVL2 [257] , FAIM2/LFG [258] , [259] , [260] , [261] , GABBR2 [262] , [263] , [264] , [265] , GRIA2/GLUR2 [266] , [267] , [268] , [269] , [270] , [271] , [272] , [273] , [274] , [275] , [276] , [277] , ITPR1 [278] , [279] , [280] , [281] , [282] , [283] , KIAA0528, LZTS1/FEZ1 [284] , [285] , NEFM, NRG1, NRXN1, NUFIP1 [286] , [287] , [288] , PPT1 [289] , [290] , [291] , [292] , [293] , [294] , [295] , [296] , [297] , [298] , [299] , [300] , [301] , PSD3, RAB3B [302] , [303] , [304] , [305] , [306] , [307] , [308] , [309] , [310] , [311] , [312] , [313] , [314] , [315] , [316] , [317] , RIMS2 [318] , [319] , [320] , [321] , SHANK2 [322] , [323] , [324] , [325] , [326] , [327] , [328] , [329] , [330] , [331] , [332] , [333] , [334] , [335] , [336] , [337] , [338] , [339] , [340] , SV2B [68] , [69] , [341] , [342] , [343] , [344] , [345] , [346] , [347] , [348] , [349] , [350] , [351] , [352] , [353] , [354] , [355] , [356] , [357] , [358] , [359] ) and those that present an upregulation pattern (CASK [360] , [361] , [362] , CDK5R1 [363] , [364] , [365] , [366] , [367] , [368] , [369] , [370] , [371] , [372] , [373] , [374] , [375] , [376] , [377] , [378] , [379] , CHRNA1, CHRNA9, CHRNB3, CTBP2, DLG1/SAP97 [380] , [381] , [382] , [383] , [384] , [385] , [386] , [387] , [388] , DLGAP2, GABRA5 [389] , [390] , [391] , [392] , [393] , [394] , GABRQ [395] , GLRA3 [396] , [397] , [398] , GRIK3/GLUR7 [399] , HOMER3 [400] , ICA1 [401] , ITGB1 [402] , [403] , MCTP1 [404] , [405] , PPP1CC [406] , SNPH [407] , [408] , [409] , [410] , [411] , [412] , [413] , [414] , SSPN [415] , SYNC1, and USH1C [416] , [417] , [418] ). The reader can consult the supplementary material ( File S2 ) for the individual expression patterns of these genes. If, in agreement with Klemmer et al. [362] , consider synapses as the most complex cellular organelle, with approximately 1500 proteins interacting in an activity dependent manner, we can argue that we must be inclusive with our list of references to help other researchers map the literature of their functions. Our aim is that experts can use this information to find ways of building novel testable hypotheses of AD neuronal plasticity impairment in the hippocampus. Our approach here has been to map what is currently known, and link it with the current biomedical literature, to facilitate experts that understand processes in detail. We have already discussed some of the increasingly downregulated genes, another important candidate for further study is NRG1 (Neuregulin 1), a gene that has already been linked to several neuronal diseases. It is a candidate for susceptibility to schizophrenia and bipolar disorder (see [419] , [420] , [421] , [422] , [423] , [424] , [425] , [426] , [427] , [428] , [429] , [430] , [431] , [432] , [433] , [434] and references therein). There have been reported links of NRG1 with AD. BACE1 (beta-Site APP-cleaving enzyme) is necessary for the cleavage of the amyloid-beta precursor protein, and BACE1 participates in the proteolytic processing of NRG1 [435] , [436] , and there exists some concerns about BACE1 inhibition as a potential therapeutic intervention due to its interaction with NRG1 and potential effects on remyelination [437] . In particular, NRG1 has been reported as a possible biomarker in cerebral spinal fluid, since its levels have been reported to be significantly increased in AD. Pankonin et al. suggest that: “While (NRG1) is not detected in human serum, a novel neuregulin antagonist activity was identified in human serum that could have prevented its detection. These results suggest that human neuregulin is selectively targeted from cortical neurons to white matter extracellular matrix where it exists in steady-state equilibrium with cerebral spinal fluid where it has the potential to serve as a biological marker in human neuronal disorders” [438] . NRG1 seems to collaborate with the ERBB4 receptor, and Li et al. propose that together they control glutamatergic synapse maturation and plasticity [439] . A single nucleotide polymorphism in NRG1 has also been associated as a risk factor to positive symptoms of psychosis in a proportion of late-onset AD [440] . With this evidence it is clear that NGR1 [439] , [441] , [442] , [443] , [444] , [445] , [446] , [447] as well as the whole panel presented here are excellent candidates for further studies due to their well supported role in synaptic function in health and disease states. OTHER BIOMARKERS OF INTEREST We should also mention some other biomarkers that could be interesting for further studies, including imaging purposes, like TSPO/PBR (translocator protein (18kDa)) also known as Mitochondrial Benzodiazepine Receptor (peripheral), thus supporting its current role as a putative imaging biomarker for AD [448] , [449] , [450] , [451] , [452] , [453] , [454] , [455] , C1S (complement component 1, s subcomponent) [456] , [457] , [458] , [459] , [460] , [461] , FDFT1 (the squalene synthase gene), which is critical for cholesterol synthesis [462] , [463] , BMP4 [92] , [96] , [464] , [465] , CD68 (as marker of enhanced lysosomal activity) [450] , [466] , [467] , [468] , [469] , [470] , [471] , [472] , SERTAD2/TRIP-Br2 [473] , [474] , [475] , LTF (Lactotransferrin) [476] , [477] , [478] , FTL (ferritin, light polypeptide; Ferritin light chain) [479] , [480] , [481] , [482] , MTF1 (Metal-regulatory transcription factor 1) [483] , [484] , [485] , GSTA3 (Glutathione S-transferase A3), GSTM4 (Glutathione S-transferase M4), MT1L (Metallothionein 1L (gene/pseudogene) [486] (a human-specific truncated protein which may have changed its function or suppressed it [487] ), MT1H (Metallothionein 1H) [488] , MT1F (Metallothionein 1F) [488] , [489] ( Figure 16 ). These last three upregulated genes need to be put in concert with other reports on methallothioneins in AD brains [490] , [491] , [492] . Figure 16 shows the upregulation of Lactotransferrin, FTL (ferritin, light polypeptide; Ferritin light chain), and the Metallothionein family with increasing AD severity. Stacked line graph of the probes related to the Metallothionein family in the 1372-probe signature. Other probes which present an upregulation trend that we would like to highlight are BCL2 [493] , [494] , FYCO1 [495] , [496] , PAX6 [111] , [497] , [498] , [499] ( Figure 17 ), and QKI [500] ( Figure 18 ). The increase of expression of these probes, together with SOX2, is intriguing as they are related to differentiation from stem cells and are considered critical in neurogenesis [501] , [502] , [503] , [504] , [505] , [506] , [507] , [508] , [509] , [510] . Our results support the combined use of them in tracking AD progression in this tissue. In addition, we have previously mentioned the relevance of EGR1 in coordinating a large number of genes that seem to be differentially expressed in this study. EGR1 also appears with a marked upregulation in severe AD patients (we refer to the supplementary material File S2 Sheet ‘1372 norm. +heat map+GO' for its gene expression profile). We found that this link is very important, as the homologues of EGR1, zif268, Egr-1 or ZENK, together with other members of the EGR family, are consolidating a key role in the neuronal plasticity in the brain [226] , [230] , [511] , [512] , [513] , [514] , [515] , [516] , [517] , [518] , [519] , [520] , [521] , [522] , [523] , [524] , [525] , [526] , [527] , [528] , [529] , [530] , [531] , [532] , [533] , [534] , [535] , [536] , [537] , [538] , [539] , [540] , [541] , [542] , [543] , [544] , [545] , [546] , [547] , [548] , [549] and links with AD and cognitive decline progression are starting to be reported [514] , [515] , [550] , [551] , [552] , [553] , [554] . The expression of a PAX6 probe shows increasing upregualtion with AD severity. At the same time, prospective studies should encompass some other genes which appear downregulated with increasing AD severity. Top of the list is perhaps LDB2/CLIM1 (LIM domain binding 2), recently pointed as a marker (with LMO4 [555] , [556] ) of the control program of the development of neuronal subtype diversity of the cerebral cortex [557] . TRIM36 is another interesting candidate for further studies [558] . A gene that shares the same trend of dowregulation is CAMK1G (calcium/calmodulin-dependent protein kinase IG) [559] , [560] , [561] , [562] , [563] , [564] . When analysing prefrontal cortical tissue from mice with inducible deletions of BDNF (Brain-derived neurotrofic factor), Glorioso et al. employed microarray gene expression profiling to show that there were alterations to early-immediate genes (including EGR1) and CAMK1G [563] . They conclude their manuscript stating that: “while altered BDNF expression may not represent the primary disturbance in AD, changed expression of, or altered responsiveness to BDNF (and subsequently decreased SST levels) may represent a critical feature of Alzheimer's disease progression.” VSNL1 (Visinin-like protein 1) [565] , a CA++ sensor protein is also down-regulated (see Figure 19 ), a finding which is paralleled in the work of Youn et al. [566] , who found similar changes in hippocampus. VSNL1, a neuronal calcium sensor that has received recent attention in AD [636] , [637] , [638] , [639] has also been linked to model systems of schizophrenia, where it has been found upregulated in hippocampus [640] . A previous result by Schnurra et al. raised the possibility that the redution of VSNL1 expressing neurons indicate a selective vulnerabilty of these cells, since they observed that VSNL1 expression enhanced hyperphosphorylation of tau protein (in contrast with nontransfected or calbindin-D28K-transfected cells) [641] . In 2001, Braunewell et al. had already reported the reduction of VSNL1-immunoactive neurons in the temporal cortex of AD patients as compared with controls [642] . DISCUSSION In late 2008, a paper was published in PLoS ONE, shortly after the publication of our signature for prediction of clinical symptoms of AD [1] appeared online [64] . In this other contribution, Saba et al. present a microRNA signature of prion induced neurodegeneration [64] . By examination of the promoter regions of putative microRNA targets, they found that some transcription factor motifs were significantly enriched, E2F-1 ( p -value = 6.01×10 −14 ), KROX ( p -value = 9.34×10 −14 ), MAZ ( p -value = 2.23×10 −11 ) and PAX6 ( p -value = 1.76×10 −9 ). Our identification of EGR1/KROX-24 and PAX-6 as upregulated with AD progression, and the identification of motif V$KROX_Q6, V$MAZ_Q6, V$E2F1_Q6_01, V$E2F1_Q3_01 as enriched in our signature were two contributing factors that motivated us to explore any further similarities that we could find. In [64] , an analysis of the predicted target genes of their microRNA signature, linked with differentially expressed genes in scrapie-infected mice [65] as well as two other publications [567] , [568] , led Saba et al. [64] to identify a network of de-regulated immune response-related genes. Additionally, they identified the putative transcription regulator genes that are targets of miRNAs similarly de-regulated. In essence, a possible hierarchy of deregulations of microRNAs, which, deregulated transcription factors that then, modify 1282 target genes. A Gene Ontology analysis also indicated that the “data sets were found to be in the significant enrichment for genes involved in cell death, regulation of the cell cycle, nervous system development and function and cell signalling pathways.” As a consequence, we have investigated if some of the 1,282 putative target genes of the miRNA signature of prion induced neurodegeneration also appear in our lists. Of those 1,282 genes we immediately noticed that there were 9 genes listed in our list of the 50 most correlated genes ( Table 3 ). These genes are BCL11A, CSF1, DLG5, FOXO1, HBEGF, NRXN1, SERTAD2, SNRK and ZBTB20. Two of these genes, CSF1 (colony stimulating factor 1 (macrophage)) and HBEGF (heparin-binding EGF-like growth factor) appear to be conspicuous mediators of cytokine and growth factor signalling as Figure 9 illustrates (we obtained this network using Pathway Studio [569] as described in the previous section), and CSF1 and HBEGF seems to be increasing with AD severity. In opposition, the probe corresponding to NRXN1 (Neurexin 1, 209915_s_at) has decreasing expression ( Figure 20 ). Although no connection has been found between NRXN1 and AD yet, this gene has been implicated in autism [570] , [571] , [572] , [573] , [574] , [575] , [576] , schizophrenia [577] , [578] , [579] , [580] , [581] , nicotine and alcoholism dependence [582] , [583] , [584] , and mental retardation [585] . SERTAD2 (SERTA domain containing 2), mentioned in the previous section, is also known as Transcriptional regulator interacting with the PHD-bromodomain 2, TRIP-Br2, a member of the TRIP-Br family of transcriptional regulators, required for the transduction of mitogenic signals and the execution of serum-inducible E2F-mediated cell cycle progression [473] . In our data, the probe for SERTAD2 is increasing with AD severity. It has also been reported that overexpression of SERTAD2 is sufficient to transform murine fibroblasts and promotes tumorigenesis in athymic nude mice due to the deregulation of the E2F/DP-transcriptional pathway thanks to the upregulation of the key E2F-responsive genes [474] . FOXO1 (Forkhead box O1) also appears upregulated with increasing AD severity, and has been reported as a negative regulator of EGR1 expression via the activation of the PI3K/Akt/Forkhead pathway [586] . The expression of FOXO1 is also induced by E2F1 [587] . The product of this gene has also been reported as a survival factor in deprivation-induced neuronal cell death [588] , [589] (see also the review in [590] ). Although FOXO1 has not been previously implicated in AD, an exception may exist. van Der Heide et al. describe in [591] how the Forkhead transcription factors are involved in insulin signalling. The “PI3K route” is a name given to common signal transduction cascade that links neuronal survival, synaptic plasticity (and, as a consequence, learning and memory) [592] . This “PI3K-Akt-FOXO1 mechanism” and its role in neurons warrant the current intensive investigation [593] , [594] , [595] , [596] , [597] , [598] , [599] , [600] . From this group of 9 genes, seven of them (NRX1, SERTAD2, SNRK, HBGEF, FOXO1, CSF1, BCL11A) and QKI have been predicted to be targeted by mmu-mir128 by two or more microRNA prediction tools. We found this to be a connection that is worth exploring. Lukiw and Pogue have reported that following metal-induced reactive oxygen species production (by iron and aluminium-sulfate at nanomolar concentrations) upregulates miR-128 in human neural cells in primary culture [601] . They also report that, together with miR-9, mir-125a, mir-128 is upregulated in AD brain. In the previously cited reference Lukiw reported that: “miR-9, miR-124a, miR-125b, miR-128, miR-132 and miR-219 are abundantly represented in fetal hippocampus, are differentially regulated in aged brain, and an alteration in specific micro-RNA complexity occurs in Alzheimer hippocampus.” We have found no previous evidence of a connection of NRXN1 and AD, but this gene has been previously implicated in autism [570] , [571] , [572] , [573] , [574] , [575] , [576] , schizophrenia [577] , [578] , [579] , [580] , [581] , nicotine and alcoholism dependence [582] , [583] , [584] , and mental retardation [585] . The expression of probes corresponding to PP2A and PP2B catalytic subunits (i.e. PPP2CA, Protein phosphatase 2 (formerly 2A), catalytic subunit, alpha isoform, and PPP3CA, Protein phosphatase 3 (formerly 2B), catalytic subunit, alpha isoform, Calcineurin A1) shows increasing downregualtion with the progression of AD., see Figure 21 . This finding supports a role for downregulation of PPP2CA, PPP3CA in AD pathology [619] – [647] . A similar plot exists for PPP3R1 (protein phosphatase 3 (formerly 2B), regulatory subunit B, alpha isoform, Calcineurin subunit B type 1). This result supports a role for downregulation of PPP2CA, PPP3CA in AD pathology [643] , [644] , [645] , [646] , [647] , [648] , [649] , [650] , [651] , [652] , [653] , [654] , [655] , [656] , [657] , [658] , [659] , [660] , [661] , [662] , [663] , [664] , [665] , [666] , [667] , [668] , [669] , [670] , [671] . Finally, in addition to the presence of hyperphosphorylated tau, the accumulation of Amyloid-beta (Abeta) peptide in brain tissue is a hallmark of AD [602] . The identification of the genes involved in the proteolytic processing of APP (beta-amyloid precursor protein), which in turn produces Abeta, is a subject of intense research. Researchers are currently looking at the alterations of APP cellular localization and endocytic trafficking as one mechanism that can modify the processing of APP to Abeta. LRPs are known to regulate APP's endocytic trafficking [603] , [604] , [605] , [606] , and seem to be a hub of a number of mounting evidences on processes that link to cholesterol metabolism and atherosclerosis [607] . In our selected panel of 50 proteins we have one member of this family, LRP10 (low density lipoprotein receptor-related protein 10), as one of the most correlated gene expression profiles. In our list of 1372 gene probe signature we also have another member of this family, LRP1B (low density lipoprotein-related protein 1B (deleted in tumors)) [608] , While LRP10 appears to be positively upregulated with cognitive decline an inverse relationship is observed for LRP1B. LRPs are also known to linked to APP via a mechanism that involves the alternative splicing of APBB3/Fe65L2 [609] , [610] , [611] . Tanahashi and Tabira have proposed that the splicing of APBB3/Fe65L2 alters the ability to bind with APP and low-density-lipoprotein-receptor-related protein. They propose that the secretion of beta-amyloid peptide Abeta40 and Abeta42 is increased following the overexpression of APBB3, but there are no visible changes of half-life and maturation of APP, or the secretion of secreted APP [612] . In our dataset, we observe APBB3 expression being upregulated with the increasing cognitive decline, following the same pattern of LRP10. Polymorphisms on these genes have previously been linked to AD. Tanahashi, Asada and Tabira have reported an association between a polymorphism in APBB3/Fe65L2 and early-onset AD [612] (the link between APBB3 and AD is being increasingly explored, we refer to [613] , [614] , [615] , [616] for further references). Using 500K SNP microarray technology, Poduslo, Huang and Spiro have identified haplotypes in LRP1B as significant for successful aging without cognitive decline in a study involving individuals that were 85 years old or older, had MMSE scores greater than 26, no history of dementia in their families, and no major illnesses (i.e. no cardiovascular problems, diabetes, obesity, or major cancer diseases) and most of them had normal cholesterol levels. Their genome-wide association screening compared these individuals with those that have late-onset AD [617] . Poduslo et al. have suggested that if the decreased production of Abeta42 in successful aging is due to the haplotypes they describe, then LRP1B may be a new target for treatment of AD [608] , [617] , Taken together these results indicate that integrative bioinformatics analytic approaches will be needed to elicit the interactome of LRPs and their role in AD. CONCLUSIONS This re-analysis of the microarray dataset hippocampal gene expression contributed by Blalock et al. has shown that there exist a relatively large number of probes (1,372) that present a clear pattern of either up or down regulation with increasing AD severity. The signature reveals alterations in calcium, insulin, phosphatidylinositol and Wnt-signalling. Among the group of most correlated gene probes with AD severity we found some linked to synaptic function, neurofilament bundle assembly, neuronal plasticity and inflammation. A transcription factors analysis of 1,372-probe gene expression signature reveals significant associations with the EGR/KROX family of proteins, MAZ, and E2F1. The gene homologous of EGR1, zif268, Egr-1 or ZENK, together with other members of the EGR family, are consolidating as key players in short and long-term memory and neuronal plasticity in the brain. We have also uncovered a large consensus of this gene expression signature with current genes putatively involved in AD progression. Our results also indicate a degree of commonality between putative genes involved in AD and prion-induced neurodegenerative processes that warrants further investigation. MATERIALS AND METHODS In this contribution, we have used a MIAME compliant, Affymetrix gene expression dataset that is public available and was contributed by Blalock et al [3] in 2004. We thank the authors of that publication for making this useful dataset available to the research community at large allowing further exploration and reanalysis. The dataset is available from GEO Dataset Browser, accession number GDS1297 ( http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE1297 ). The Affymetrix human GeneChip, HG-U133A, containing 22,283 targets was used. The dataset is de-identified and the methods for disease classification, based on MMSE and NFT scores, are described in full detail by Blalock et al. in Ref. [3] . The hippocampal samples used by Blalock et al. were obtained from the autopsy of 31 subjects through the Brain Bank of the University of Kentucky Alzheimer's Disease Research Center (ADRC), Sanders-Brown Center on Aging, University of Kentucky. The ADRC was established in 1985 and in operation since 1989 a pool of research volunteers that have agreed in principle to be research participants. Participants were asked questions based on NINCDS/ADRDA criteria [618] to establish their physical and mental condition to determine if their were eligible for the study. When a mutual agreement existed, the individuals were visted in their homes to review and sign the informed-consent document (which was approved by the University of Kentucky Institutional Review Board). Participants also signed a donor card, and the visit also aimed to establish their baseline mental-status testing. Elegibility for the purpose of the study included having a Mini-Mental State Exam score above 24 [619] , passing a series of cognitive tests, and a previous history of absence of neurological disease [620] , as well as neither substance abuse nor major psychiatric illnesses. All eligible volunteers were 60 years of age or older and satisfactorily performed normal activities of daily living. The Wechsler Adult Intelligence Scale (Vocabulary) was also applied to exclude significant other medical diseases that could affect cognition and elegible participants must had no previous history of head injury with loss of consciousness. The research participants that were deemed eligible also signed a form (in addition to the consent document) indicating their agreement to donate their brain to the Sanders-Brown Center on Aging. A full description of the methods used can be found in Brain Donation in Normal Aging Procedures, Motivations, and Donor Characteristics from the Biologically Resilient Adults in Neurological Studies (BRAiNS) Project [621] . Blalock et al. [3] categorized the samples in four groups, with a labelling that indicates different “levels of severity”. These labels were decided based on the MiniMental State Examination (MMSE) and the Neurofibrillary Tangle count (NFT) of each sample [622] . Samples are then separated in the types ‘Control’, ‘Incipient AD’, ‘Moderate AD’ and ‘Severe AD’. Table 1 of Blalock et al. shows the mean values of MMSE and NFT for each one of these groups. In addition, they give the mean Braak stage [623] , [624] , [625] for each one of the groups (2.1 for ‘Control’, 5 for ‘Incipient’, 5.6 for ‘Moderate’ and 5.9 for ‘Severe’). We are grateful to Dr. Blalock who has kindly given us these values of the Braak stage for each sample in the dataset. Together with the individual values of MMSE, NFT, the Braak stage of each sample is included in the Supplementary Material ( File S2 sheet ‘Braak’) section of this publication. METHODOLOGY Our analysis method consisted of four steps: abundance quantization and filtering of probes; a feature selection algorithm to refine the probe selection; a Jensen-Shannon divergence computation; and finally, a correlation analysis. Each of these steps is described below. As mentioned in the Results section, we only used the samples labelled as “Control” or “Severe AD” for feature selection, thus we have a two-class probe/gene selection task. We did not use the samples labelled as “Incipient AD” or “Moderate AD” for the probe selection steps. Those samples were only used in the final step, at the time of computing the correlation of the gene profile, across all samples, with the Jensen-Shannon divergences computed for the “Control” and “Severe” classes as explained later in this section. For the first step, the quantization of the expression values, as well as for the initial data pruning, we used Fayyad and Irani's algorithm [626] . The heuristic algorithm minimises the feature-class entropy and discards genes according to the Minimum Description Length principle. The application of Fayyad and Irani's algorithm not only filters several thousand genes, it also provides thresholds for each probe remaining in the dataset. These quantized values of gene expression leave us with an instance of a combinatorial optimization problem, the (α, β)-k-Feature Set problem [13] , [627] , [628] . The (α, β)-k-Feature Set problem is a combinatorial optimisation problem introduced by Cotta, Sloper and Moscato [628] in 2004 to address the problem of feature selection in high-dimensional datasets. We solve an instance of this problem numerically using an integer programming formulation. This approach has been previously employed to obtain molecular biomarker signatures in Alzheimer's Disease [1] , [629] , models of Parkinson disease [630] , prostate cancer [631] , electrode selection in EEGs [632] , and elsewhere. To obtain mathematically proven optimal solutions of the integer programming formulation, the CPLEX commercial optimization solver was used. As in previous contributions of our group, we found gene expression signatures corresponding to values of α maximum and β maximal [1] , [13] , [627] , [628] , [633] . We refer the reader to these previous contributions for a detailed explanation of the methodology. At this point, we have a selection of 1,372 probes, a set which we denote as Ω. For each sample m and probe , let f im be its expression value. We now define a probability distribution function (PDF) for each sample. For sample, m its PDF , is given by We can now compute an average PDF profile for samples in the “Control” and “Severe AD” groups, denoted by and respectively. Let C and S be the set of samples with the labels “Control” and “Severe AD” respectively. The average profile , is then: where where represents the number of samples in class C . is analogously defined. The Jensen-Shannon divergence between two sample PDFs, i.e. samples l and k ( P (l) and P (k) ) is defined as where S [ P ] is the Shannon Entropy for a specific PDF sample with N states. It is well known that the square root of the JSD ( sqrtJSD ) is a metric, which means that for a given set of PDFs the following four properties are satisfied: Once the sqrtJSD between each patient and the two average profiles ( and ) has been computed, the genes most correlated with these metrics can be uncovered. We used the Spearman rank correlation, which is a well-known non-parametric method, and can thus be used even when the data does not satisfy assumptions about normality, homoscedasticity and linearity. SUPPLEMENTARY MATERIAL Supplementary ‘ File S1 ’ provides a glossary of each gene referenced in this paper including synoms and refrences to iHOP ( http://www.ihop-net.org/ ). The results referenced in this manuscript are provided in supplementary ‘ File S2 ’ and ‘ File S3 ’ in Microsoft Excel format. SUPPORTING INFORMATION IHop Glossary of Genes. (0.15 MB DOC) Supplementary Data 1. (4.10 MB XLS) Supplementary Data 2. (1.26 MB XLS) REFERENCES [1] Gomez Ravetti M Moscato P 2008 Identification of a 5-Protein Biomarker Molecular Signature for Predicting Alzheimer's Disease. PLoS One 3 e3111 [2] Ray S Britschgi M Herbert C Takeda-Uchimura Y Boxer A 2007 Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med 13 1359 1362 [3] Blalock EM Geddes JW Chen KC Porter NM Markesbery WR 2004 Incipient Alzheimer's disease: Microarray correlation analyses reveal major transcriptional and tumor suppressor responses. Proceedings of the National Academy of Sciences of the United States of America 101 2173 2178 [4] Schmitt FA Davis DG Wekstein DR Smith CD Ashford JW 2000 “Preclinical” AD revisited: Neuropathology of cognitively normal older adults. Neurology 55 370 376 [5] Haroutunian V Purohit DP Perl DP Marin D Khan K 1999 Neurofibrillary Tangles in Nondemented Elderly Subjects and Mild Alzheimer Disease. Arch Neurol 56 713 718 [6] Price DL Sisodia SS 1998 Mutant genes in familial Alzheimer's disease and transgenic models. Annual Review of Neuroscience 21 479 505 [7] Price JL 1993 The relationship between tangle and plaque formation during healthy aging and mild dementia. Neurobiology of Aging 14 661 663 [8] Price JL Davis PB Morris JC White DL 1991 The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer's disease. Neurobiology of Aging 12 295 312 [9] Robbins K Sandeep J Zhang W Rekaya R 2006 Classification of incipient Alzheimer patients using gene expression data: Dealing with potential misdiagnosis. Online Journal of Bioinformatics 7 9 [10] Sandeep J Robbins K Zhang W Rekaya R 2008 Effects of Misdiagnosis in Input Data on the Identification of Differential Expression Genes in Incipient Alzheimer Patients. In Silico Biology 8 9 [11] Grosse I Bernaola-Galvan P Carpena P Roman-Roldan R Oliver J 2002 Analysis of symbolic sequences using the Jensen-Shannon divergence. Phys Rev E Stat Nonlin Soft Matter Phys 65 041905 [12] Moscato P Mendes A Berretta R 2007 Benchmarking a memetic algorithm for ordering microarray data. Biosystems 88 56 75 [13] Berretta R Costa W Moscato P 2008 Combinatorial Optimization Models for Finding Genetic Signatures from Gene Expression Datasets. Keith JM Bioinformatics Humana Press 363 377 [14] Gubern C Hurtado O Rodriguez R Morales JR Romera VG 2009 Validation of housekeeping genes for quantitative real-time PCR in in-vivo and in-vitro models of cerebral ischaemia. BMC Mol Biol 10 57 [15] Santos AR Duarte CB 2008 Validation of internal control genes for expression studies: effects of the neurotrophin BDNF on hippocampal neurons. J Neurosci Res 86 3684 3692 [16] Johansson S Fuchs A Okvist A Karimi M Harper C 2007 Validation of endogenous controls for quantitative gene expression analysis: application on brain cortices of human chronic alcoholics. Brain Res 1132 20 28 [17] Hughes V Smith S Garcia-Sanchez A Sales J Stevenson K 2007 Proteomic comparison of Mycobacterium avium subspecies paratuberculosis grown in vitro and isolated from clinical cases of ovine paratuberculosis. Microbiology 153 196 205 [18] Preece P Cairns NJ 2003 Quantifying mRNA in postmortem human brain: influence of gender, age at death, postmortem interval, brain pH, agonal state and inter-lobe mRNA variance. Brain Res Mol Brain Res 118 60 71 [19] Chang JT Nevins JR 2006 GATHER: a systems approach to interpreting genomic signatures. Bioinformatics 22 2926 2933 [20] Ariadne Genomics I 2007 Pathway Studio™. 5.0 ed [21] Ongwijitwat S Wong-Riley MT 2004 Functional analysis of the rat cytochrome c oxidase subunit 6A1 promoter in primary neurons. Gene 337 163 171 [22] Wong-Riley M Guo A Bachman NJ Lomax MI 2000 Human COX6A1 gene: promoter analysis, cDNA isolation and expression in the monkey brain. Gene 247 63 75 [23] Ben-Shachar D Karry R 2008 Neuroanatomical pattern of mitochondrial complex I pathology varies between schizophrenia, bipolar disorder and major depression. PLoS One 3 e3676 [24] Ji B La Y Gao L Zhu H Tian N 2009 A Comparative Proteomics Analysis of Rat Mitochondria from the Cerebral Cortex and Hippocampus in Response to Antipsychotic Medications. J Proteome Res 8 3633 3641 [25] Zhang J Li X Wang Y Ji J Yang F 2009 Association study on the mitochondrial gene NDUFV2 and bipolar disorder in the Chinese Han population. J Neural Transm 116 357 361 [26] Washizuka S Iwamoto K Kakiuchi C Bundo M Kato T 2009 Expression of mitochondrial complex I subunit gene NDUFV2 in the lymphoblastoid cells derived from patients with bipolar disorder and schizophrenia. Neurosci Res 63 199 204 [27] Xu C Li PP Kennedy JL Green M Hughes B 2008 Further support for association of the mitochondrial complex I subunit gene NDUFV2 with bipolar disorder. Bipolar Disord 10 105 110 [28] Ben-Shachar D Karry R 2007 Sp1 expression is disrupted in schizophrenia; a possible mechanism for the abnormal expression of mitochondrial complex I genes, NDUFV1 and NDUFV2. PLoS One 2 e817 [29] Lazarou M McKenzie M Ohtake A Thorburn DR Ryan MT 2007 Analysis of the assembly profiles for mitochondrial- and nuclear-DNA-encoded subunits into complex I. Mol Cell Biol 27 4228 4237 [30] Nakatani N Hattori E Ohnishi T Dean B Iwayama Y 2006 Genome-wide expression analysis detects eight genes with robust alterations specific to bipolar I disorder: relevance to neuronal network perturbation. Hum Mol Genet 15 1949 1962 [31] Spires TL Molnar Z Kind PC Cordery PM Upton AL 2005 Activity-dependent regulation of synapse and dendritic spine morphology in developing barrel cortex requires phospholipase C-beta1 signalling. Cereb Cortex 15 385 393 [32] Litosch I 2002 Novel mechanisms for feedback regulation of phospholipase C-beta activity. IUBMB Life 54 253 260 [33] Bohm D Schwegler H Kotthaus L Nayernia K Rickmann M 2002 Disruption of PLC-beta 1-mediated signal transduction in mutant mice causes age-dependent hippocampal mossy fiber sprouting and neurodegeneration. Mol Cell Neurosci 21 584 601 [34] Hannan AJ Blakemore C Katsnelson A Vitalis T Huber KM 2001 PLC-beta1, activated via mGluRs, mediates activity-dependent differentiation in cerebral cortex. Nat Neurosci 4 282 288 [35] Tiveci S Akin A Cakir T Saybasili H Ulgen K 2005 Modelling of calcium dynamics in brain energy metabolism and Alzheimer's disease. Comput Biol Chem 29 151 162 [36] Moreira PI Santos MS Seica R Oliveira CR 2007 Brain mitochondrial dysfunction as a link between Alzheimer's disease and diabetes. J Neurol Sci 257 206 214 [37] Laughton JD Bittar P Charnay Y Pellerin L Kovari E 2007 Metabolic compartmentalization in the human cortex and hippocampus: evidence for a cell- and region-specific localization of lactate dehydrogenase 5 and pyruvate dehydrogenase. BMC Neurosci 8 35 [38] Landfield PW Blalock EM Chen KC Porter NM 2007 A new glucocorticoid hypothesis of brain aging: implications for Alzheimer's disease. Curr Alzheimer Res 4 205 212 [39] Elgh E Lindqvist Astot A Fagerlund M Eriksson S Olsson T 2006 Cognitive dysfunction, hippocampal atrophy and glucocorticoid feedback in Alzheimer's disease. Biol Psychiatry 59 155 161 [40] Bao AM Meynen G Swaab DF 2008 The stress system in depression and neurodegeneration: focus on the human hypothalamus. Brain Res Rev 57 531 553 [41] Lee HK Kumar P Fu Q Rosen KM Querfurth HW 2009 The insulin/Akt signaling pathway is targeted by intracellular beta-amyloid. Mol Biol Cell 20 1533 1544 [42] Escribano L Simon AM Perez-Mediavilla A Salazar-Colocho P Del Rio J 2009 Rosiglitazone reverses memory decline and hippocampal glucocorticoid receptor down-regulation in an Alzheimer's disease mouse model. Biochem Biophys Res Commun 379 406 410 [43] Bonomo SM Rigamonti AE Giunta M Galimberti D Guaita A 2009 Menopausal transition: a possible risk factor for brain pathologic events. Neurobiol Aging 30 71 80 [44] Aisa B Gil-Bea FJ Marcos B Tordera R Lasheras B 2009 Neonatal stress affects vulnerability of cholinergic neurons and cognition in the rat: Involvement of the HPA axis. Psychoneuroendocrinology [45] Sotiropoulos I Cerqueira JJ Catania C Takashima A Sousa N 2008 Stress and glucocorticoid footprints in the brain-the path from depression to Alzheimer's disease. Neurosci Biobehav Rev 32 1161 1173 [46] Jing H Iwasaki Y Nishiyama M Taguchi T Tsugita M 2008 Multisignal regulation of the rat NMDA1 receptor subunit gene–a pivotal role of glucocorticoid-dependent transcription. Life Sci 82 1137 1141 [47] White LD Cory-Slechta DA Gilbert ME Tiffany-Castiglioni E Zawia NH 2007 New and evolving concepts in the neurotoxicology of lead. Toxicol Appl Pharmacol 225 1 27 [48] Green KN Billings LM Roozendaal B McGaugh JL LaFerla FM 2006 Glucocorticoids increase amyloid-beta and tau pathology in a mouse model of Alzheimer's disease. J Neurosci 26 9047 9056 [49] de Quervain DJ Poirier R Wollmer MA Grimaldi LM Tsolaki M 2004 Glucocorticoid-related genetic susceptibility for Alzheimer's disease. Hum Mol Genet 13 47 52 [50] Dai J Buijs R Swaab D 2004 Glucocorticoid hormone (cortisol) affects axonal transport in human cortex neurons but shows resistance in Alzheimer's disease. Br J Pharmacol 143 606 610 [51] Polleri A Gianelli MV Murialdo G 2002 Dementia: a neuroendocrine perspective. J Endocrinol Invest 25 73 83 [52] Chen H Sun S Mei Y Liu C Liu A 2002 The effect of beta-amyloid on neurons and the influence of glucocorticoid and age on such effect. J Huazhong Univ Sci Technolog Med Sci 22 250 252 [53] Aisen PS 2002 The potential of anti-inflammatory drugs for the treatment of Alzheimer's disease. Lancet Neurol 1 279 284 [54] Rasmuson S Andrew R Nasman B Seckl JR Walker BR 2001 Increased glucocorticoid production and altered cortisol metabolism in women with mild to moderate Alzheimer's disease. Biol Psychiatry 49 547 552 [55] Pedersen WA McCullers D Culmsee C Haughey NJ Herman JP 2001 Corticotropin-releasing hormone protects neurons against insults relevant to the pathogenesis of Alzheimer's disease. Neurobiol Dis 8 492 503 [56] Dubois M Lalonde R Julien JP Strazielle C 2005 Mice with the deleted neurofilament of low-molecular-weight (Nefl) gene: 1. Effects on regional brain metabolism. J Neurosci Res 80 741 750 [57] Jordanova A De Jonghe P Boerkoel CF Takashima H De Vriendt E 2003 Mutations in the neurofilament light chain gene (NEFL) cause early onset severe Charcot-Marie-Tooth disease. Brain 126 590 597 [58] Abe A Numakura C Saito K Koide H Oka N 2009 Neurofilament light chain polypeptide gene mutations in Charcot-Marie-Tooth disease: nonsense mutation probably causes a recessive phenotype. J Hum Genet 54 94 97 [59] Tradewell ML Durham HD Mushynski WE Gentil BJ 2009 Mitochondrial and axonal abnormalities precede disruption of the neurofilament network in a model of charcot-marie-tooth disease type 2E and are prevented by heat shock proteins in a mutant-specific fashion. J Neuropathol Exp Neurol 68 642 652 [60] Evgrafov OV Mersiyanova I Irobi J Van Den Bosch L Dierick I 2004 Mutant small heat-shock protein 27 causes axonal Charcot-Marie-Tooth disease and distal hereditary motor neuropathy. Nat Genet 36 602 606 [61] Nakagawa M Takashima H 2004 [Update on hereditary neuropathy]. Rinsho Shinkeigaku 44 991 994 [62] Takashima H 2006 [Molecular genetics of inherited neuropathies]. Rinsho Shinkeigaku 46 1 18 [63] Lus G Nelis E Jordanova A Lofgren A Cavallaro T 2003 Charcot-Marie-Tooth disease with giant axons: a clinicopathological and genetic entity. Neurology 61 988 990 [64] Saba R Goodman CD Huzarewich RL Robertson C Booth SA 2008 A miRNA signature of prion induced neurodegeneration. PLoS One 3 e3652 [65] Sorensen G Medina S Parchaliuk D Phillipson C Robertson C 2008 Comprehensive transcriptional profiling of prion infection in mouse models reveals networks of responsive genes. BMC Genomics 9 114 [66] Heese K Nagai Y Sawada T 2001 Identification of a new synaptic vesicle protein 2B mRNA transcript which is up-regulated in neurons by amyloid beta peptide fragment (1–42). Biochem Biophys Res Commun 289 924 928 [67] Heese K Nagai Y Sawada T 2002 The 3′ untranslated region of the new rat synaptic vesicle protein 2B mRNA transcript inhibits translational efficiency. Brain Res Mol Brain Res 104 127 131 [68] Morgans CW Kensel-Hammes P Hurley JB Burton K Idzerda R 2009 Loss of the Synaptic Vesicle Protein SV2B results in reduced neurotransmission and altered synaptic vesicle protein expression in the retina. PLoS One 4 e5230 [69] Lazzell DR Belizaire R Thakur P Sherry DM Janz R 2004 SV2B regulates synaptotagmin 1 by direct interaction. J Biol Chem 279 52124 52131 [70] Veinbergs I Mante M Jung MW Van Uden E Masliah E 1999 Synaptotagmin and synaptic transmission alterations in apolipoprotein E-deficient mice. Prog Neuropsychopharmacol Biol Psychiatry 23 519 531 [71] Davidsson P Blennow K 1998 Neurochemical dissection of synaptic pathology in Alzheimer's disease. Int Psychogeriatr 10 11 23 [72] Ferrer I Marti E Tortosa A Blasi J 1998 Dystrophic neurites of senile plaques are defective in proteins involved in exocytosis and neurotransmission. J Neuropathol Exp Neurol 57 218 225 [73] Shimohama S Kamiya S Taniguchi T Akagawa K Kimura J 1997 Differential involvement of synaptic vesicle and presynaptic plasma membrane proteins in Alzheimer's disease. Biochem Biophys Res Commun 236 239 242 [74] Davidsson P Jahn R Bergquist J Ekman R Blennow K 1996 Synaptotagmin, a synaptic vesicle protein, is present in human cerebrospinal fluid: a new biochemical marker for synaptic pathology in Alzheimer disease? Mol Chem Neuropathol 27 195 210 [75] Reddy PH Mani G Park BS Jacques J Murdoch G 2005 Differential loss of synaptic proteins in Alzheimer's disease: implications for synaptic dysfunction. J Alzheimers Dis 7 103 117 discussion 173–180 [76] Kirikoshi H Katoh M 2002 Expression of WNT7A in human normal tissues and cancer, and regulation of WNT7A and WNT7B in human cancer. Int J Oncol 21 895 900 [77] Wang Y Liu S Zhu H Zhang W Zhang G 2008 FRAT1 overexpression leads to aberrant activation of beta-catenin/TCF pathway in esophageal squamous cell carcinoma. Int J Cancer 123 561 568 [78] Hongisto V Vainio JC Thompson R Courtney MJ Coffey ET 2008 The Wnt pool of glycogen synthase kinase 3beta is critical for trophic-deprivation-induced neuronal death. Mol Cell Biol 28 1515 1527 [79] Hagen T Cross DA Culbert AA West A Frame S 2006 FRAT1, a substrate-specific regulator of glycogen synthase kinase-3 activity, is a cellular substrate of protein kinase A. J Biol Chem 281 35021 35029 [80] Hongisto V Smeds N Brecht S Herdegen T Courtney MJ 2003 Lithium blocks the c-Jun stress response and protects neurons via its action on glycogen synthase kinase 3. Mol Cell Biol 23 6027 6036 [81] Hino S Michiue T Asashima M Kikuchi A 2003 Casein kinase I epsilon enhances the binding of Dvl-1 to Frat-1 and is essential for Wnt-3a-induced accumulation of beta-catenin. J Biol Chem 278 14066 14073 [82] Hay E Faucheu C Suc-Royer I Touitou R Stiot V 2005 Interaction between LRP5 and Frat1 mediates the activation of the Wnt canonical pathway. J Biol Chem 280 13616 13623 [83] Fraser E Young N Dajani R Franca-Koh J Ryves J 2002 Identification of the Axin and Frat binding region of glycogen synthase kinase-3. J Biol Chem 277 2176 2185 [84] Franca-Koh J Yeo M Fraser E Young N Dale TC 2002 The regulation of glycogen synthase kinase-3 nuclear export by Frat/GBP. J Biol Chem 277 43844 43848 [85] Saitoh T Moriwaki J Koike J Takagi A Miwa T 2001 Molecular cloning and characterization of FRAT2, encoding a positive regulator of the WNT signaling pathway. Biochem Biophys Res Commun 281 815 820 [86] Killick R Pollard CC Asuni AA Mudher AK Richardson JC 2001 Presenilin 1 independently regulates beta-catenin stability and transcriptional activity. J Biol Chem 276 48554 48561 [87] Culbert AA Brown MJ Frame S Hagen T Cross DA 2001 GSK-3 inhibition by adenoviral FRAT1 overexpression is neuroprotective and induces Tau dephosphorylation and beta-catenin stabilisation without elevation of glycogen synthase activity. FEBS Lett 507 288 294 [88] Crowder RJ Freeman RS 2000 Glycogen synthase kinase-3 beta activity is critical for neuronal death caused by inhibiting phosphatidylinositol 3-kinase or Akt but not for death caused by nerve growth factor withdrawal. J Biol Chem 275 34266 34271 [89] Katoh M 2007 Networking of WNT, FGF, Notch, BMP, and Hedgehog signaling pathways during carcinogenesis. Stem Cell Rev 3 30 38 [90] Liu C Wang Y Smallwood PM Nathans J 2008 An essential role for Frizzled5 in neuronal survival in the parafascicular nucleus of the thalamus. J Neurosci 28 5641 5653 [91] Carmon KS Loose DS 2008 Wnt7a interaction with Fzd5 and detection of signaling activation using a split eGFP. Biochem Biophys Res Commun 368 285 291 [92] Steventon B Araya C Linker C Kuriyama S Mayor R 2009 Differential requirements of BMP and Wnt signalling during gastrulation and neurulation define two steps in neural crest induction. Development 136 771 779 [93] Lee MY Lim HW Lee SH Han HJ 2009 Smad, PI3K/Akt, and Wnt-Dependent Signaling Pathways are Involved in BMP-4-Induced ES Cell Self-Renewal. Stem Cells [94] Kelberman D de Castro SC Huang S Crolla JA Palmer R 2008 SOX2 plays a critical role in the pituitary, forebrain, and eye during human embryonic development. J Clin Endocrinol Metab 93 1865 1873 [95] Shi Y Sun G Zhao C Stewart R 2008 Neural stem cell self-renewal. Crit Rev Oncol Hematol 65 43 53 [96] Linker C Stern CD 2004 Neural induction requires BMP inhibition only as a late step, and involves signals other than FGF and Wnt antagonists. Development 131 5671 5681 [97] Tam WL Lim CY Han J Zhang J Ang YS 2008 T-cell factor 3 regulates embryonic stem cell pluripotency and self-renewal by the transcriptional control of multiple lineage pathways. Stem Cells 26 2019 2031 [98] Ruzov A Hackett JA Prokhortchouk A Reddington JP Madej MJ 2009 The interaction of xKaiso with xTcf3: a revised model for integration of epigenetic and Wnt signalling pathways. Development 136 723 727 [99] Fancy SP Baranzini SE Zhao C Yuk DI Irvine KA 2009 Dysregulation of the Wnt pathway inhibits timely myelination and remyelination in the mammalian CNS. Genes Dev 23 1571 1585 [100] Koslowski MJ Kubler I Chamaillard M Schaeffeler E Reinisch W 2009 Genetic variants of Wnt transcription factor TCF-4 (TCF7L2) putative promoter region are associated with small intestinal Crohn's disease. PLoS ONE 4 e4496 [101] Schinner S 2009 Wnt-signalling and the metabolic syndrome. Horm Metab Res 41 159 163 [102] Nazwar TA Glassmann A Schilling K 2009 Expression and molecular diversity of Tcf7l2 in the developing murine cerebellum and brain. J Neurosci Res 87 1532 1546 [103] Ye F Chen Y Hoang T Montgomery RL Zhao XH 2009 HDAC1 and HDAC2 regulate oligodendrocyte differentiation by disrupting the beta-catenin-TCF interaction. Nat Neurosci 12 829 838 [104] Murray KD Rubin CM Jones EG Chalupa LM 2008 Molecular correlates of laminar differences in the macaque dorsal lateral geniculate nucleus. J Neurosci 28 12010 12022 [105] Murray KD Choudary PV Jones EG 2007 Nucleus- and cell-specific gene expression in monkey thalamus. Proc Natl Acad Sci U S A 104 1989 1994 [106] Lukas J Mazna P Valenta T Doubravska L Pospichalova V 2009 Dazap2 modulates transcription driven by the Wnt effector TCF-4. Nucleic Acids Res 37 3007 3020 [107] Lepourcelet M Shivdasani RA 2002 Characterization of a novel mammalian Groucho isoform and its role in transcriptional regulation. J Biol Chem 277 47732 47740 [108] Bachar-Dahan L Goltzmann J Yaniv A Gazit A 2006 Engrailed-1 negatively regulates beta-catenin transcriptional activity by destabilizing beta-catenin via a glycogen synthase kinase-3beta-independent pathway. Mol Biol Cell 17 2572 2580 [109] Daniels DL Weis WI 2005 Beta-catenin directly displaces Groucho/TLE repressors from Tcf/Lef in Wnt-mediated transcription activation. Nat Struct Mol Biol 12 364 371 [110] Bauer J Plaschke K Martin E Bardenheuer HJ Hoyer S 1997 Causes and consequences of neuronal energy deficit in sporadic Alzheimer's disease. Ann N Y Acad Sci 826 379 381 [111] Lu Y He X Zhong S 2007 Cross-species microarray analysis with the OSCAR system suggests an INSR→Pax6→NQO1 neuro-protective pathway in aging and Alzheimer's disease. Nucleic Acids Res 35 W105 114 [112] Wang H Wang R Zhao Z Ji Z Xu S 2009 Coexistences of insulin signaling-related proteins and choline acetyltransferase in neurons. Brain Res 1249 237 243 [113] Frolich L Blum-Degen D Riederer P Hoyer S 1999 A disturbance in the neuronal insulin receptor signal transduction in sporadic Alzheimer's disease. Ann N Y Acad Sci 893 290 293 [114] Hoyer S 1994 Age as risk factor for sporadic dementia of the Alzheimer type? Ann N Y Acad Sci 719 248 256 [115] Hoyer S Lannert H 1999 Inhibition of the neuronal insulin receptor causes Alzheimer-like disturbances in oxidative/energy brain metabolism and in behavior in adult rats. Ann N Y Acad Sci 893 301 303 [116] Hoyer S Lee SK Loffler T Schliebs R 2000 Inhibition of the neuronal insulin receptor. An in vivo model for sporadic Alzheimer disease? Ann N Y Acad Sci 920 256 258 [117] Hoyer S 1996 Oxidative metabolism deficiencies in brains of patients with Alzheimer's disease. Acta Neurol Scand Suppl 165 18 24 [118] Verkhratsky A Toescu EC 2003 Endoplasmic reticulum Ca(2+) homeostasis and neuronal death. J Cell Mol Med 7 351 361 [119] Norris CM Kadish I Blalock EM Chen KC Thibault V 2005 Calcineurin triggers reactive/inflammatory processes in astrocytes and is upregulated in aging and Alzheimer's models. J Neurosci 25 4649 4658 [120] Bojarski L Herms J Kuznicki J 2008 Calcium dysregulation in Alzheimer's disease. Neurochem Int 52 621 633 [121] Cowburn RF Popescu BO Ankarcrona M Dehvari N Cedazo-Minguez A 2007 Presenilin-mediated signal transduction. Physiol Behav 92 93 97 [122] Giacomello M Barbiero L Zatti G Squitti R Binetti G 2005 Reduction of Ca2+ stores and capacitative Ca2+ entry is associated with the familial Alzheimer's disease presenilin-2 T122R mutation and anticipates the onset of dementia. Neurobiol Dis 18 638 648 [123] Peers C Smith IF Boyle JP Pearson HA 2004 Remodelling of Ca2+ homeostasis in type I cortical astrocytes by hypoxia: evidence for association with Alzheimer's disease. Biol Chem 385 285 289 [124] LaFerla FM 2002 Calcium dyshomeostasis and intracellular signalling in Alzheimer's disease. Nat Rev Neurosci 3 862 872 [125] Eckert A Forstl H Zerfass R Hennerici M Muller WE 1997 Free intracellular calcium in peripheral cells in Alzheimer's disease. Neurobiol Aging 18 281 284 [126] Schubert P Ogata T Miyazaki H Marchini C Ferroni S 1998 Pathological immuno-reactions of glial cells in Alzheimer's disease and possible sites of interference. J Neural Transm Suppl 54 167 174 [127] Eckert A Forstl H Zerfass R Hartmann H Muller WE 1996 Lymphocytes and neutrophils as peripheral models to study the effect of beta-amyloid on cellular calcium signalling in Alzheimer's disease. Life Sci 59 499 510 [128] Salkovic-Petrisic M Hoyer S 2007 Central insulin resistance as a trigger for sporadic Alzheimer-like pathology: an experimental approach. J Neural Transm Suppl 217 233 [129] Qin W Zhao W Ho L Wang J Walsh K 2008 Regulation of forkhead transcription factor FoxO3a contributes to calorie restriction-induced prevention of Alzheimer's disease-type amyloid neuropathology and spatial memory deterioration. Ann N Y Acad Sci 1147 335 347 [130] Carro E Trejo JL Spuch C Bohl D Heard JM 2006 Blockade of the insulin-like growth factor I receptor in the choroid plexus originates Alzheimer's-like neuropathology in rodents: new cues into the human disease? Neurobiol Aging 27 1618 1631 [131] Rhein V Eckert A 2007 Effects of Alzheimer's amyloid-beta and tau protein on mitochondrial function – role of glucose metabolism and insulin signalling. Arch Physiol Biochem 113 131 141 [132] Abbas T Faivre E Holscher C 2009 Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: Interaction between type 2 diabetes and Alzheimer's disease. Behav Brain Res [133] Castri P Iacovelli L De Blasi A Giubilei F Moretti A 2007 Reduced insulin-induced phosphatidylinositol-3-kinase activation in peripheral blood mononuclear leucocytes from patients with Alzheimer's disease. Eur J Neurosci 26 2469 2472 [134] Li L Holscher C 2007 Common pathological processes in Alzheimer disease and type 2 diabetes: a review. Brain Res Rev 56 384 402 [135] Salkovic-Petrisic M Tribl F Schmidt M Hoyer S Riederer P 2006 Alzheimer-like changes in protein kinase B and glycogen synthase kinase-3 in rat frontal cortex and hippocampus after damage to the insulin signalling pathway. J Neurochem 96 1005 1015 [136] Biessels GJ Kappelle LJ 2005 Increased risk of Alzheimer's disease in Type II diabetes: insulin resistance of the brain or insulin-induced amyloid pathology? Biochem Soc Trans 33 1041 1044 [137] Nelson TJ Alkon DL 2005 Insulin and cholesterol pathways in neuronal function, memory and neurodegeneration. Biochem Soc Trans 33 1033 1036 [138] Biessels GJ Bravenboer B Gispen WH 2004 Glucose, insulin and the brain: modulation of cognition and synaptic plasticity in health and disease: a preface. Eur J Pharmacol 490 1 4 [139] Morgan C Colombres M Nunez MT Inestrosa NC 2004 Structure and function of amyloid in Alzheimer's disease. Prog Neurobiol 74 323 349 [140] Zhao WQ Townsend M 2009 Insulin resistance and amyloidogenesis as common molecular foundation for type 2 diabetes and Alzheimer's disease. Biochim Biophys Acta 1792 482 496 [141] De Felice FG Vieira MN Bomfim TR Decker H Velasco PT 2009 Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers. Proc Natl Acad Sci U S A 106 1971 1976 [142] Chen Y Zhou K Wang R Liu Y Kwak YD 2009 Antidiabetic drug metformin (GlucophageR) increases biogenesis of Alzheimer's amyloid peptides via up-regulating BACE1 transcription. Proc Natl Acad Sci U S A 106 3907 3912 [143] Puglielli L 2008 Aging of the brain, neurotrophin signaling, and Alzheimer's disease: is IGF1-R the common culprit? Neurobiol Aging 29 795 811 [144] Jolivalt CG Lee CA Beiswenger KK Smith JL Orlov M 2008 Defective insulin signaling pathway and increased glycogen synthase kinase-3 activity in the brain of diabetic mice: parallels with Alzheimer's disease and correction by insulin. J Neurosci Res 86 3265 3274 [145] de Tullio MB Morelli L Castano EM 2008 The irreversible binding of amyloid peptide substrates to insulin-degrading enzyme: a biological perspective. Prion 2 51 56 [146] Dore S Kar S Quirion R 1997 Insulin-like growth factor I protects and rescues hippocampal neurons against beta-amyloid- and human amylin-induced toxicity. Proc Natl Acad Sci U S A 94 4772 4777 [147] Gandy S Czernik AJ Greengard P 1988 Phosphorylation of Alzheimer disease amyloid precursor peptide by protein kinase C and Ca2+/calmodulin-dependent protein kinase II. Proc Natl Acad Sci U S A 85 6218 6221 [148] Deutsch SI Rosse RB Lakshman RM 2006 Dysregulation of tau phosphorylation is a hypothesized point of convergence in the pathogenesis of alzheimer's disease, frontotemporal dementia and schizophrenia with therapeutic implications. Prog Neuropsychopharmacol Biol Psychiatry 30 1369 1380 [149] Wickelgren I 1998 Tracking insulin to the mind. Science 280 517 519 [150] Jafferali S Dumont Y Sotty F Robitaille Y Quirion R 2000 Insulin-like growth factor-I and its receptor in the frontal cortex, hippocampus, and cerebellum of normal human and alzheimer disease brains. Synapse 38 450 459 [151] Brune S Kolsch H Ptok U Majores M Schulz A 2003 Polymorphism in the peroxisome proliferator-activated receptor alpha gene influences the risk for Alzheimer's disease. J Neural Transm 110 1041 1050 [152] Frolich L Blum-Degen D Bernstein HG Engelsberger S Humrich J 1998 Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease. J Neural Transm 105 423 438 [153] Grunblatt E Hoyer S Riederer P 2004 Gene expression profile in streptozotocin rat model for sporadic Alzheimer's disease. J Neural Transm 111 367 386 [154] Hoyer S 1998 Is sporadic Alzheimer disease the brain type of non-insulin dependent diabetes mellitus? A challenging hypothesis. J Neural Transm 105 415 422 [155] Hoyer S 2002 The aging brain. Changes in the neuronal insulin/insulin receptor signal transduction cascade trigger late-onset sporadic Alzheimer disease (SAD). A mini-review. J Neural Transm 109 991 1002 [156] Hoyer S 2002 The brain insulin signal transduction system and sporadic (type II) Alzheimer disease: an update. J Neural Transm 109 341 360 [157] Hoyer S Nitsch R 1989 Cerebral excess release of neurotransmitter amino acids subsequent to reduced cerebral glucose metabolism in early-onset dementia of Alzheimer type. J Neural Transm 75 227 232 [158] Xu WH Huber R Riepe MW 2007 Gender- and region-specific expression of insulin receptor protein in mouse brain: effect of mild inhibition of oxidative phosphorylation. J Neural Transm 114 373 377 [159] Hoyer S Nitsch R Oesterreich K 1991 Predominant abnormality in cerebral glucose utilization in late-onset dementia of the Alzheimer type: a cross-sectional comparison against advanced late-onset and incipient early-onset cases. J Neural Transm Park Dis Dement Sect 3 1 14 [160] Blum-Degen D Frolich L Hoyer S Riederer P 1995 Altered regulation of brain glucose metabolism as a cause of neurodegenerative disorders? J Neural Transm Suppl 46 139 147 [161] Hoyer S 1997 Models of Alzheimer's disease: cellular and molecular aspects. J Neural Transm Suppl 49 11 21 [162] Hoyer S Muller D Plaschke K 1994 Desensitization of brain insulin receptor. Effect on glucose/energy and related metabolism. J Neural Transm Suppl 44 259 268 [163] Aguado-Llera D Arilla-Ferreiro E Campos-Barros A Puebla-Jimenez L Barrios V 2005 Protective effects of insulin-like growth factor-I on the somatostatinergic system in the temporal cortex of beta-amyloid-treated rats. J Neurochem 92 607 615 [164] Crews FT McElhaney R Freund G Ballinger WE Jr Raizada MK 1992 Insulin-like growth factor I receptor binding in brains of Alzheimer's and alcoholic patients. J Neurochem 58 1205 1210 [165] Hoyer S 1987 Somatostatin and Alzheimer's disease. J Neurol 234 266 267 [166] De Ferrari GV Moon RT 2006 The ups and downs of Wnt signaling in prevalent neurological disorders. Oncogene 25 7545 7553 [167] Balaraman Y Limaye AR Levey AI Srinivasan S 2006 Glycogen synthase kinase 3beta and Alzheimer's disease: pathophysiological and therapeutic significance. Cell Mol Life Sci 63 1226 1235 [168] Widelitz R 2005 Wnt signaling through canonical and non-canonical pathways: recent progress. Growth Factors 23 111 116 [169] Cerpa W Dinamarca MC Inestrosa NC 2008 Structure-function implications in Alzheimer's disease: effect of Abeta oligomers at central synapses. Curr Alzheimer Res 5 233 243 [170] Mercado-Gomez O Hernandez-Fonseca K Villavicencio-Queijeiro A Massieu L Chimal-Monroy J 2008 Inhibition of Wnt and PI3K signaling modulates GSK-3beta activity and induces morphological changes in cortical neurons: role of tau phosphorylation. Neurochem Res 33 1599 1609 [171] Magdesian MH Carvalho MM Mendes FA Saraiva LM Juliano MA 2008 Amyloid-beta binds to the extracellular cysteine-rich domain of Frizzled and inhibits Wnt/beta-catenin signaling. J Biol Chem 283 9359 9368 [172] Esposito G Scuderi C Lu J Savani C De Filippis D 2008 S100B induces tau protein hyperphosphorylation via Dickopff-1 up-regulation and disrupts the Wnt pathway in human neural stem cells. J Cell Mol Med 12 914 927 [173] Ferrero A Cereseto M Sifonios L 2006 [The relationship between the Wnt signaling and the psychiatric diseases]. Vertex 17 165 171 [174] De Ferrari GV Papassotiropoulos A Biechele T Wavrant De-Vrieze F Avila ME 2007 Common genetic variation within the low-density lipoprotein receptor-related protein 6 and late-onset Alzheimer's disease. Proc Natl Acad Sci U S A 104 9434 9439 [175] Inestrosa NC Varela-Nallar L Grabowski CP Colombres M 2007 Synaptotoxicity in Alzheimer's disease: the Wnt signaling pathway as a molecular target. IUBMB Life 59 316 321 [176] Maiese K Chong ZZ Shang YC 2007 Mechanistic insights into diabetes mellitus and oxidative stress. Curr Med Chem 14 1729 1738 [177] Repetto E Yoon IS Zheng H Kang DE 2007 Presenilin 1 regulates epidermal growth factor receptor turnover and signaling in the endosomal-lysosomal pathway. J Biol Chem 282 31504 31516 [178] Fuentealba RA Farias G Scheu J Bronfman M Marzolo MP 2004 Signal transduction during amyloid-beta-peptide neurotoxicity: role in Alzheimer disease. Brain Res Brain Res Rev 47 275 289 [179] Inestrosa NC Urra S Colombres M 2004 Acetylcholinesterase (AChE)–amyloid-beta-peptide complexes in Alzheimer's disease. the Wnt signaling pathway. Curr Alzheimer Res 1 249 254 [180] De Ferrari GV Inestrosa NC 2000 Wnt signaling function in Alzheimer's disease. Brain Res Brain Res Rev 33 1 12 [181] Inestrosa NC Alvarez A Godoy J Reyes A De Ferrari GV 2000 Acetylcholinesterase-amyloid-beta-peptide interaction and Wnt signaling involvement in Abeta neurotoxicity. Acta Neurol Scand Suppl 176 53 59 [182] Small DH 2000 Alzheimer Symposium. Gamma-secretase, presenilins and WNT proteins. IDrugs 3 740 741 [183] De Strooper B Annaert W 2001 Where Notch and Wnt signaling meet. The presenilin hub. J Cell Biol 152 F17 20 [184] Caricasole A Copani A Caruso A Caraci F Iacovelli L 2003 The Wnt pathway, cell-cycle activation and beta-amyloid: novel therapeutic strategies in Alzheimer's disease? Trends Pharmacol Sci 24 233 238 [185] De Ferrari GV Chacon MA Barria MI Garrido JL Godoy JA 2003 Activation of Wnt signaling rescues neurodegeneration and behavioral impairments induced by beta-amyloid fibrils. Mol Psychiatry 8 195 208 [186] Grilli M Ferrari Toninelli G Uberti D Spano P Memo M 2003 Alzheimer's disease linking neurodegeneration with neurodevelopment. Funct Neurol 18 145 148 [187] Selkoe D Kopan R 2003 Notch and Presenilin: regulated intramembrane proteolysis links development and degeneration. Annu Rev Neurosci 26 565 597 [188] Alvarez AR Godoy JA Mullendorff K Olivares GH Bronfman M 2004 Wnt-3a overcomes beta-amyloid toxicity in rat hippocampal neurons. Exp Cell Res 297 186 196 [189] Busby V Goossens S Nowotny P Hamilton G Smemo S 2004 Alpha-T-catenin is expressed in human brain and interacts with the Wnt signaling pathway but is not responsible for linkage to chromosome 10 in Alzheimer's disease. Neuromolecular Med 5 133 146 [190] Caricasole A Copani A Caraci F Aronica E Rozemuller AJ 2004 Induction of Dickkopf-1, a negative modulator of the Wnt pathway, is associated with neuronal degeneration in Alzheimer's brain. J Neurosci 24 6021 6027 [191] Chong ZZ Maiese K 2004 Targeting WNT, protein kinase B, and mitochondrial membrane integrity to foster cellular survival in the nervous system. Histol Histopathol 19 495 504 [192] Toledo EM Colombres M Inestrosa NC 2008 Wnt signaling in neuroprotection and stem cell differentiation. Prog Neurobiol 86 281 296 [193] Boonen RA van Tijn P Zivkovic D 2009 Wnt signaling in Alzheimer's disease: up or down, that is the question. Ageing Res Rev 8 71 82 [194] Cairney CJ Sanguinetti G Ranghini E Chantry AD Nostro MC 2009 A systems biology approach to Down syndrome: identification of Notch/Wnt dysregulation in a model of stem cells aging. Biochim Biophys Acta 1792 353 363 [195] Caricasole A Bakker A Copani A Nicoletti F Gaviraghi G 2005 Two sides of the same coin: Wnt signaling in neurodegeneration and neuro-oncology. Biosci Rep 25 309 327 [196] Lee EO Shin YJ Chong YH 2004 Mechanisms involved in prostaglandin E2-mediated neuroprotection against TNF-alpha: possible involvement of multiple signal transduction and beta-catenin/T-cell factor. J Neuroimmunol 155 21 31 [197] Doble BW Woodgett JR 2003 GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci 116 1175 1186 [198] Anderton BH Dayanandan R Killick R Lovestone S 2000 Does dysregulation of the Notch and wingless/Wnt pathways underlie the pathogenesis of Alzheimer's disease? Mol Med Today 6 54 59 [199] Weihl CC Ghadge GD Kennedy SG Hay N Miller RJ 1999 Mutant presenilin-1 induces apoptosis and downregulates Akt/PKB. J Neurosci 19 5360 5369 [200] Ray A Dhar S Shakya A Ray P Okada Y 2009 SAF-3, a novel splice variant of the SAF-1/MAZ/Pur-1 family, is expressed during inflammation. FEBS J [201] Jordan-Sciutto KL Dragich JM Caltagarone J Hall DJ Bowser R 2000 Fetal Alz-50 clone 1 (FAC1) protein interacts with the Myc-associated zinc finger protein (ZF87/MAZ) and alters its transcriptional activity. Biochemistry 39 3206 3215 [202] Bowden NA Weidenhofer J Scott RJ Schall U Todd J 2006 Preliminary investigation of gene expression profiles in peripheral blood lymphocytes in schizophrenia. Schizophr Res 82 175 183 [203] Bataller L Wade DF Graus F Rosenfeld MR Dalmau J 2003 The MAZ protein is an autoantigen of Hodgkin's disease and paraneoplastic cerebellar dysfunction. Ann Neurol 53 123 127 [204] Sajan FD Martiniuk F Marcus DL Frey WH 2nd Hite R 2007 Apoptotic gene expression in Alzheimer's disease hippocampal tissue. Am J Alzheimers Dis Other Demen 22 319 328 [205] Lim AC Qi RZ 2003 Cyclin-dependent kinases in neural development and degeneration. J Alzheimers Dis 5 329 335 [206] Jordan-Sciutto KL Malaiyandi LM Bowser R 2002 Altered distribution of cell cycle transcriptional regulators during Alzheimer disease. J Neuropathol Exp Neurol 61 358 367 [207] Jordan-Sciutto K Rhodes J Bowser R 2001 Altered subcellular distribution of transcriptional regulators in response to Abeta peptide and during Alzheimer's disease. Mech Ageing Dev 123 11 20 [208] Motonaga K Itoh M Hirayama A Hirano S Becker LE 2001 Up-regulation of E2F-1 in Down's syndrome brain exhibiting neuropathological features of Alzheimer-type dementia. Brain Res 905 250 253 [209] Putzer BM 2006 Targeting E2F1 Death Signaling: Opposing Role in Cancer Control and Neurodegeneration. Discov Med 6 123 127 [210] Strachan GD Koike MA Siman R Hall DJ Jordan-Sciutto KL 2005 E2F1 induces cell death, calpain activation, and MDMX degradation in a transcription independent manner implicating a novel role for E2F1 in neuronal loss in SIV encephalitis. J Cell Biochem 96 728 740 [211] Fortin A MacLaurin JG Arbour N Cregan SP Kushwaha N 2004 The proapoptotic gene SIVA is a direct transcriptional target for the tumor suppressors p53 and E2F1. J Biol Chem 279 28706 28714 [212] Jordan-Sciutto KL Wang G Murphey-Corb M Wiley CA 2002 Cell cycle proteins exhibit altered expression patterns in lentiviral-associated encephalitis. J Neurosci 22 2185 2195 [213] Jordan-Sciutto KL Murray Fenner BA Wiley CA Achim CL 2001 Response of cell cycle proteins to neurotrophic factor and chemokine stimulation in human neuroglia. Exp Neurol 167 205 214 [214] Jordan-Sciutto KL Wang G Murphy-Corb M Wiley CA 2000 Induction of cell-cycle regulators in simian immunodeficiency virus encephalitis. Am J Pathol 157 497 507 [215] Strachan GD Kopp AS Koike MA Morgan KL Jordan-Sciutto KL 2005 Chemokine- and neurotrophic factor-induced changes in E2F1 localization and phosphorylation of the retinoblastoma susceptibility gene product (pRb) occur by distinct mechanisms in murine cortical cultures. Exp Neurol 193 455 468 [216] Verdaguer E Susana Gde A Clemens A Pallas M Camins A 2007 Implication of the transcription factor E2F-1 in the modulation of neuronal apoptosis. Biomed Pharmacother 61 390 399 [217] Ranganathan S Bowser R 2003 Alterations in G(1) to S phase cell-cycle regulators during amyotrophic lateral sclerosis. Am J Pathol 162 823 835 [218] MacManus JP Jian M Preston E Rasquinha I Webster J 2003 Absence of the transcription factor E2F1 attenuates brain injury and improves behavior after focal ischemia in mice. J Cereb Blood Flow Metab 23 1020 1028 [219] Konishi Y Bonni A 2003 The E2F-Cdc2 cell-cycle pathway specifically mediates activity deprivation-induced apoptosis of postmitotic neurons. J Neurosci 23 1649 1658 [220] Cooper-Kuhn CM Vroemen M Brown J Ye H Thompson MA 2002 Impaired adult neurogenesis in mice lacking the transcription factor E2F1. Mol Cell Neurosci 21 312 323 [221] MacGibbon GA Lawlor PA Walton M Sirimanne E Faull RL 1997 Expression of Fos, Jun, and Krox family proteins in Alzheimer's disease. Exp Neurol 147 316 332 [222] Revest JM Di Blasi F Kitchener P Rouge-Pont F Desmedt A 2005 The MAPK pathway and Egr-1 mediate stress-related behavioral effects of glucocorticoids. Nat Neurosci 8 664 672 [223] Illing RB Michler SA Kraus KS Laszig R 2002 Transcription factor modulation and expression in the rat auditory brainstem following electrical intracochlear stimulation. Exp Neurol 175 226 244 [224] Bozon B Davis S Laroche S 2003 A requirement for the immediate early gene zif268 in reconsolidation of recognition memory after retrieval. Neuron 40 695 701 [225] Knapska E Kaczmarek L 2004 A gene for neuronal plasticity in the mammalian brain: Zif268/Egr-1/NGFI-A/Krox-24/TIS8/ZENK? Prog Neurobiol 74 183 211 [226] Bozon B Kelly A Josselyn SA Silva AJ Davis S 2003 MAPK, CREB and zif268 are all required for the consolidation of recognition memory. Philos Trans R Soc Lond B Biol Sci 358 805 814 [227] Alder J Thakker-Varia S Bangasser DA Kuroiwa M Plummer MR 2003 Brain-derived neurotrophic factor-induced gene expression reveals novel actions of VGF in hippocampal synaptic plasticity. J Neurosci 23 10800 10808 [228] Illing RB 2001 Activity-dependent plasticity in the adult auditory brainstem. Audiol Neurootol 6 319 345 [229] Poirier R Cheval H Mailhes C Garel S Charnay P 2008 Distinct functions of egr gene family members in cognitive processes. Front Neurosci 2 47 55 [230] Poirier R Cheval H Mailhes C Charnay P Davis S 2007 Paradoxical role of an egr transcription factor family member, egr2/krox20, in learning and memory. Front Behav Neurosci 1 6 [231] Desjardins S Mayo W Vallee M Hancock D Le Moal M 1997 Effect of aging on the basal expression of c-Fos, c-Jun, and Egr-1 proteins in the hippocampus. Neurobiol Aging 18 37 44 [232] Dong S Replogle KL Hasadsri L Imai BS Yau PM 2009 Discrete molecular states in the brain accompany changing responses to a vocal signal. Proc Natl Acad Sci U S A 106 11364 11369 [233] Velho TA Mello CV 2008 Synapsins are late activity-induced genes regulated by birdsong. J Neurosci 28 11871 11882 [234] Velho TA Lovell P Mello CV 2007 Enriched expression and developmental regulation of the middle-weight neurofilament (NF-M) gene in song control nuclei of the zebra finch. J Comp Neurol 500 477 497 [235] Zhu MX 2005 Multiple roles of calmodulin and other Ca(2+)-binding proteins in the functional regulation of TRP channels. Pflugers Arch 451 105 115 [236] Zhou H Yu K McCoy KL Lee A 2005 Molecular mechanism for divergent regulation of Cav1.2 Ca2+ channels by calmodulin and Ca2+-binding protein-1. J Biol Chem 280 29612 29619 [237] Wingard JN Chan J Bosanac I Haeseleer F Palczewski K 2005 Structural analysis of Mg2+ and Ca2+ binding to CaBP1, a neuron-specific regulator of calcium channels. J Biol Chem 280 37461 37470 [238] Li C Chan J Haeseleer F Mikoshiba K Palczewski K 2009 Structural insights into Ca2+-dependent regulation of inositol 1,4,5-trisphosphate receptors by CaBP1. J Biol Chem 284 2472 2481 [239] Chen ML Chen YC Peng IW Kang RL Wu MP 2008 Ca2+ binding protein-1 inhibits Ca2+ currents and exocytosis in bovine chromaffin cells. J Biomed Sci 15 169 181 [240] Tippens AL Lee A 2007 Caldendrin, a neuron-specific modulator of Cav/1.2 (L-type) Ca2+ channels. J Biol Chem 282 8464 8473 [241] Haynes LP Fitzgerald DJ Wareing B O'Callaghan DW Morgan A 2006 Analysis of the interacting partners of the neuronal calcium-binding proteins L-CaBP1, hippocalcin, NCS-1 and neurocalcin delta. Proteomics 6 1822 1832 [242] Lautermilch NJ Few AP Scheuer T Catterall WA 2005 Modulation of CaV2.1 channels by the neuronal calcium-binding protein visinin-like protein-2. J Neurosci 25 7062 7070 [243] Haeseleer F Imanishi Y Maeda T Possin DE Maeda A 2004 Essential role of Ca2+-binding protein 4, a Cav1.4 channel regulator, in photoreceptor synaptic function. Nat Neurosci 7 1079 1087 [244] Eran A Graham KR Vatalaro K McCarthy J Collins C 2009 Comment on “Autistic-like phenotypes in Cadps2-knockout mice and aberrant CADPS2 splicing in autistic patients”. J Clin Invest 119 679 680 author reply 680–671 [245] Sadakata T Furuichi T 2009 Developmentally Regulated Ca(2+)-Dependent Activator Protein for Secretion 2 (CAPS2) is Involved in BDNF Secretion and is Associated with Autism Susceptibility. Cerebellum [246] Sadakata T Washida M Furuichi T 2007 Alternative splicing variations in mouse CAPS2: differential expression and functional properties of splicing variants. BMC Neurosci 8 25 [247] Sadakata T Washida M Iwayama Y Shoji S Sato Y 2007 Autistic-like phenotypes in Cadps2-knockout mice and aberrant CADPS2 splicing in autistic patients. J Clin Invest 117 931 943 [248] Sadakata T Kakegawa W Mizoguchi A Washida M Katoh-Semba R 2007 Impaired cerebellar development and function in mice lacking CAPS2, a protein involved in neurotrophin release. J Neurosci 27 2472 2482 [249] Sadakata T Washida M Morita N Furuichi T 2007 Tissue distribution of Ca2+-dependent activator protein for secretion family members CAPS1 and CAPS2 in mice. J Histochem Cytochem 55 301 311 [250] Feng G Krejci E Molgo J Cunningham JM Massoulie J 1999 Genetic analysis of collagen Q: roles in acetylcholinesterase and butyrylcholinesterase assembly and in synaptic structure and function. J Cell Biol 144 1349 1360 [251] Fritschy JM Schweizer C Brunig I Luscher B 2003 Pre- and post-synaptic mechanisms regulating the clustering of type A gamma-aminobutyric acid receptors (GABAA receptors). Biochem Soc Trans 31 889 892 [252] Banks GB Chamberlain JS Froehner SC 2009 Truncated dystrophins can influence neuromuscular synapse structure. Mol Cell Neurosci 40 433 441 [253] Fradkin LG Baines RA van der Plas MC Noordermeer JN 2008 The dystrophin Dp186 isoform regulates neurotransmitter release at a central synapse in Drosophila. J Neurosci 28 5105 5114 [254] Bogdanik L Framery B Frolich A Franco B Mornet D 2008 Muscle dystroglycan organizes the postsynapse and regulates presynaptic neurotransmitter release at the Drosophila neuromuscular junction. PLoS One 3 e2084 [255] Minatel E Neto HS Marques MJ 2003 Acetylcholine receptor distribution and synapse elimination at the developing neuromuscular junction of mdx mice. Muscle Nerve 28 561 569 [256] Marchand S Stetzkowski-Marden F Cartaud J 2001 Differential targeting of components of the dystrophin complex to the postsynaptic membrane. Eur J Neurosci 13 221 229 [257] Monroig O Rotllant J Sanchez E Cerda-Reverter JM Tocher DR 2009 Expression of long-chain polyunsaturated fatty acid (LC-PUFA) biosynthesis genes during zebrafish Danio rerio early embryogenesis. Biochim Biophys Acta [258] Fernandez M Segura MF Sole C Colino A Comella JX 2007 Lifeguard/neuronal membrane protein 35 regulates Fas ligand-mediated apoptosis in neurons via microdomain recruitment. J Neurochem 103 190 203 [259] Reimers K Choi CY Mau-Thek E Vogt PM 2006 Sequence analysis shows that Lifeguard belongs to a new evolutionarily conserved cytoprotective family. Int J Mol Med 18 729 734 [260] Chen W Lee J Cho SY Fine HA 2004 Proteasome-mediated destruction of the cyclin a/cyclin-dependent kinase 2 complex suppresses tumor cell growth in vitro and in vivo. Cancer Res 64 3949 3957 [261] Somia NV Schmitt MJ Vetter DE Van Antwerp D Heinemann SF 1999 LFG: an anti-apoptotic gene that provides protection from Fas-mediated cell death. Proc Natl Acad Sci U S A 96 12667 12672 [262] Lopez-Bendito G Shigemoto R Kulik A Paulsen O Fairen A 2002 Expression and distribution of metabotropic GABA receptor subtypes GABABR1 and GABABR2 during rat neocortical development. Eur J Neurosci 15 1766 1778 [263] Fatemi SH Folsom TD Reutiman TJ Thuras PD 2009 Expression of GABA(B) receptors is altered in brains of subjects with autism. Cerebellum 8 64 69 [264] Correa SA Munton R Nishimune A Fitzjohn S Henley JM 2004 Development of GABAB subunits and functional GABAB receptors in rat cultured hippocampal neurons. Neuropharmacology 47 475 484 [265] Straessle A Loup F Arabadzisz D Ohning GV Fritschy JM 2003 Rapid and long-term alterations of hippocampal GABAB receptors in a mouse model of temporal lobe epilepsy. Eur J Neurosci 18 2213 2226 [266] Mead AN Morris HV Dixon CI Rulten SL Mayne LV 2006 AMPA receptor GluR2, but not GluR1, subunit deletion impairs emotional response conditioning in mice. Behav Neurosci 120 241 248 [267] Beveridge NJ Tooney PA Carroll AP Gardiner E Bowden N 2008 Dysregulation of miRNA 181b in the temporal cortex in schizophrenia. Hum Mol Genet 17 1156 1168 [268] Le-Niculescu H Balaraman Y Patel S Tan J Sidhu K 2007 Towards understanding the schizophrenia code: an expanded convergent functional genomics approach. Am J Med Genet B Neuropsychiatr Genet 144B 129 158 [269] Dhar SS Liang HL Wong-Riley MT 2009 Nuclear respiratory factor 1 co-regulates AMPA glutamate receptor subunit 2 and cytochrome c oxidase: tight coupling of glutamatergic transmission and energy metabolism in neurons. J Neurochem 108 1595 1606 [270] Mead AN Stephens DN 2003 Involvement of AMPA receptor GluR2 subunits in stimulus-reward learning: evidence from glutamate receptor gria2 knock-out mice. J Neurosci 23 9500 9507 [271] Williams C Mehrian Shai R Wu Y Hsu YH Sitzer T 2009 Transcriptome analysis of synaptoneurosomes identifies neuroplasticity genes overexpressed in incipient Alzheimer's disease. PLoS One 4 e4936 [272] Perlis RH Smoller JW Ferreira MA McQuillin A Bass N 2009 A genomewide association study of response to lithium for prevention of recurrence in bipolar disorder. Am J Psychiatry 166 718 725 [273] Medvedev NI Rodriguez-Arellano JJ Popov VI Davies HA Tigaret CM 2008 The glutamate receptor 2 subunit controls post-synaptic density complexity and spine shape in the dentate gyrus. Eur J Neurosci 27 315 325 [274] Hou Q Zhang D Jarzylo L Huganir RL Man HY 2008 Homeostatic regulation of AMPA receptor expression at single hippocampal synapses. Proc Natl Acad Sci U S A 105 775 780 [275] Heine M Thoumine O Mondin M Tessier B Giannone G 2008 Activity-independent and subunit-specific recruitment of functional AMPA receptors at neurexin/neuroligin contacts. Proc Natl Acad Sci U S A 105 20947 20952 [276] Bagal AA Kao JP Tang CM Thompson SM 2005 Long-term potentiation of exogenous glutamate responses at single dendritic spines. Proc Natl Acad Sci U S A 102 14434 14439 [277] Passafaro M Nakagawa T Sala C Sheng M 2003 Induction of dendritic spines by an extracellular domain of AMPA receptor subunit GluR2. Nature 424 677 681 [278] Tsim KW Choi RC Siow NL Cheng AW Ling KK 2003 ATP induces post-synaptic gene expressions in vertebrate skeletal neuromuscular junctions. J Neurocytol 32 603 617 [279] Zhang GC Mao LM Liu XY Parelkar NK Arora A 2007 In vivo regulation of Homer1a expression in the striatum by cocaine. Mol Pharmacol 71 1148 1158 [280] Todd KJ Auld DS Robitaille R 2007 Neurotrophins modulate neuron-glia interactions at a vertebrate synapse. Eur J Neurosci 25 1287 1296 [281] Mao L Yang L Tang Q Samdani S Zhang G 2005 The scaffold protein Homer1b/c links metabotropic glutamate receptor 5 to extracellular signal-regulated protein kinase cascades in neurons. J Neurosci 25 2741 2752 [282] Ogasawara H Doi T Kawato M 2008 Systems biology perspectives on cerebellar long-term depression. Neurosignals 16 300 317 [283] Faraut B Barbier J Ravel-Chapuis A Doyennette MA Jandrot-Perrus M 2003 Thrombin downregulates muscle acetylcholine receptors via an IP3 signaling pathway by activating its G-protein-coupled protease-activated receptor-1. J Cell Physiol 196 105 112 [284] Sakae N Yamasaki N Kitaichi K Fukuda T Yamada M 2008 Mice lacking the schizophrenia-associated protein FEZ1 manifest hyperactivity and enhanced responsiveness to psychostimulants. Hum Mol Genet 17 3191 3203 [285] Konno D Ko JA Usui S Hori K Maruoka H 2002 The postsynaptic density and dendritic raft localization of PSD-Zip70, which contains an N-myristoylation sequence and leucine-zipper motifs. J Cell Sci 115 4695 4706 [286] Bardoni B Giglio S Schenck A Rocchi M Mandel JL 2000 Assignment of NUFIP1 (nuclear FMRP interacting protein 1) gene to chromosome 13q14 and assignment of a pseudogene to chromosome 6q12. Cytogenet Cell Genet 89 11 13 [287] Bardoni B Schenck A Mandel JL 1999 A novel RNA-binding nuclear protein that interacts with the fragile X mental retardation (FMR1) protein. Hum Mol Genet 8 2557 2566 [288] Bardoni B Willemsen R Weiler IJ Schenck A Severijnen LA 2003 NUFIP1 (nuclear FMRP interacting protein 1) is a nucleocytoplasmic shuttling protein associated with active synaptoneurosomes. Exp Cell Res 289 95 107 [289] Macauley SL Wozniak DF Kielar C Tan Y Cooper JD 2009 Cerebellar pathology and motor deficits in the palmitoyl protein thioesterase 1-deficient mouse. Exp Neurol 217 124 135 [290] Tardy C Sabourdy F Garcia V Jalanko A Therville N 2009 Palmitoyl protein thioesterase 1 modulates tumor necrosis factor alpha-induced apoptosis. Biochim Biophys Acta 1793 1250 1258 [291] Kim SJ Zhang Z Sarkar C Tsai PC Lee YC 2008 Palmitoyl protein thioesterase-1 deficiency impairs synaptic vesicle recycling at nerve terminals, contributing to neuropathology in humans and mice. J Clin Invest 118 3075 3086 [292] Zhang Z Lee YC Kim SJ Choi MS Tsai PC 2007 Production of lysophosphatidylcholine by cPLA2 in the brain of mice lacking PPT1 is a signal for phagocyte infiltration. Hum Mol Genet 16 837 847 [293] Ramadan H Al-Din AS Ismail A Balen F Varma A 2007 Adult neuronal ceroid lipofuscinosis caused by deficiency in palmitoyl protein thioesterase 1. Neurology 68 387 388 [294] Qiao X Lu JY Hofmann SL 2007 Gene expression profiling in a mouse model of infantile neuronal ceroid lipofuscinosis reveals upregulation of immediate early genes and mediators of the inflammatory response. BMC Neurosci 8 95 [295] Lyly A von Schantz C Salonen T Kopra O Saarela J 2007 Glycosylation, transport, and complex formation of palmitoyl protein thioesterase 1 (PPT1)–distinct characteristics in neurons. BMC Cell Biol 8 22 [296] Kielar C Maddox L Bible E Pontikis CC Macauley SL 2007 Successive neuron loss in the thalamus and cortex in a mouse model of infantile neuronal ceroid lipofuscinosis. Neurobiol Dis 25 150 162 [297] Kalviainen R Eriksson K Losekoot M Sorri I Harvima I 2007 Juvenile-onset neuronal ceroid lipofuscinosis with infantile CLN1 mutation and palmitoyl-protein thioesterase deficiency. Eur J Neurol 14 369 372 [298] Ahtiainen L Kolikova J Mutka AL Luiro K Gentile M 2007 Palmitoyl protein thioesterase 1 (Ppt1)-deficient mouse neurons show alterations in cholesterol metabolism and calcium homeostasis prior to synaptic dysfunction. Neurobiol Dis 28 52 64 [299] Zhang Z Lee YC Kim SJ Choi MS Tsai PC 2006 Palmitoyl-protein thioesterase-1 deficiency mediates the activation of the unfolded protein response and neuronal apoptosis in INCL. Hum Mol Genet 15 337 346 [300] Bible E Gupta P Hofmann SL Cooper JD 2004 Regional and cellular neuropathology in the palmitoyl protein thioesterase-1 null mutant mouse model of infantile neuronal ceroid lipofuscinosis. Neurobiol Dis 16 346 359 [301] Ahtiainen L Van Diggelen OP Jalanko A Kopra O 2003 Palmitoyl protein thioesterase 1 is targeted to the axons in neurons. J Comp Neurol 455 368 377 [302] Francis SC Sunshine C Kirk KL 2002 Coordinate regulation of catecholamine uptake by rab3 and phosphoinositide 3-kinase. J Biol Chem 277 7816 7823 [303] Schluter OM Basu J Sudhof TC Rosenmund C 2006 Rab3 superprimes synaptic vesicles for release: implications for short-term synaptic plasticity. J Neurosci 26 1239 1246 [304] Sons MS Plomp JJ 2006 Rab3A deletion selectively reduces spontaneous neurotransmitter release at the mouse neuromuscular synapse. Brain Res 1089 126 134 [305] Nishioka H Haraoka J 2005 Significance of immunohistochemical expression of Rab3B and SNAP-25 in growth hormone-producing pituitary adenomas. Acta Neuropathol 109 598 602 [306] Schluter OM Schmitz F Jahn R Rosenmund C Sudhof TC 2004 A complete genetic analysis of neuronal Rab3 function. J Neurosci 24 6629 6637 [307] Matsuno A Itoh J Takekoshi S Itoh Y Ohsugi Y 2003 Dynamics of subcellular organelles, growth hormone, Rab3B, SNAP-25, and syntaxin in rat pituitary cells caused by growth hormone releasing hormone and somatostatin. Microsc Res Tech 62 232 239 [308] Sidhu RS Bhullar RP 2001 Rab3B in human platelet is membrane bound and interacts with Ca(2+)/calmodulin. Biochem Biophys Res Commun 289 1039 1043 [309] Masumoto N Ikebuchi Y Tahara M Yokoi T Tasaka K 1998 Expression of Rab3A in the cortical region in mouse metaphase II eggs. J Exp Zool 280 91 96 [310] Madison DL Kruger WH Kim T Pfeiffer SE 1996 Differential expression of rab3 isoforms in oligodendrocytes and astrocytes. J Neurosci Res 45 258 268 [311] Grabs D Bergmann M Urban M Post A Gratzl M 1996 Rab3 proteins and SNAP-25, essential components of the exocytosis machinery in conventional synapses, are absent from ribbon synapses of the mouse retina. Eur J Neurosci 8 162 168 [312] Stettler O Nothias F Tavitian B Vernier P 1995 Double in situ hybridization reveals overlapping neuronal populations expressing the low molecular weight GTPases Rab3a and Rab3b in Rat brain. Eur J Neurosci 7 702 713 [313] Redecker P Cetin Y Grube D 1995 Differential distribution of synaptotagmin I and rab3 in the anterior pituitary of four mammalian species. Neuroendocrinology 62 101 110 [314] Fischer von Mollard G Stahl B Khokhlatchev A Sudhof TC Jahn R 1994 Rab3C is a synaptic vesicle protein that dissociates from synaptic vesicles after stimulation of exocytosis. J Biol Chem 269 10971 10974 [315] Lledo PM Vernier P Vincent JD Mason WT Zorec R 1993 Inhibition of Rab3B expression attenuates Ca(2+)-dependent exocytosis in rat anterior pituitary cells. Nature 364 540 544 [316] Lledo PM Johannes L Vernier P Henry JP Vincent JD 1993 [Calcium-dependent regulated secretion is controlled by GTPase Rab3 in neuroendocrine cells]. C R Seances Soc Biol Fil 187 726 736 [317] Karniguian A Zahraoui A Tavitian A 1993 Identification of small GTP-binding rab proteins in human platelets: thrombin-induced phosphorylation of rab3B, rab6, and rab8 proteins. Proc Natl Acad Sci U S A 90 7647 7651 [318] Weidenhofer J Scott RJ Tooney PA 2009 Investigation of the expression of genes affecting cytomatrix active zone function in the amygdala in schizophrenia: effects of antipsychotic drugs. J Psychiatr Res 43 282 290 [319] Fujimoto K Shibasaki T Yokoi N Kashima Y Matsumoto M 2002 Piccolo, a Ca2+ sensor in pancreatic beta-cells. Involvement of cAMP-GEFII.Rim2.Piccolo complex in cAMP-dependent exocytosis. J Biol Chem 277 50497 50502 [320] Kashima Y Miki T Shibasaki T Ozaki N Miyazaki M 2001 Critical role of cAMP-GEFII–Rim2 complex in incretin-potentiated insulin secretion. J Biol Chem 276 46046 46053 [321] Ozaki N Shibasaki T Kashima Y Miki T Takahashi K 2000 cAMP-GEFII is a direct target of cAMP in regulated exocytosis. Nat Cell Biol 2 805 811 [322] Brandstatter JH Dick O Boeckers TM 2004 The postsynaptic scaffold proteins ProSAP1/Shank2 and Homer1 are associated with glutamate receptor complexes at rat retinal synapses. J Comp Neurol 475 551 563 [323] Uemura T Mori H Mishina M 2004 Direct interaction of GluRdelta2 with Shank scaffold proteins in cerebellar Purkinje cells. Mol Cell Neurosci 26 330 341 [324] Bockers TM Segger-Junius M Iglauer P Bockmann J Gundelfinger ED 2004 Differential expression and dendritic transcript localization of Shank family members: identification of a dendritic targeting element in the 3′ untranslated region of Shank1 mRNA. Mol Cell Neurosci 26 182 190 [325] Qualmann B Boeckers TM Jeromin M Gundelfinger ED Kessels MM 2004 Linkage of the actin cytoskeleton to the postsynaptic density via direct interactions of Abp1 with the ProSAP/Shank family. J Neurosci 24 2481 2495 [326] de Bartolomeis A Fiore G 2004 Postsynaptic density scaffolding proteins at excitatory synapse and disorders of synaptic plasticity: implications for human behavior pathologies. Int Rev Neurobiol 59 221 254 [327] Hwang JI Kim HS Lee JR Kim E Ryu SH 2005 The interaction of phospholipase C-beta3 with Shank2 regulates mGluR-mediated calcium signal. J Biol Chem 280 12467 12473 [328] Bresler T Shapira M Boeckers T Dresbach T Futter M 2004 Postsynaptic density assembly is fundamentally different from presynaptic active zone assembly. J Neurosci 24 1507 1520 [329] Kim JY Han W Namkung W Lee JH Kim KH 2004 Inhibitory regulation of cystic fibrosis transmembrane conductance regulator anion-transporting activities by Shank2. J Biol Chem 279 10389 10396 [330] Park E Na M Choi J Kim S Lee JR 2003 The Shank family of postsynaptic density proteins interacts with and promotes synaptic accumulation of the beta PIX guanine nucleotide exchange factor for Rac1 and Cdc42. J Biol Chem 278 19220 19229 [331] Kreienkamp HJ Soltau M Richter D Bockers T 2002 Interaction of G-protein-coupled receptors with synaptic scaffolding proteins. Biochem Soc Trans 30 464 468 [332] Boeckers TM Bockmann J Kreutz MR Gundelfinger ED 2002 ProSAP/Shank proteins - a family of higher order organizing molecules of the postsynaptic density with an emerging role in human neurological disease. J Neurochem 81 903 910 [333] Ehlers MD 2002 Molecular morphogens for dendritic spines. Trends Neurosci 25 64 67 [334] Okamoto PM Gamby C Wells D Fallon J Vallee RB 2001 Dynamin isoform-specific interaction with the shank/ProSAP scaffolding proteins of the postsynaptic density and actin cytoskeleton. J Biol Chem 276 48458 48465 [335] Kreienkamp HJ Zitzer H Richter D 2000 Identification of proteins interacting with the rat somatostatin receptor subtype 2. J Physiol Paris 94 193 198 [336] Tobaben S Sudhof TC Stahl B 2000 The G protein-coupled receptor CL1 interacts directly with proteins of the Shank family. J Biol Chem 275 36204 36210 [337] Sheng M Kim E 2000 The Shank family of scaffold proteins. J Cell Sci 113(Pt 11) 1851 1856 [338] Ehlers MD 1999 Synapse structure: glutamate receptors connected by the shanks. Curr Biol 9 R848 850 [339] Boeckers TM Winter C Smalla KH Kreutz MR Bockmann J 1999 Proline-rich synapse-associated proteins ProSAP1 and ProSAP2 interact with synaptic proteins of the SAPAP/GKAP family. Biochem Biophys Res Commun 264 247 252 [340] Lim S Naisbitt S Yoon J Hwang JI Suh PG 1999 Characterization of the Shank family of synaptic proteins. Multiple genes, alternative splicing, and differential expression in brain and development. J Biol Chem 274 29510 29518 [341] Bajjalieh SM Peterson K Linial M Scheller RH 1993 Brain contains two forms of synaptic vesicle protein 2. Proc Natl Acad Sci U S A 90 2150 2154 [342] Lynch BA Lambeng N Nocka K Kensel-Hammes P Bajjalieh SM 2004 The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A 101 9861 9866 [343] Bindra PS Knowles R Buckley KM 1993 Conservation of the amino acid sequence of SV2, a transmembrane transporter in synaptic vesicles and endocrine cells. Gene 137 299 302 [344] Schivell AE Batchelor RH Bajjalieh SM 1996 Isoform-specific, calcium-regulated interaction of the synaptic vesicle proteins SV2 and synaptotagmin. J Biol Chem 271 27770 27775 [345] Yao J Bajjalieh SM 2008 Synaptic vesicle protein 2 binds adenine nucleotides. J Biol Chem 283 20628 20634 [346] Iezzi M Theander S Janz R Loze C Wollheim CB 2005 SV2A and SV2C are not vesicular Ca2+ transporters but control glucose-evoked granule recruitment. J Cell Sci 118 5647 5660 [347] Lockhart ST Mead JN Pisano JM Slonimsky JD Birren SJ 2000 Nerve growth factor collaborates with myocyte-derived factors to promote development of presynaptic sites in cultured sympathetic neurons. J Neurobiol 42 460 476 [348] Hayashi M Yamamoto A Yatsushiro S Yamada H Futai M 1998 Synaptic vesicle protein SV2B, but not SV2A, is predominantly expressed and associated with microvesicles in rat pinealocytes. J Neurochem 71 356 365 [349] Scranton TW Iwata M Carlson SS 1993 The SV2 protein of synaptic vesicles is a keratan sulfate proteoglycan. J Neurochem 61 29 44 [350] Bajjalieh SM Frantz GD Weimann JM McConnell SK Scheller RH 1994 Differential expression of synaptic vesicle protein 2 (SV2) isoforms. J Neurosci 14 5223 5235 [351] Custer KL Austin NS Sullivan JM Bajjalieh SM 2006 Synaptic vesicle protein 2 enhances release probability at quiescent synapses. J Neurosci 26 1303 1313 [352] Janz R Hofmann K Sudhof TC 1998 SVOP, an evolutionarily conserved synaptic vesicle protein, suggests novel transport functions of synaptic vesicles. J Neurosci 18 9269 9281 [353] Dong M Liu H Tepp WH Johnson EA Janz R 2008 Glycosylated SV2A and SV2B mediate the entry of botulinum neurotoxin E into neurons. Mol Biol Cell 19 5226 5237 [354] Schivell AE Mochida S Kensel-Hammes P Custer KL Bajjalieh SM 2005 SV2A and SV2C contain a unique synaptotagmin-binding site. Mol Cell Neurosci 29 56 64 [355] Janz R Goda Y Geppert M Missler M Sudhof TC 1999 SV2A and SV2B function as redundant Ca2+ regulators in neurotransmitter release. Neuron 24 1003 1016 [356] Lambeng N Grossmann M Chatelain P Fuks B 2006 Solubilization and immunopurification of rat brain synaptic vesicle protein 2A with maintained binding properties. Neurosci Lett 398 107 112 [357] Janz R Sudhof TC 1999 SV2C is a synaptic vesicle protein with an unusually restricted localization: anatomy of a synaptic vesicle protein family. Neuroscience 94 1279 1290 [358] Clegg N Ferguson C True LD Arnold H Moorman A 2003 Molecular characterization of prostatic small-cell neuroendocrine carcinoma. Prostate 55 55 64 [359] Dong M Yeh F Tepp WH Dean C Johnson EA 2006 SV2 is the protein receptor for botulinum neurotoxin A. Science 312 592 596 [360] Leonoudakis D Conti LR Radeke CM McGuire LM Vandenberg CA 2004 A multiprotein trafficking complex composed of SAP97, CASK, Veli, and Mint1 is associated with inward rectifier Kir2 potassium channels. J Biol Chem 279 19051 19063 [361] Atasoy D Schoch S Ho A Nadasy KA Liu X 2007 Deletion of CASK in mice is lethal and impairs synaptic function. Proc Natl Acad Sci U S A 104 2525 2530 [362] Klemmer P Smit AB Li KW 2009 Proteomics analysis of immuno-precipitated synaptic protein complexes. J Proteomics 72 82 90 [363] Hernandez-Ortega K Ferrera P Arias C 2007 Sequential expression of cell-cycle regulators and Alzheimer's disease-related proteins in entorhinal cortex after hippocampal excitotoxic damage. J Neurosci Res 85 1744 1751 [364] Utreras E Maccioni R Gonzalez-Billault C 2009 Cyclin-dependent kinase 5 activator p35 over-expression and amyloid beta synergism increase apoptosis in cultured neuronal cells. Neuroscience 161 978 987 [365] Ubeda M Kemp DM Habener JF 2004 Glucose-induced expression of the cyclin-dependent protein kinase 5 activator p35 involved in Alzheimer's disease regulates insulin gene transcription in pancreatic beta-cells. Endocrinology 145 3023 3031 [366] Mateo I Vazquez-Higuera JL Sanchez-Juan P Rodriguez-Rodriguez E Infante J 2008 Epistasis between tau phosphorylation regulating genes (CDK5R1 and GSK-3beta) and Alzheimer's disease risk. Acta Neurol Scand [367] Moncini S Bevilacqua A Venturin M Fallini C Ratti A 2007 The 3′ untranslated region of human Cyclin-Dependent Kinase 5 Regulatory subunit 1 contains regulatory elements affecting transcript stability. BMC Mol Biol 8 111 [368] Rademakers R Sleegers K Theuns J Van den Broeck M Bel Kacem S 2005 Association of cyclin-dependent kinase 5 and neuronal activators p35 and p39 complex in early-onset Alzheimer's disease. Neurobiol Aging 26 1145 1151 [369] Lopes JP Oliveira CR Agostinho P 2007 Role of cyclin-dependent kinase 5 in the neurodegenerative process triggered by amyloid-Beta and prion peptides: implications for Alzheimer's disease and prion-related encephalopathies. Cell Mol Neurobiol 27 943 957 [370] Monaco EA 3rd 2004 Recent evidence regarding a role for Cdk5 dysregulation in Alzheimer's disease. Curr Alzheimer Res 1 33 38 [371] Maccioni RB Otth C Concha II Munoz JP 2001 The protein kinase Cdk5. Structural aspects, roles in neurogenesis and involvement in Alzheimer's pathology. Eur J Biochem 268 1518 1527 [372] Sato S Xu J Okuyama S Martinez LB Walsh SM 2008 Spatial learning impairment, enhanced CDK5/p35 activity, and downregulation of NMDA receptor expression in transgenic mice expressing tau-tubulin kinase 1. J Neurosci 28 14511 14521 [373] Patrick GN Zukerberg L Nikolic M de la Monte S Dikkes P 1999 Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature 402 615 622 [374] Orellana DI Quintanilla RA Maccioni RB 2007 Neuroprotective effect of TNFalpha against the beta-amyloid neurotoxicity mediated by CDK5 kinase. Biochim Biophys Acta 1773 254 263 [375] Ubeda M Rukstalis JM Habener JF 2006 Inhibition of cyclin-dependent kinase 5 activity protects pancreatic beta cells from glucotoxicity. J Biol Chem 281 28858 28864 [376] Camins A Verdaguer E Folch J Canudas AM Pallas M 2006 The role of CDK5/P25 formation/inhibition in neurodegeneration. Drug News Perspect 19 453 460 [377] Quintanilla RA Orellana DI Gonzalez-Billault C Maccioni RB 2004 Interleukin-6 induces Alzheimer-type phosphorylation of tau protein by deregulating the cdk5/p35 pathway. Exp Cell Res 295 245 257 [378] Lee MS Tsai LH 2003 Cdk5: one of the links between senile plaques and neurofibrillary tangles? J Alzheimers Dis 5 127 137 [379] Kesavapany S Li BS Pant HC 2003 Cyclin-dependent kinase 5 in neurofilament function and regulation. Neurosignals 12 252 264 [380] Mauceri D Gardoni F Marcello E Di Luca M 2007 Dual role of CaMKII-dependent SAP97 phosphorylation in mediating trafficking and insertion of NMDA receptor subunit NR2A. J Neurochem 100 1032 1046 [381] Surena AL de Faria GP Studler JM Peiretti F Pidoux M 2009 DLG1/SAP97 modulates transforming growth factor alpha bioavailability. Biochim Biophys Acta 1793 264 272 [382] Sato J Shimazu D Yamamoto N Nishikawa T 2008 An association analysis of synapse-associated protein 97 (SAP97) gene in schizophrenia. J Neural Transm 115 1355 1365 [383] Cai C Li H Kangasniemi A Pihlajamaa T Von Ossowski L 2008 Somatostatin receptor subtype 1 is a PDZ ligand for synapse-associated protein 97 and a potential regulator of growth cone dynamics. Neuroscience 157 833 843 [384] Migues PV Cammarota M Kavanagh J Atkinson R Powis DA 2007 Maturational changes in the subunit composition of AMPA receptors and the functional consequences of their activation in chicken forebrain. Dev Neurosci 29 232 240 [385] Cai C Li H Rivera C Keinanen K 2006 Interaction between SAP97 and PSD-95, two Maguk proteins involved in synaptic trafficking of AMPA receptors. J Biol Chem 281 4267 4273 [386] Nash JE Johnston TH Collingridge GL Garner CC Brotchie JM 2005 Subcellular redistribution of the synapse-associated proteins PSD-95 and SAP97 in animal models of Parkinson's disease and L-DOPA-induced dyskinesia. FASEB J 19 583 585 [387] Wakabayashi K Narisawa-Saito M Iwakura Y Arai T Ikeda K 1999 Phenotypic down-regulation of glutamate receptor subunit GluR1 in Alzheimer's disease. Neurobiol Aging 20 287 295 [388] Tavalin SJ 2008 AKAP79 selectively enhances protein kinase C regulation of GluR1 at a Ca2+-calmodulin-dependent protein kinase II/protein kinase C site. J Biol Chem 283 11445 11452 [389] Gerdjikov TV Rudolph U Keist R Mohler H Feldon J 2008 Hippocampal alpha 5 subunit-containing GABA A receptors are involved in the development of the latent inhibition effect. Neurobiol Learn Mem 89 87 94 [390] Glykys J Mann EO Mody I 2008 Which GABA(A) receptor subunits are necessary for tonic inhibition in the hippocampus? J Neurosci 28 1421 1426 [391] Bonin RP Martin LJ MacDonald JF Orser BA 2007 Alpha5GABAA receptors regulate the intrinsic excitability of mouse hippocampal pyramidal neurons. J Neurophysiol 98 2244 2254 [392] Dawson GR Maubach KA Collinson N Cobain M Everitt BJ 2006 An inverse agonist selective for alpha5 subunit-containing GABAA receptors enhances cognition. J Pharmacol Exp Ther 316 1335 1345 [393] Caraiscos VB Newell JG You-Ten KE Elliott EM Rosahl TW 2004 Selective enhancement of tonic GABAergic inhibition in murine hippocampal neurons by low concentrations of the volatile anesthetic isoflurane. J Neurosci 24 8454 8458 [394] Zarnowska ED Keist R Rudolph U Pearce RA 2009 GABAA receptor alpha5 subunits contribute to GABAA,slow synaptic inhibition in mouse hippocampus. J Neurophysiol 101 1179 1191 [395] Fernandez F Esposito T Lea RA Colson NJ Ciccodicola A 2008 Investigation of gamma-aminobutyric acid (GABA) A receptors genes and migraine susceptibility. BMC Med Genet 9 109 [396] Weiss J O'Sullivan GA Heinze L Chen HX Betz H 2008 Glycinergic input of small-field amacrine cells in the retinas of wildtype and glycine receptor deficient mice. Mol Cell Neurosci 37 40 55 [397] Ramanathan S Woodroffe A Flodman PL Mays LZ Hanouni M 2004 A case of autism with an interstitial deletion on 4q leading to hemizygosity for genes encoding for glutamine and glycine neurotransmitter receptor sub-units (AMPA 2, GLRA3, GLRB) and neuropeptide receptors NPY1R, NPY5R. BMC Med Genet 5 10 [398] Nikolic Z Laube B Weber RG Lichter P Kioschis P 1998 The human glycine receptor subunit alpha3. Glra3 gene structure, chromosomal localization, and functional characterization of alternative transcripts. J Biol Chem 273 19708 19714 [399] Hunter RG Bellani R Bloss E Costa A McCarthy K 2009 Regulation of kainate receptor subunit mRNA by stress and corticosteroids in the rat hippocampus. PLoS One 4 e4328 [400] Parisiadou L Bethani I Michaki V Krousti K Rapti G 2008 Homer2 and Homer3 interact with amyloid precursor protein and inhibit Abeta production. Neurobiol Dis 30 353 364 [401] Cao M Xu J Shen C Kam C Huganir RL 2007 PICK1-ICA69 heteromeric BAR domain complex regulates synaptic targeting and surface expression of AMPA receptors. J Neurosci 27 12945 12956 [402] Huang Z Shimazu K Woo NH Zang K Muller U 2006 Distinct roles of the beta 1-class integrins at the developing and the mature hippocampal excitatory synapse. J Neurosci 26 11208 11219 [403] Thomas U 2002 Modulation of synaptic signalling complexes by Homer proteins. J Neurochem 81 407 413 [404] Scott LJ Muglia P Kong XQ Guan W Flickinger M 2009 Genome-wide association and meta-analysis of bipolar disorder in individuals of European ancestry. Proc Natl Acad Sci U S A 106 7501 7506 [405] Shin OH Han W Wang Y Sudhof TC 2005 Evolutionarily conserved multiple C2 domain proteins with two transmembrane regions (MCTPs) and unusual Ca2+ binding properties. J Biol Chem 280 1641 1651 [406] Enz R Croci C 2003 Different binding motifs in metabotropic glutamate receptor type 7b for filamin A, protein phosphatase 1C, protein interacting with protein kinase C (PICK) 1 and syntenin allow the formation of multimeric protein complexes. Biochem J 372 183 191 [407] Boczan J Leenders AG Sheng ZH 2004 Phosphorylation of syntaphilin by cAMP-dependent protein kinase modulates its interaction with syntaxin-1 and annuls its inhibitory effect on vesicle exocytosis. J Biol Chem 279 18911 18919 [408] Kang JS Tian JH Pan PY Zald P Li C 2008 Docking of axonal mitochondria by syntaphilin controls their mobility and affects short-term facilitation. Cell 132 137 148 [409] Das S Gerwin C Sheng ZH 2003 Syntaphilin binds to dynamin-1 and inhibits dynamin-dependent endocytosis. J Biol Chem 278 41221 41226 [410] Das S Boczan J Gerwin C Zald PB Sheng ZH 2003 Regional and developmental regulation of syntaphilin expression in the brain: a candidate molecular element of synaptic functional differentiation. Brain Res Mol Brain Res 116 38 49 [411] Lao G Scheuss V Gerwin CM Su Q Mochida S 2000 Syntaphilin: a syntaxin-1 clamp that controls SNARE assembly. Neuron 25 191 201 [412] Mahad DJ Ziabreva I Campbell G Lax N White K 2009 Mitochondrial changes within axons in multiple sclerosis. Brain 132 1161 1174 [413] Funakoshi E Hamano A Fukui M Nishiyama N Ogita K 2006 Molecular cloning of the m-Golsyn gene and its expression in the mouse brain. Gene Expr 13 27 40 [414] Funakoshi E Nakagawa KY Hamano A Hori T Shimizu A 2005 Molecular cloning and characterization of gene for Golgi-localized syntaphilin-related protein on human chromosome 8q23. Gene 344 259 271 [415] Zhou D Wang J Zapala MA Xue J Schork NJ 2008 Gene expression in mouse brain following chronic hypoxia: role of sarcospan in glial cell death. Physiol Genomics 32 370 379 [416] Williams D Aleman T Lillo C Lopes VS Hughes LC 2009 Harmonin in the murine retina and the retinal phenotypes of Ush1c-mutant mice and human USH1C. Invest Ophthalmol Vis Sci [417] Lillo C Kitamoto J Williams DS 2006 Roles and interactions of usher 1 proteins in the outer retina. Adv Exp Med Biol 572 341 348 [418] Reiners J Nagel-Wolfrum K Jurgens K Marker T Wolfrum U 2006 Molecular basis of human Usher syndrome: deciphering the meshes of the Usher protein network provides insights into the pathomechanisms of the Usher disease. Exp Eye Res 83 97 119 [419] Keri S Seres I Kelemen O Benedek G 2009 The Relationship Among Neuregulin 1-Stimulated Phosphorylation of AKT, Psychosis Proneness, and Habituation of Arousal in Nonclinical Individuals. Schizophr Bull [420] Le Strat Y Ramoz N Gorwood P 2009 The role of genes involved in neuroplasticity and neurogenesis in the observation of a gene-environment interaction (GxE) in schizophrenia. Curr Mol Med 9 506 518 [421] Schijndel JE Loo KM Zweeden MV Djurovic S Andreassen OA 2009 Three-cohort targeted gene screening reveals a non-synonymous TRKA polymorphism associated with schizophrenia. J Psychiatr Res [422] So HC Fong PY Chen RY Hui TC Ng MY 2009 Identification of neuroglycan C and interacting partners as potential susceptibility genes for schizophrenia in a Southern Chinese population. Am J Med Genet B Neuropsychiatr Genet [423] Wood JD Bonath F Kumar S Ross CA Cunliffe VT 2009 Disrupted-in-schizophrenia 1 and neuregulin 1 are required for the specification of oligodendrocytes and neurones in the zebrafish brain. Hum Mol Genet 18 391 404 [424] Wong J Weickert CS 2009 Transcriptional Interaction of an Estrogen Receptor Splice Variant and ErbB4 Suggests Convergence in Gene Susceptibility Pathways in Schizophrenia. J Biol Chem 284 18824 18832 [425] Wang F Jiang T Sun Z Teng SL Luo X 2009 Neuregulin 1 genetic variation and anterior cingulum integrity in patients with schizophrenia and healthy controls. J Psychiatry Neurosci 34 181 186 [426] Voineskos D De Luca V Macgregor S Likhodi O Miller L 2009 Neuregulin 1 and age of onset in the major psychoses. J Neural Transm 116 479 486 [427] Tabares-Seisdedos R Rubenstein JL 2009 Chromosome 8p as a potential hub for developmental neuropsychiatric disorders: implications for schizophrenia, autism and cancer. Mol Psychiatry 14 563 589 [428] Reinhard S Vela E Bombara N Devries GH Raabe TD 2009 Developmental regulation of Neuregulin1 isoforms and erbB receptor expression in intact rat dorsal root ganglia. Neurochem Res 34 17 22 [429] Prata DP Breen G Osborne S Munro J St Clair D 2009 An association study of the neuregulin 1 gene, bipolar affective disorder and psychosis. Psychiatr Genet 19 113 116 [430] Pedrosa E Nolan KA Stefanescu R Hershcovitz P Novak T 2009 Analysis of a Promoter Polymorphism in the SMDF Neuregulin 1 Isoform in Schizophrenia. Neuropsychobiology 59 205 212 [431] Mata I Perez-Iglesias R Roiz-Santianez R Tordesillas-Gutierrez D Gonzalez-Mandly A 2009 A neuregulin 1 variant is associated with increased lateral ventricle volume in patients with first-episode schizophrenia. Biol Psychiatry 65 535 540 [432] Kircher T Thienel R Wagner M Reske M Habel U 2009 Neuregulin 1 ICE-single nucleotide polymorphism in first episode schizophrenia correlates with cerebral activation in fronto-temporal areas. Eur Arch Psychiatry Clin Neurosci 259 72 79 [433] Kircher T Krug A Markov V Whitney C Krach S 2009 Genetic variation in the schizophrenia-risk gene neuregulin 1 correlates with brain activation and impaired speech production in a verbal fluency task in healthy individuals. Hum Brain Mapp [434] Keri S Seres I Kelemen O Benedek G 2009 Neuregulin 1-stimulated phosphorylation of AKT in psychotic disorders and its relationship with neurocognitive functions. Neurochem Int [435] Willem M Garratt AN Novak B Citron M Kaufmann S 2006 Control of peripheral nerve myelination by the beta-secretase BACE1. Science 314 664 666 [436] Savonenko AV Melnikova T Laird FM Stewart KA Price DL 2008 Alteration of BACE1-dependent NRG1/ErbB4 signaling and schizophrenia-like phenotypes in BACE1-null mice. Proc Natl Acad Sci U S A 105 5585 5590 [437] Hu X He W Diaconu C Tang X Kidd GJ 2008 Genetic deletion of BACE1 in mice affects remyelination of sciatic nerves. FASEB J 22 2970 2980 [438] Pankonin MS Sohi J Kamholz J Loeb JA 2009 Differential distribution of neuregulin in human brain and spinal fluid. Brain Res 1258 1 11 [439] Li B Woo RS Mei L Malinow R 2007 The neuregulin-1 receptor erbB4 controls glutamatergic synapse maturation and plasticity. Neuron 54 583 597 [440] Go RC Perry RT Wiener H Bassett SS Blacker D 2005 Neuregulin-1 polymorphism in late onset Alzheimer's disease families with psychoses. Am J Med Genet B Neuropsychiatr Genet 139B 28 32 [441] Gallagher JP Orozco-Cabal LF Liu J Shinnick-Gallagher P 2008 Synaptic physiology of central CRH system. Eur J Pharmacol 583 215 225 [442] Liu Y Tao YM Woo RS Xiong WC Mei L 2007 Stimulated ErbB4 internalization is necessary for neuregulin signaling in neurons. Biochem Biophys Res Commun 354 505 510 [443] MacDonald AW 3rd Chafee MV 2006 Translational and developmental perspective on N-methyl-D-aspartate synaptic deficits in schizophrenia. Dev Psychopathol 18 853 876 [444] Jaworski A Burden SJ 2006 Neuromuscular synapse formation in mice lacking motor neuron- and skeletal muscle-derived Neuregulin-1. J Neurosci 26 655 661 [445] Jacobson C Duggan D Fischbach G 2004 Neuregulin induces the expression of transcription factors and myosin heavy chains typical of muscle spindles in cultured human muscle. Proc Natl Acad Sci U S A 101 12218 12223 [446] Okada M Corfas G 2004 Neuregulin1 downregulates postsynaptic GABAA receptors at the hippocampal inhibitory synapse. Hippocampus 14 337 344 [447] Bennett AOM 2008 Dual constraints on synapse formation and regression in schizophrenia: neuregulin, neuroligin, dysbindin, DISC1, MuSK and agrin. Aust N Z J Psychiatry 42 662 677 [448] Papadopoulos V Lecanu L Brown RC Han Z Yao ZX 2006 Peripheral-type benzodiazepine receptor in neurosteroid biosynthesis, neuropathology and neurological disorders. Neuroscience 138 749 756 [449] Hazell AS 2002 Astrocytes and manganese neurotoxicity. Neurochem Int 41 271 277 [450] Roberts JC Friel SL Roman S Perren M Harper A 2009 Autoradiographical imaging of PPARgamma agonist effects on PBR/TSPO binding in TASTPM mice. Exp Neurol 216 459 470 [451] Ji B Maeda J Sawada M Ono M Okauchi T 2008 Imaging of peripheral benzodiazepine receptor expression as biomarkers of detrimental versus beneficial glial responses in mouse models of Alzheimer's and other CNS pathologies. J Neurosci 28 12255 12267 [452] Gulyas B Makkai B Kasa P Gulya K Bakota L 2009 A comparative autoradiography study in post mortem whole hemisphere human brain slices taken from Alzheimer patients and age-matched controls using two radiolabelled DAA1106 analogues with high affinity to the peripheral benzodiazepine receptor (PBR) system. Neurochem Int 54 28 36 [453] Wang M Gao M Hutchins GD Zheng QH 2009 Synthesis of [11C]FEDAA1106 as a new PET imaging probe of peripheral benzodiazepine receptor expression. Eur J Med Chem 44 2748 2753 [454] Yasuno F Ota M Kosaka J Ito H Higuchi M 2008 Increased binding of peripheral benzodiazepine receptor in Alzheimer's disease measured by positron emission tomography with [11C]DAA1106. Biol Psychiatry 64 835 841 [455] Laquintana V Denora N Lopedota A Suzuki H Sawada M 2007 N-benzyl-2-(6,8-dichloro-2-(4-chlorophenyl)imidazo[1,2-a]pyridin-3-yl)-N-( 6-(7-nitrobenzo[c][1,2,5]oxadiazol-4-ylamino)hexyl)acetamide as a new fluorescent probe for peripheral benzodiazepine receptor and microglial cell visualization. Bioconjug Chem 18 1397 1407 [456] Walker DG Dalsing-Hernandez JE Lue LF 2008 Human postmortem brain-derived cerebrovascular smooth muscle cells express all genes of the classical complement pathway: a potential mechanism for vascular damage in cerebral amyloid angiopathy and Alzheimer's disease. Microvasc Res 75 411 419 [457] Veerhuis R Janssen I De Groot CJ Van Muiswinkel FL Hack CE 1999 Cytokines associated with amyloid plaques in Alzheimer's disease brain stimulate human glial and neuronal cell cultures to secrete early complement proteins, but not C1-inhibitor. Exp Neurol 160 289 299 [458] Yasojima K McGeer EG McGeer PL 1999 Complement regulators C1 inhibitor and CD59 do not significantly inhibit complement activation in Alzheimer disease. Brain Res 833 297 301 [459] Bergamaschini L Canziani S Bottasso B Cugno M Braidotti P 1999 Alzheimer's beta-amyloid peptides can activate the early components of complement classical pathway in a C1q-independent manner. Clin Exp Immunol 115 526 533 [460] Yasojima K Schwab C McGeer EG McGeer PL 1999 Up-regulated production and activation of the complement system in Alzheimer's disease brain. Am J Pathol 154 927 936 [461] Terai K Walker DG McGeer EG McGeer PL 1997 Neurons express proteins of the classical complement pathway in Alzheimer disease. Brain Res 769 385 390 [462] Mori M Sawashita J Higuchi K 2007 Functional polymorphisms of the Lss and Fdft1 genes in laboratory rats. Exp Anim 56 93 101 [463] Funfschilling U Saher G Xiao L Mobius W Nave KA 2007 Survival of adult neurons lacking cholesterol synthesis in vivo. BMC Neurosci 8 1 [464] Tang J Song M Wang Y Fan X Xu H 2009 Noggin and BMP4 co-modulate adult hippocampal neurogenesis in the APP(swe)/PS1(DeltaE9) transgenic mouse model of Alzheimer's disease. Biochem Biophys Res Commun 385 341 345 [465] Li D Tang J Xu H Fan X Bai Y 2008 Decreased hippocampal cell proliferation correlates with increased expression of BMP4 in the APPswe/PS1DeltaE9 mouse model of Alzheimer's disease. Hippocampus 18 692 698 [466] Malm TM Magga J Kuh GF Vatanen T Koistinaho M 2008 Minocycline reduces engraftment and activation of bone marrow-derived cells but sustains their phagocytic activity in a mouse model of Alzheimer's disease. Glia 56 1767 1779 [467] Kobayashi K Hayashi M Nakano H Fukutani Y Sasaki K 2002 Apoptosis of astrocytes with enhanced lysosomal activity and oligodendrocytes in white matter lesions in Alzheimer's disease. Neuropathol Appl Neurobiol 28 238 251 [468] Fiala M Liu QN Sayre J Pop V Brahmandam V 2002 Cyclooxygenase-2-positive macrophages infiltrate the Alzheimer's disease brain and damage the blood-brain barrier. Eur J Clin Invest 32 360 371 [469] Heneka MT Wiesinger H Dumitrescu-Ozimek L Riederer P Feinstein DL 2001 Neuronal and glial coexpression of argininosuccinate synthetase and inducible nitric oxide synthase in Alzheimer disease. J Neuropathol Exp Neurol 60 906 916 [470] Kobayashi K Muramori F Aoki T Hayashi M Miyazu K 1998 KP-1 is a marker for extraneuronal neurofibrillary tangles and senile plaques in Alzheimer diseased brains. Dement Geriatr Cogn Disord 9 13 19 [471] Reynolds WF Rhees J Maciejewski D Paladino T Sieburg H 1999 Myeloperoxidase polymorphism is associated with gender specific risk for Alzheimer's disease. Exp Neurol 155 31 41 [472] Damjanac M Rioux Bilan A Barrier L Pontcharraud R Anne C 2007 Fluoro-Jade B staining as useful tool to identify activated microglia and astrocytes in a mouse transgenic model of Alzheimer's disease. Brain Res 1128 40 49 [473] Sim KG Cheong JK Hsu SI 2006 The TRIP-Br family of transcriptional regulators is essential for the execution of cyclin E-mediated cell cycle progression. Cell Cycle 5 1111 1115 [474] Cheong JK Gunaratnam L Zang ZJ Yang CM Sun X 2009 TRIP-Br2 promotes oncogenesis in nude mice and is frequently overexpressed in multiple human tumors. J Transl Med 7 8 [475] Zang ZJ Sim KG Cheong JK Yang CM Yap CS 2007 Exploiting the TRIP-Br family of cell cycle regulatory proteins as chemotherapeutic drug targets in human cancer. Cancer Biol Ther 6 712 718 [476] An L Sato H Konishi Y Walker DG Beach TG 2009 Expression and localization of lactotransferrin messenger RNA in the cortex of Alzheimer's disease. Neurosci Lett 452 277 280 [477] Leveugle B Spik G Perl DP Bouras C Fillit HM 1994 The iron-binding protein lactotransferrin is present in pathologic lesions in a variety of neurodegenerative disorders: a comparative immunohistochemical analysis. Brain Res 650 20 31 [478] Kawamata T Tooyama I Yamada T Walker DG McGeer PL 1993 Lactotransferrin immunocytochemistry in Alzheimer and normal human brain. Am J Pathol 142 1574 1585 [479] Morozova N Khrapko K Panee J Liu W Harney JW 2007 Glutathione depletion in hippocampal cells increases levels of H and L ferritin and glutathione S-transferase mRNAs. Genes Cells 12 561 567 [480] Connor JR Snyder BS Arosio P Loeffler DA LeWitt P 1995 A quantitative analysis of isoferritins in select regions of aged, parkinsonian, and Alzheimer's diseased brains. J Neurochem 65 717 724 [481] Vidal R Miravalle L Gao X Barbeito AG Baraibar MA 2008 Expression of a mutant form of the ferritin light chain gene induces neurodegeneration and iron overload in transgenic mice. J Neurosci 28 60 67 [482] Thomas M Jankovic J 2004 Neurodegenerative disease and iron storage in the brain. Curr Opin Neurol 17 437 442 [483] Wimmer U Wang Y Georgiev O Schaffner W 2005 Two major branches of anti-cadmium defense in the mouse: MTF-1/metallothioneins and glutathione. Nucleic Acids Res 33 5715 5727 [484] Bellingham SA Coleman LA Masters CL Camakaris J Hill AF 2009 Regulation of prion gene expression by transcription factors SP1 and metal transcription factor-1. J Biol Chem 284 1291 1301 [485] Colangelo V Schurr J Ball MJ Pelaez RP Bazan NG 2002 Gene expression profiling of 12633 genes in Alzheimer hippocampal CA1: transcription and neurotrophic factor down-regulation and up-regulation of apoptotic and pro-inflammatory signaling. J Neurosci Res 70 462 473 [486] Holloway AF Stennard FA West AK 1997 Human metallothionein gene MT1L mRNA is present in several human tissues but is unlikely to produce a metallothionein protein. FEBS Lett 404 41 44 [487] Hahn Y Lee B 2006 Human-specific nonsense mutations identified by genome sequence comparisons. Hum Genet 119 169 178 [488] Choi KH Elashoff M Higgs BW Song J Kim S 2008 Putative psychosis genes in the prefrontal cortex: combined analysis of gene expression microarrays. BMC Psychiatry 8 87 [489] Goncalves I Quintela T Baltazar G Almeida MR Saraiva MJ 2008 Transthyretin interacts with metallothionein 2. Biochemistry 47 2244 2251 [490] Aschner M West AK 2005 The role of MT in neurological disorders. J Alzheimers Dis 8 139 145 discussion 209–115 [491] Richarz AN Bratter P 2002 Speciation analysis of trace elements in the brains of individuals with Alzheimer's disease with special emphasis on metallothioneins. Anal Bioanal Chem 372 412 417 [492] Irie Y Keung WM 2001 Metallothionein-III antagonizes the neurotoxic and neurotrophic effects of amyloid beta peptides. Biochem Biophys Res Commun 282 416 420 [493] Kobayashi K Hayashi M Nakano H Shimazaki M Sugimori K 2004 Correlation between astrocyte apoptosis and Alzheimer changes in gray matter lesions in Alzheimer's disease. J Alzheimers Dis 6 623 632 discussion 673–681 [494] Mattson MP 2008 Glutamate and neurotrophic factors in neuronal plasticity and disease. Ann N Y Acad Sci 1144 97 112 [495] Stahelin RV Long F Diraviyam K Bruzik KS Murray D 2002 Phosphatidylinositol 3-phosphate induces the membrane penetration of the FYVE domains of Vps27p and Hrs. J Biol Chem 277 26379 26388 [496] Falasca M Maffucci T 2006 Emerging roles of phosphatidylinositol 3-monophosphate as a dynamic lipid second messenger. Arch Physiol Biochem 112 274 284 [497] Sansom SN Griffiths DS Faedo A Kleinjan DJ Ruan Y 2009 The level of the transcription factor Pax6 is essential for controlling the balance between neural stem cell self-renewal and neurogenesis. PLoS Genet 5 e1000511 [498] von Bohlen Und Halbach O 2007 Immunohistological markers for staging neurogenesis in adult hippocampus. Cell Tissue Res 329 409 420 [499] Kallur T Gisler R Lindvall O Kokaia Z 2008 Pax6 promotes neurogenesis in human neural stem cells. Mol Cell Neurosci 38 616 628 [500] Levers TE Edgar JM Price DJ 2001 The fates of cells generated at the end of neurogenesis in developing mouse cortex. J Neurobiol 48 265 277 [501] Hardy RJ 1998 QKI expression is regulated during neuron-glial cell fate decisions. J Neurosci Res 54 46 57 [502] Bibel M Richter J Schrenk K Tucker KL Staiger V 2004 Differentiation of mouse embryonic stem cells into a defined neuronal lineage. Nat Neurosci 7 1003 1009 [503] Baer K Eriksson PS Faull RL Rees MI Curtis MA 2007 Sox-2 is expressed by glial and progenitor cells and Pax-6 is expressed by neuroblasts in the human subventricular zone. Exp Neurol 204 828 831 [504] Nacher J Varea E Blasco-Ibanez JM Castillo-Gomez E Crespo C 2005 Expression of the transcription factor Pax 6 in the adult rat dentate gyrus. J Neurosci Res 81 753 761 [505] Malaterre J Mantamadiotis T Dworkin S Lightowler S Yang Q 2008 c-Myb is required for neural progenitor cell proliferation and maintenance of the neural stem cell niche in adult brain. Stem Cells 26 173 181 [506] Lauriat TL Shiue L Haroutunian V Verbitsky M Ares M Jr 2008 Developmental expression profile of quaking, a candidate gene for schizophrenia, and its target genes in human prefrontal cortex and hippocampus shows regional specificity. J Neurosci Res 86 785 796 [507] Chen Y Tian D Ku L Osterhout DJ Feng Y 2007 The selective RNA-binding protein quaking I (QKI) is necessary and sufficient for promoting oligodendroglia differentiation. J Biol Chem 282 23553 23560 [508] Zhao L Ku L Chen Y Xia M LoPresti P 2006 QKI binds MAP1B mRNA and enhances MAP1B expression during oligodendrocyte development. Mol Biol Cell 17 4179 4186 [509] Aberg K Saetre P Jareborg N Jazin E 2006 Human QKI, a potential regulator of mRNA expression of human oligodendrocyte-related genes involved in schizophrenia. Proc Natl Acad Sci U S A 103 7482 7487 [510] Galarneau A Richard S 2005 Target RNA motif and target mRNAs of the Quaking STAR protein. Nat Struct Mol Biol 12 691 698 [511] Valjent E Aubier B Corbille AG Brami-Cherrier K Caboche J 2006 Plasticity-associated gene Krox24/Zif268 is required for long-lasting behavioral effects of cocaine. J Neurosci 26 4956 4960 [512] Nikitin VP Kozyrev SA 2007 Effects of antisense oligonucleotides to mRNA for the early gene zif268 on the mechanisms of synapse-specific plasticity. Neurosci Behav Physiol 37 607 612 [513] Poirier GL Amin E Aggleton JP 2008 Qualitatively different hippocampal subfield engagement emerges with mastery of a spatial memory task by rats. J Neurosci 28 1034 1045 [514] Renaudineau S Poucet B Laroche S Davis S Save E 2009 Impaired long-term stability of CA1 place cell representation in mice lacking the transcription factor zif268/egr1. Proc Natl Acad Sci U S A 106 11771 11775 [515] Romcy-Pereira RN Erraji-Benchekroun L Smyrniotopoulos P Ogawa S Mello CV 2009 Sleep-dependent gene expression in the hippocampus and prefrontal cortex following long-term potentiation. Physiol Behav 98 44 52 [516] Bailey DJ Wade J 2003 Differential expression of the immediate early genes FOS and ZENK following auditory stimulation in the juvenile male and female zebra finch. Brain Res Mol Brain Res 116 147 154 [517] Eda-Fujiwara H Satoh R Bolhuis JJ Kimura T 2003 Neuronal activation in female budgerigars is localized and related to male song complexity. Eur J Neurosci 17 149 154 [518] Shimizu T Bowers AN Budzynski CA Kahn MC Bingman VP 2004 What does a pigeon (Columba livia) brain look like during homing? selective examination of ZENK expression. Behav Neurosci 118 845 851 [519] Terpstra NJ Bolhuis JJ den Boer-Visser AM 2004 An analysis of the neural representation of birdsong memory. J Neurosci 24 4971 4977 [520] Bailey DJ Wade J 2005 FOS and ZENK responses in 45-day-old zebra finches vary with auditory stimulus and brain region, but not sex. Behav Brain Res 162 108 115 [521] Terpstra NJ Bolhuis JJ Den Boer-Visser AM Ten Cate C 2005 Neuronal activation related to auditory perception in the brain of a non-songbird, the ring dove. J Comp Neurol 488 342 351 [522] Bischofe HJ Lieshoff C Watanabe S 2006 Spatial memory and hippocampal function in a non-foodstoring songbird, the zebra finch (Taeniopygia guttata). Rev Neurosci 17 43 52 [523] Brito I Britto LR Ferrari EA 2006 Classical tone-shock conditioning induces Zenk expression in the pigeon (Columba livia) hippocampus. Behav Neurosci 120 353 361 [524] Terpstra NJ Bolhuis JJ Riebel K van der Burg JM den Boer-Visser AM 2006 Localized brain activation specific to auditory memory in a female songbird. J Comp Neurol 494 784 791 [525] Vignal C Bouchut C Mathevon N 2008 Sound-induced brain activity depends on stimulus subjective salience in female zebra finches. C R Biol 331 347 356 [526] Fischer AJ McGuire JJ Schaeffel F Stell WK 1999 Light- and focus-dependent expression of the transcription factor ZENK in the chick retina. Nat Neurosci 2 706 712 [527] Mello CV Vicario DS Clayton DF 1992 Song presentation induces gene expression in the songbird forebrain. Proc Natl Acad Sci U S A 89 6818 6822 [528] Mello CV Clayton DF 1994 Song-induced ZENK gene expression in auditory pathways of songbird brain and its relation to the song control system. J Neurosci 14 6652 6666 [529] Mello C Nottebohm F Clayton D 1995 Repeated exposure to one song leads to a rapid and persistent decline in an immediate early gene's response to that song in zebra finch telencephalon. J Neurosci 15 6919 6925 [530] Mello CV Clayton DF 1995 Differential induction of the ZENK gene in the avian forebrain and song control circuit after metrazole-induced depolarization. J Neurobiol 26 145 161 [531] Mello CV Ribeiro S 1998 ZENK protein regulation by song in the brain of songbirds. J Comp Neurol 393 426 438 [532] Ribeiro S Cecchi GA Magnasco MO Mello CV 1998 Toward a song code: evidence for a syllabic representation in the canary brain. Neuron 21 359 371 [533] Tischmeyer W Grimm R 1999 Activation of immediate early genes and memory formation. Cell Mol Life Sci 55 564 574 [534] Nedivi E Hevroni D Naot D Israeli D Citri Y 1993 Numerous candidate plasticity-related genes revealed by differential cDNA cloning. Nature 363 718 722 [535] Li L Yun SH Keblesh J Trommer BL Xiong H 2007 Egr3, a synaptic activity regulated transcription factor that is essential for learning and memory. Mol Cell Neurosci 35 76 88 [536] Soule J Penke Z Kanhema T Alme MN Laroche S 2008 Object-place recognition learning triggers rapid induction of plasticity-related immediate early genes and synaptic proteins in the rat dentate gyrus. Neural Plast 2008 269097 [537] Takahata T Higo N Kaas JH Yamamori T 2009 Expression of immediate-early genes reveals functional compartments within ocular dominance columns after brief monocular inactivation. Proc Natl Acad Sci U S A [538] Lam BY Zhang W Enticknap N Haggis E Cader MZ 2009 Inverse regulation of plasticity-related immediate early genes by calcineurin in hippocampal neurons. J Biol Chem 284 12562 12571 [539] Pfenning AR Schwartz R Barth AL 2007 A comparative genomics approach to identifying the plasticity transcriptome. BMC Neurosci 8 20 [540] Nikitin VP 2007 A new mechanism of synapse-specific neuronal plasticity. Neurosci Behav Physiol 37 559 570 [541] Toscano CD McGlothan JL Guilarte TR 2006 Experience-dependent regulation of zif268 gene expression and spatial learning. Exp Neurol 200 209 215 [542] Jenkins TA Amin E Brown MW Aggleton JP 2006 Changes in immediate early gene expression in the rat brain after unilateral lesions of the hippocampus. Neuroscience 137 747 759 [543] James AB Conway AM Morris BJ 2006 Regulation of the neuronal proteasome by Zif268 (Egr1). J Neurosci 26 1624 1634 [544] Ihara H Mie M Funabashi H Takahashi F Sawasaki T 2006 In vitro selection of zinc finger DNA-binding proteins through ribosome display. Biochem Biophys Res Commun 345 1149 1154 [545] Hernandez PJ Schiltz CA Kelley AE 2006 Dynamic shifts in corticostriatal expression patterns of the immediate early genes Homer 1a and Zif268 during early and late phases of instrumental training. Learn Mem 13 599 608 [546] James AB Conway AM Morris BJ 2005 Genomic profiling of the neuronal target genes of the plasticity-related transcription factor – Zif268. J Neurochem 95 796 810 [547] Lee JL Everitt BJ Thomas KL 2004 Independent cellular processes for hippocampal memory consolidation and reconsolidation. Science 304 839 843 [548] Korzus E 2003 The relation of transcription to memory formation. Acta Biochim Pol 50 775 782 [549] Davis S Bozon B Laroche S 2003 How necessary is the activation of the immediate early gene zif268 in synaptic plasticity and learning? Behav Brain Res 142 17 30 [550] Blanchard J Decorte L Nogues X Micheau J 2009 Characterization of cognition alteration across the course of the disease in APP751SL mice with parallel estimation of cerebral Abeta deposition. Behav Brain Res 201 147 157 [551] Blanchard J Martel G Guillou JL Nogues X Micheau J 2008 Impairment of spatial memory consolidation in APP(751SL) mice results in cue-guided response. Neurobiol Aging 29 1011 1021 [552] Becker M Lavie V Solomon B 2007 Stimulation of endogenous neurogenesis by anti-EFRH immunization in a transgenic mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 104 1691 1696 [553] Dickey CA Loring JF Montgomery J Gordon MN Eastman PS 2003 Selectively reduced expression of synaptic plasticity-related genes in amyloid precursor protein+presenilin-1 transgenic mice. J Neurosci 23 5219 5226 [554] Dickey CA Gordon MN Mason JE Wilson NJ Diamond DM 2004 Amyloid suppresses induction of genes critical for memory consolidation in APP+PS1 transgenic mice. J Neurochem 88 434 442 [555] Kashani AH Qiu Z Jurata L Lee SK Pfaff S 2006 Calcium activation of the LMO4 transcription complex and its role in the patterning of thalamocortical connections. J Neurosci 26 8398 8408 [556] Bulchand S Subramanian L Tole S 2003 Dynamic spatiotemporal expression of LIM genes and cofactors in the embryonic and postnatal cerebral cortex. Dev Dyn 226 460 469 [557] Azim E Shnider SJ Cederquist GY Sohur US Macklis JD 2009 Lmo4 and Clim1 progressively delineate cortical projection neuron subtypes during development. Cereb Cortex 19 Suppl 1 i62 69 [558] Miyajima N Maruyama S Nonomura K Hatakeyama S 2009 TRIM36 interacts with the kinetochore protein CENP-H and delays cell cycle progression. Biochem Biophys Res Commun 381 383 387 [559] Harrill JA Li Z Wright FA Radio NM Mundy WR 2008 Transcriptional response of rat frontal cortex following acute in vivo exposure to the pyrethroid insecticides permethrin and deltamethrin. BMC Genomics 9 546 [560] Takemoto-Kimura S Terai H Takamoto M Ohmae S Kikumura S 2003 Molecular cloning and characterization of CLICK-III/CaMKIgamma, a novel membrane-anchored neuronal Ca2+/calmodulin-dependent protein kinase (CaMK). J Biol Chem 278 18597 18605 [561] Takemoto-Kimura S Ageta-Ishihara N Nonaka M Adachi-Morishima A Mano T 2007 Regulation of dendritogenesis via a lipid-raft-associated Ca2+/calmodulin-dependent protein kinase CLICK-III/CaMKIgamma. Neuron 54 755 770 [562] Korostynski M Piechota M Kaminska D Solecki W Przewlocki R 2007 Morphine effects on striatal transcriptome in mice. Genome Biol 8 R128 [563] Glorioso C Sabatini M Unger T Hashimoto T Monteggia LM 2006 Specificity and timing of neocortical transcriptome changes in response to BDNF gene ablation during embryogenesis or adulthood. Mol Psychiatry 11 633 648 [564] Nishimura H Sakagami H Uezu A Fukunaga K Watanabe M 2003 Cloning, characterization and expression of two alternatively splicing isoforms of Ca2+/calmodulin-dependent protein kinase I gamma in the rat brain. J Neurochem 85 1216 1227 [565] Zhao C Braunewell KH 2008 Expression of the neuronal calcium sensor visinin-like protein-1 in the rat hippocampus. Neuroscience 153 1202 1212 [566] Youn H Jeoung M Koo Y Ji H Markesbery WR 2007 Kalirin is under-expressed in Alzheimer's disease hippocampus. J Alzheimers Dis 11 385 397 [567] Huang JC Babak T Corson TW Chua G Khan S 2007 Using expression profiling data to identify human microRNA targets. Nat Methods 4 1045 1049 [568] Liu T Papagiannakopoulos T Puskar K Qi S Santiago F 2007 Detection of a microRNA signal in an in vivo expression set of mRNAs. PLoS One 2 e804 [569] Nikitin A Egorov S Daraselia N Mazo I 2003 Pathway studio–the analysis and navigation of molecular networks. Bioinformatics 19 2155 2157 [570] Bucan M Abrahams BS Wang K Glessner JT Herman EI 2009 Genome-wide analyses of exonic copy number variants in a family-based study point to novel autism susceptibility genes. PLoS Genet 5 e1000536 [571] Bourgeron T 2009 A synaptic trek to autism. Curr Opin Neurobiol [572] Glessner JT Wang K Cai G Korvatska O Kim CE 2009 Autism genome-wide copy number variation reveals ubiquitin and neuronal genes. Nature 459 569 573 [573] Kumar RA Christian SL 2009 Genetics of autism spectrum disorders. Curr Neurol Neurosci Rep 9 188 197 [574] Bourgeron T 2007 The possible interplay of synaptic and clock genes in autism spectrum disorders. Cold Spring Harb Symp Quant Biol 72 645 654 [575] Marshall CR Noor A Vincent JB Lionel AC Feuk L 2008 Structural variation of chromosomes in autism spectrum disorder. Am J Hum Genet 82 477 488 [576] Kim HG Kishikawa S Higgins AW Seong IS Donovan DJ 2008 Disruption of neurexin 1 associated with autism spectrum disorder. Am J Hum Genet 82 199 207 [577] Owen MJ Williams HJ O'Donovan MC 2009 Schizophrenia genetics: advancing on two fronts. Curr Opin Genet Dev 19 266 270 [578] Need AC Ge D Weale ME Maia J Feng S 2009 A genome-wide investigation of SNPs and CNVs in schizophrenia. PLoS Genet 5 e1000373 [579] Rujescu D Ingason A Cichon S Pietilainen OP Barnes MR 2009 Disruption of the neurexin 1 gene is associated with schizophrenia. Hum Mol Genet 18 988 996 [580] Vrijenhoek T Buizer-Voskamp JE van der Stelt I Strengman E Sabatti C 2008 Recurrent CNVs disrupt three candidate genes in schizophrenia patients. Am J Hum Genet 83 504 510 [581] Kirov G Gumus D Chen W Norton N Georgieva L 2008 Comparative genome hybridization suggests a role for NRXN1 and APBA2 in schizophrenia. Hum Mol Genet 17 458 465 [582] Nussbaum J Xu Q Payne TJ Ma JZ Huang W 2008 Significant association of the neurexin-1 gene (NRXN1) with nicotine dependence in European- and African-American smokers. Hum Mol Genet 17 1569 1577 [583] Bierut LJ Madden PA Breslau N Johnson EO Hatsukami D 2007 Novel genes identified in a high-density genome wide association study for nicotine dependence. Hum Mol Genet 16 24 35 [584] Yang HC Chang CC Lin CY Chen CL Fann CS 2005 A genome-wide scanning and fine mapping study of COGA data. BMC Genet 6 Suppl 1 S30 [585] Zahir FR Baross A Delaney AD Eydoux P Fernandes ND 2008 A patient with vertebral, cognitive and behavioural abnormalities and a de novo deletion of NRXN1alpha. J Med Genet 45 239 243 [586] Cabodi S Morello V Masi A Cicchi R Broggio C 2009 Convergence of integrins and EGF receptor signaling via PI3K/Akt/FoxO pathway in early gene Egr-1 expression. J Cell Physiol 218 294 303 [587] Nowak K Killmer K Gessner C Lutz W 2007 E2F-1 regulates expression of FOXO1 and FOXO3a. Biochim Biophys Acta 1769 244 252 [588] Yuan Z Lehtinen MK Merlo P Villen J Gygi S 2009 Regulation of neuronal cell death by MST1-FOXO1 signaling. J Biol Chem 284 11285 11292 [589] Yuan Z Becker EB Merlo P Yamada T DiBacco S 2008 Activation of FOXO1 by Cdk1 in cycling cells and postmitotic neurons. Science 319 1665 1668 [590] Kim AH Bonni A 2008 Cdk1-FOXO1: a mitotic signal takes center stage in post-mitotic neurons. Cell Cycle 7 3819 3822 [591] van der Heide LP Ramakers GM Smidt MP 2006 Insulin signaling in the central nervous system: learning to survive. Prog Neurobiol 79 205 221 [592] Horwood JM Dufour F Laroche S Davis S 2006 Signalling mechanisms mediated by the phosphoinositide 3-kinase/Akt cascade in synaptic plasticity and memory in the rat. Eur J Neurosci 23 3375 3384 [593] Polter A Yang S Zmijewska AA van Groen T Paik JH 2009 Forkhead box, class O transcription factors in brain: regulation and behavioral manifestation. Biol Psychiatry 65 150 159 [594] Wu H Lu D Jiang H Xiong Y Qu C 2008 Increase in phosphorylation of Akt and its downstream signaling targets and suppression of apoptosis by simvastatin after traumatic brain injury. J Neurosurg 109 691 698 [595] Sasaki T Han F Shioda N Moriguchi S Kasahara J 2006 Lithium-induced activation of Akt and CaM kinase II contributes to its neuroprotective action in a rat microsphere embolism model. Brain Res 1108 98 106 [596] Hoekman MF Jacobs FM Smidt MP Burbach JP 2006 Spatial and temporal expression of FoxO transcription factors in the developing and adult murine brain. Gene Expr Patterns 6 134 140 [597] Samarin J Cicha I Goppelt-Struebe M 2009 Cell type-specific regulation of CCN2 protein expression by PI3K-AKT-FoxO signaling. J Cell Commun Signal 3 79 84 [598] Fukuda M Jones JE Olson D Hill J Lee CE 2008 Monitoring FoxO1 localization in chemically identified neurons. J Neurosci 28 13640 13648 [599] Tajes M Yeste-Velasco M Zhu X Chou SP Smith MA 2009 Activation of Akt by lithium: pro-survival pathways in aging. Mech Ageing Dev 130 253 261 [600] Chiang CW Yan L Yang E 2008 Phosphatases and regulation of cell death. Methods Enzymol 446 237 257 [601] Lukiw WJ Pogue AI 2007 Induction of specific micro RNA (miRNA) species by ROS-generating metal sulfates in primary human brain cells. J Inorg Biochem 101 1265 1269 [602] Alafuzoff I Arzberger T Al-Sarraj S Bodi I Bogdanovic N 2008 Staging of neurofibrillary pathology in Alzheimer's disease: a study of the BrainNet Europe Consortium. Brain Pathol 18 484 496 [603] Marzolo MP Bu G 2009 Lipoprotein receptors and cholesterol in APP trafficking and proteolytic processing, implications for Alzheimer's disease. Semin Cell Dev Biol 20 191 200 [604] Jaeger S Pietrzik CU 2008 Functional role of lipoprotein receptors in Alzheimer's disease. Curr Alzheimer Res 5 15 25 [605] Cam JA Bu G 2006 Modulation of beta-amyloid precursor protein trafficking and processing by the low density lipoprotein receptor family. Mol Neurodegener 1 8 [606] Bu G Cam J Zerbinatti C 2006 LRP in amyloid-beta production and metabolism. Ann N Y Acad Sci 1086 35 53 [607] Carter CJ 2007 Convergence of genes implicated in Alzheimer's disease on the cerebral cholesterol shuttle: APP, cholesterol, lipoproteins, and atherosclerosis. Neurochem Int 50 12 38 [608] Cam JA Zerbinatti CV Knisely JM Hecimovic S Li Y 2004 The low density lipoprotein receptor-related protein 1B retains beta-amyloid precursor protein at the cell surface and reduces amyloid-beta peptide production. J Biol Chem 279 29639 29646 [609] Duilio A Faraonio R Minopoli G Zambrano N Russo T 1998 Fe65L2: a new member of the Fe65 protein family interacting with the intracellular domain of the Alzheimer's beta-amyloid precursor protein. Biochem J 330(Pt 1) 513 519 [610] Tanahashi H Tabira T 1999 Genome structure and chromosomal mapping of the gene for Fe65L2 interacting with Alzheimer's beta-amyloid precursor protein. Biochem Biophys Res Commun 258 385 389 [611] Tanahashi H Tabira T 1999 Molecular cloning of human Fe65L2 and its interaction with the Alzheimer's beta-amyloid precursor protein. Neurosci Lett 261 143 146 [612] Tanahashi H Asada T Tabira T 2002 c954C→T polymorphism in the Fe65L2 gene is associated with early-onset Alzheimer's disease. Ann Neurol 52 691 693 [613] Tamayev R Zhou D D'Adamio L 2009 The interactome of the amyloid beta precursor protein family members is shaped by phosphorylation of their intracellular domains. Mol Neurodegener 4 28 [614] Zhou D Zambrano N Russo T D'Adamio L 2009 Phosphorylation of a tyrosine in the amyloid-beta protein precursor intracellular domain inhibits Fe65 binding and signaling. J Alzheimers Dis 16 301 307 [615] McLoughlin DM Miller CC 2008 The FE65 proteins and Alzheimer's disease. J Neurosci Res 86 744 754 [616] Chang Y Tesco G Jeong WJ Lindsley L Eckman EA 2003 Generation of the beta-amyloid peptide and the amyloid precursor protein C-terminal fragment gamma are potentiated by FE65L1. J Biol Chem 278 51100 51107 [617] Poduslo SE Huang R Spiro A 3rd 2010 A genome screen of successful aging without cognitive decline identifies LRP1B by haplotype analysis. Am J Med Genet B Neuropsychiatr Geneti 153B [618] McKhann G Drachman D Folstein M Katzman R Price D 1984 Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34 939 [619] Folstein MF Folstein SE McHugh PR 1975 “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research 12 189 198 [620] Rosen W Mohs R Davis K 1984 A new rating scale for Alzheimer's disease. Am J Psychiatry 141 1356 1364 [621] Schmitt FA Wetherby MMC Wekstein DR Dearth CMS Markesbery WR 2001 Brain Donation in Normal Aging: Procedures, Motivations, and Donor Characteristics From the Biologically Resilient Adults in Neurological Studies (BRAiNS) Project. Gerontologist 41 716 722 [622] Geddes JW Tekirian TL Soultanian NS Ashford JW Davis DG 1997 Comparison of neuropathologic criteria for the diagnosis of Alzheimer's disease. Neurobiol Aging 18 S99 105 [623] Braak H Braak E 1991 Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82 239 259 [624] Bancher C Braak H Fischer P Jellinger KA 1993 Neuropathological staging of Alzheimer lesions and intellectual status in Alzheimer's and Parkinson's disease patients. Neurosci Lett 162 179 182 [625] Braak H Braak E 1995 Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol Aging 16 271 278 discussion 278–284 [626] Fayyad UM Irani KB 1993 Multi-Interval Discretization of Continuous-Valued Attributes for Classification Learning Morgan Kaufmann 1022 1029 [627] Berretta R Mendes A Moscato P 2007 Selection of Discriminative Genes in Microarray Experiments Using Mathematical Programming. Journal of Research and Practice in Information Technology 39 287 299 [628] Cotta C Sloper C Moscato P 2004 Evolutionary Search of Thresholds for Robust Feature Set Selection: Application to the Analysis of Microarray Data. Raidl GR Cagnoni S Branke J Corne DW Drechsler R Applications of Evolutionary Computing Springer Berlin/Heidelberg 21 30 [629] Gómez Ravetti M Berretta R Moscato P 2009 Novel Biomarkers for Prostate Cancer Revealed by (α,β)-k-Feature Sets. 149 175 Foundations of Computational Intelligence Volume 5 [630] Hourani M Berretta R Mendes A Moscato P 2008 Genetic signatures for a rodent model of Parkinson's disease using combinatorial optimization methods. Methods Mol Biol 453 379 392 [631] Mendes A Scott RJ Moscato P 2008 Microarrays–identifying molecular portraits for prostate tumors with different Gleason patterns. Methods Mol Med 141 131 151 [632] Rosso OA Mendes A Berretta R Rostas JA Hunter M 2009 Distinguishing childhood absence epilepsy patients from controls by the analysis of their background brain electrical activity (II): a combinatorial optimization approach for electrode selection. J Neurosci Methods 181 257 267 [633] Cotta C Langston MA Moscato P 2007 Combinatorial and Algorithmic Issues for Microarray Analysis. Gonzalez TF Handbook of Approximation Algorithms and Metaheuristics Chapman & Hall/CRC 74.71 74.14 [634] Chang JT Nevins JR 2006 GATHER: a systems approach to interpreting genomic signatures. Bioinformatics 22 2926 2933 [635] Blalock EM Geddes JW Chen KC Porter NM Markesbery WR 2004 Incipient Alzheimer's disease: microarray correlation analyses reveal major transcriptional and tumor suppressor responses. Proc Natl Acad Sci U S A 101 2173 2178 [636] Zhao CJ Noack C Brackmann M Gloveli T Maelicke A 2009 Neuronal Ca2+ sensor VILIP-1 leads to the upregulation of functional alpha4beta2 nicotinic acetylcholine receptors in hippocampal neurons. Mol Cell Neurosci 40 280 292 [637] Bernstein HG Braunewell KH 2009 Some notes on visinin-like protein 1 and Alzheimer disease. Clin Chem 55 1041 1043 [638] Lee JM Blennow K Andreasen N Laterza O Modur V 2008 The brain injury biomarker VLP-1 is increased in the cerebrospinal fluid of Alzheimer disease patients. Clin Chem 54 1617 1623 [639] Zhao C Anand R Braunewell KH 2009 Nicotine-induced Ca2+-myristoyl switch of neuronal Ca2+ sensor VILIP-1 in hippocampal neurons: a possible crosstalk mechanism for nicotinic receptors. Cell Mol Neurobiol 29 273 286 [640] Gierke P Zhao C Bernstein HG Noack C Anand R 2008 Implication of neuronal Ca2+ -sensor protein VILIP-1 in the glutamate hypothesis of schizophrenia. Neurobiol Dis 32 162 175 [641] Schnurra I Bernstein HG Riederer P Braunewell KH 2001 The neuronal calcium sensor protein VILIP-1 is associated with amyloid plaques and extracellular tangles in Alzheimer's disease and promotes cell death and tau phosphorylation in vitro: a link between calcium sensors and Alzheimer's disease? Neurobiol Dis 8 900 909 [642] Braunewell K Riederer P Spilker C Gundelfinger ED Bogerts B 2001 Abnormal localization of two neuronal calcium sensor proteins, visinin-like proteins (vilips)-1 and -3, in neocortical brain areas of Alzheimer disease patients. Dement Geriatr Cogn Disord 12 110 116 [643] Killick R Scales G Leroy K Causevic M Hooper C 2009 Deletion of Irs2 reduces amyloid deposition and rescues behavioural deficits in APP transgenic mice. Biochem Biophys Res Commun 386 257 262 [644] Bulbarelli A Lonati E Cazzaniga E Gregori M Masserini M 2009 Pin1 affects Tau phosphorylation in response to Abeta oligomers. Mol Cell Neurosci 42 75 80 [645] Zhao WQ Feng C Alkon DL 2003 Impairment of phosphatase 2A contributes to the prolonged MAP kinase phosphorylation in Alzheimer's disease fibroblasts. Neurobiol Dis 14 458 469 [646] Vafai SB Stock JB 2002 Protein phosphatase 2A methylation: a link between elevated plasma homocysteine and Alzheimer's Disease. FEBS Lett 518 1 4 [647] Wei Q Holzer M Brueckner MK Liu Y Arendt T 2002 Dephosphorylation of tau protein by calcineurin triturated into neural living cells. Cell Mol Neurobiol 22 13 24 [648] Tian Q Wang J 2002 Role of serine/threonine protein phosphatase in Alzheimer's disease. Neurosignals 11 262 269 [649] Gong CX Wang JZ Iqbal K Grundke-Iqbal I 2003 Inhibition of protein phosphatase 2A induces phosphorylation and accumulation of neurofilaments in metabolically active rat brain slices. Neurosci Lett 340 107 110 [650] Munch G Kuhla B Luth HJ Arendt T Robinson SR 2003 Anti-AGEing defences against Alzheimer's disease. Biochem Soc Trans 31 1397 1399 [651] Sontag E Luangpirom A Hladik C Mudrak I Ogris E 2004 Altered expression levels of the protein phosphatase 2A ABalphaC enzyme are associated with Alzheimer disease pathology. J Neuropathol Exp Neurol 63 287 301 [652] Rametti A Esclaire F Yardin C Terro F 2004 Linking alterations in tau phosphorylation and cleavage during neuronal apoptosis. J Biol Chem 279 54518 54528 [653] Iqbal K Liu F Gong CX Alonso Adel C Grundke-Iqbal I 2009 Mechanisms of tau-induced neurodegeneration. Acta Neuropathol 118 53 69 [654] Deters N Ittner LM Gotz J 2009 Substrate-specific reduction of PP2A activity exaggerates tau pathology. Biochem Biophys Res Commun 379 400 405 [655] Liang Z Liu F Iqbal K Grundke-Iqbal I Wegiel J 2008 Decrease of protein phosphatase 2A and its association with accumulation and hyperphosphorylation of tau in Down syndrome. J Alzheimers Dis 13 295 302 [656] Chen S Li B Grundke-Iqbal I Iqbal K 2008 I1PP2A affects tau phosphorylation via association with the catalytic subunit of protein phosphatase 2A. J Biol Chem 283 10513 10521 [657] Liu R Zhou XW Tanila H Bjorkdahl C Wang JZ 2008 Phosphorylated PP2A (tyrosine 307) is associated with Alzheimer neurofibrillary pathology. J Cell Mol Med 12 241 257 [658] Meske V Albert F Ohm TG 2008 Coupling of mammalian target of rapamycin with phosphoinositide 3-kinase signaling pathway regulates protein phosphatase 2A- and glycogen synthase kinase-3 -dependent phosphorylation of Tau. J Biol Chem 283 100 109 [659] Walton JR 2007 An aluminum-based rat model for Alzheimer's disease exhibits oxidative damage, inhibition of PP2A activity, hyperphosphorylated tau, and granulovacuolar degeneration. J Inorg Biochem 101 1275 1284 [660] Nowotny P Bertelsen S Hinrichs AL Kauwe JS Mayo K 2007 Association studies between common variants in prolyl isomerase Pin1 and the risk for late-onset Alzheimer's disease. Neurosci Lett 419 15 17 [661] Chohan MO Khatoon S Iqbal IG Iqbal K 2006 Involvement of I2PP2A in the abnormal hyperphosphorylation of tau and its reversal by Memantine. FEBS Lett 580 3973 3979 [662] Plattner F Angelo M Giese KP 2006 The roles of cyclin-dependent kinase 5 and glycogen synthase kinase 3 in tau hyperphosphorylation. J Biol Chem 281 25457 25465 [663] Kerr F Rickle A Nayeem N Brandner S Cowburn RF 2006 PTEN, a negative regulator of PI3 kinase signalling, alters tau phosphorylation in cells by mechanisms independent of GSK-3. FEBS Lett 580 3121 3128 [664] Liu F Grundke-Iqbal I Iqbal K Gong CX 2005 Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation. Eur J Neurosci 22 1942 1950 [665] Madeira A Pommet JM Prochiantz A Allinquant B 2005 SET protein (TAF1beta, I2PP2A) is involved in neuronal apoptosis induced by an amyloid precursor protein cytoplasmic subdomain. FASEB J 19 1905 1907 [666] Snyder EM Nong Y Almeida CG Paul S Moran T 2005 Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci 8 1051 1058 [667] Rahman A Grundke-Iqbal I Iqbal K 2006 PP2B isolated from human brain preferentially dephosphorylates Ser-262 and Ser-396 of the Alzheimer disease abnormally hyperphosphorylated tau. J Neural Transm 113 219 230 [668] Rahman A Grundke-Iqbal I Iqbal K 2005 Phosphothreonine-212 of Alzheimer abnormally hyperphosphorylated tau is a preferred substrate of protein phosphatase-1. Neurochem Res 30 277 287 [669] Cheng LY Wang JZ Gong CX Pei JJ Zaidi T 2000 Multiple forms of phosphatase from human brain: isolation and partial characterization of affi-gel blue binding phosphatases. Neurochem Res 25 107 120 [670] Garver TD Lehman RA Billingsley ML 1996 Microtubule assembly competence analysis of freshly-biopsied human tau, dephosphorylated tau, and Alzheimer tau. J Neurosci Res 44 12 20 [671] Matsuo ES Shin RW Billingsley ML Van deVoorde A O'Connor M 1994 Biopsy-derived adult human brain tau is phosphorylated at many of the same sites as Alzheimer's disease paired helical filament tau. Neuron 13 989 1002 [672] Bajo M Yoo BC Cairns N Gratzer M Lubec G 2001 Neurofilament proteins NF-L, NF-M and NF-H in brain of patients with Down syndrome and Alzheimer's disease. Amino Acids 21 293 301 [673] Blass JP Markesbery WR Ko LW DeGiorgio L Sheu KF 1994 Presence of neuronal proteins in serially cultured cells from autopsy human brain. J Neurol Sci 121 132 138 [674] Cairns NJ Uryu K Bigio EH Mackenzie IR Gearing M 2004 alpha-Internexin aggregates are abundant in neuronal intermediate filament inclusion disease (NIFID) but rare in other neurodegenerative diseases. Acta Neuropathol 108 213 223 [675] DeGiorgio LA Sheu KF Blass JP 1994 Culture from human leptomeninges of cells containing neurofilament protein and neuron-specific enolase. J Neurol Sci 124 141 148 [676] Deng Y Li B Liu F Iqbal K Grundke-Iqbal I 2008 Regulation between O-GlcNAcylation and phosphorylation of neurofilament-M and their dysregulation in Alzheimer disease. Faseb J 22 138 145 [677] Faigon M Hadas E Alroy G Chapman J Auerbach JM 1991 Monoclonal antibodies to the heavy neurofilament subunit (NF-H) of Torpedo cholinergic neurons. J Neurosci Res 29 490 498 [678] Hollosi M Holly S Majer Z Laczko I Fasman GD 1995 Complexes of aluminium with peptide ligands: a Fourier transform IR spectroscopic study. Biopolymers 36 381 389 [679] Hollosi M Shen ZM Perczel A Fasman GD 1994 Stable intrachain and interchain complexes of neurofilament peptides: a putative link between Al3+ and Alzheimer disease. Proc Natl Acad Sci U S A 91 4902 4906 [680] Hollosi M Urge L Perczel A Kajtar J Teplan I 1992 Metal ion-induced conformational changes of phosphorylated fragments of human neurofilament (NF-M) protein. J Mol Biol 223 673 682 [681] Holly S Laczko I Fasman GD Hollosi M 1993 FT-IR spectroscopy indicates that Ca(2+)-binding to phosphorylated C-terminal fragments of the midsized neurofilament protein subunit results in beta-sheet formation and beta-aggregation. Biochem Biophys Res Commun 197 755 762 [682] Hu YY He SS Wang XC Duan QH Khatoon S 2002 Elevated levels of phosphorylated neurofilament proteins in cerebrospinal fluid of Alzheimer disease patients. Neurosci Lett 320 156 160 [683] Julien JP Mushynski WE 1998 Neurofilaments in health and disease. Prog Nucleic Acid Res Mol Biol 61 1 23 [684] Kittur S Hoh J Endo H Tourtellotte W Weeks BS 1994 Cytoskeletal neurofilament gene expression in brain tissue from Alzheimer's disease patients. I. Decrease in NF-L and NF-M message. J Geriatr Psychiatry Neurol 7 153 158 [685] Ksiezak-Reding H Yen SH 1987 Two monoclonal antibodies recognize Alzheimer's neurofibrillary tangles, neurofilament, and microtubule-associated proteins. J Neurochem 48 455 462 [686] Lee VM Otvos L Jr Carden MJ Hollosi M Dietzschold B 1988 Identification of the major multiphosphorylation site in mammalian neurofilaments. Proc Natl Acad Sci U S A 85 1998 2002 [687] Li SP Deng YQ Wang XC Wang YP Wang JZ 2004 Melatonin protects SH-SY5Y neuroblastoma cells from calyculin A-induced neurofilament impairment and neurotoxicity. J Pineal Res 36 186 191 [688] Miller CC Brion JP Calvert R Chin TK Eagles PA 1986 Alzheimer's paired helical filaments share epitopes with neurofilament side arms. Embo J 5 269 276 [689] Pollak D Cairns N Lubec G 2003 Cytoskeleton derangement in brain of patients with Down syndrome, Alzheimer's disease and Pick's disease. J Neural Transm Suppl 149 158 [690] Roder HM Ingram VM 1991 Two novel kinases phosphorylate tau and the KSP site of heavy neurofilament subunits in high stoichiometric ratios. J Neurosci 11 3325 3343 [691] Save MP Shetty VP Shetty KT Antia NH 2004 Alterations in neurofilament protein(s) in human leprous nerves: morphology, immunohistochemistry and Western immunoblot correlative study. Neuropathol Appl Neurobiol 30 635 650 [692] Schmidt ML Lee VM Trojanowski JQ 1989 Analysis of epitopes shared by Hirano bodies and neurofilament proteins in normal and Alzheimer's disease hippocampus. Lab Invest 60 513 522 [693] Schmidt ML Lee VM Trojanowski JQ 1991 Comparative epitope analysis of neuronal cytoskeletal proteins in Alzheimer's disease senile plaque neurites and neuropil threads. Lab Invest 64 352 357 [694] Shen ZM Perczel A Hollosi M Nagypal I Fasman GD 1994 Study of Al3+ binding and conformational properties of the alanine-substituted C-terminal domain of the NF-M protein and its relevance to Alzheimer's disease. Biochemistry 33 9627 9636 [695] Trojanowski JQ Schmidt ML Otvos L Jr Gur RC Gur RE 1989 Selective expression of epitopes in multiphosphorylation repeats of the high and middle molecular weight neurofilament proteins in Alzheimer neurofibrillary tangles. Ann Med 21 113 116 [696] Troy CM Greene LA Shelanski ML 1992 Neurite outgrowth in peripherin-depleted PC12 cells. J Cell Biol 117 1085 1092 [697] Wang J Tung YC Wang Y Li XT Iqbal K 2001 Hyperphosphorylation and accumulation of neurofilament proteins in Alzheimer disease brain and in okadaic acid-treated SY5Y cells. FEBS Lett 507 81 87 [698] Wang Y Wang Q Wang J 2002 [Detection of level and mutation of neurofilament mRNA in Alzheimer's disease]. Zhonghua Yi Xue Za Zhi 82 519 522 [699] Wang YP Wei ZL Wang XC Wang Q Wang JZ 2001 [Comparative study of the expression and phosphorylation of neurofilament proteins of brain gray matter in Alzheimer's disease]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 23 445 449 [700] Wurtman RJ Ulus IH Cansev M Watkins CJ Wang L 2006 Synaptic proteins and phospholipids are increased in gerbil brain by administering uridine plus docosahexaenoic acid orally. Brain Res 1088 83 92 [701] Yang X Yang Y Luo Y Li G Wang J 2009 Hyperphosphorylation and Accumulation of Neurofilament Proteins in Transgenic Mice with Alzheimer Presenilin 1 Mutation. Cell Mol Neurobiol [702] Yao PJ Coleman PD 1998 Reduced O-glycosylated clathrin assembly protein AP180: implication for synaptic vesicle recycling dysfunction in Alzheimer's disease. Neurosci Lett 252 33 36 [703] Laterza OF Modur VR Crimmins DL Olander JV Landt Y 2006 Identification of novel brain biomarkers. Clin Chem 52 1713 1721 [704] Zhao C Anand R Braunewell KH 2008 Nicotine-induced Ca(2+)-myristoyl Switch of Neuronal Ca(2+) Sensor VILIP-1 in Hippocampal Neurons: A Possible Crosstalk Mechanism for Nicotinic Receptors. Cell Mol Neurobiol [705] Zhao C Noack C Brackmann M Gloveli T Maelicke A 2008 Neuronal Ca(2+) sensor VILIP-1 leads to the upregulation of functional alpha4beta2 nicotinic acetylcholine receptors in hippocampal neurons. Mol Cell Neurosci [706] Briand C Kozlov SV Sonderegger P Grutter MG 2001 Crystal structure of neuroserpin: a neuronal serpin involved in a conformational disease. FEBS Lett 505 18 22 [707] Bruno MA Cuello AC 2006 Activity-dependent release of precursor nerve growth factor, conversion to mature nerve growth factor, and its degradation by a protease cascade. Proc Natl Acad Sci U S A 103 6735 6740 [708] Carrell RW 2005 Cell toxicity and conformational disease. Trends Cell Biol 15 574 580 [709] Crowther DC 2002 Familial conformational diseases and dementias. Hum Mutat 20 1 14 [710] Dufour A Corsini E Gelati M Massa G Tarcic N 2000 Mutations in the neuroserpin gene are rare in familial dementia. French Alzheimer's Disease and Fronto-Temporal Dementia Genetics Study Groups. Ann Neurol 47 688 [711] Kinghorn KJ Crowther DC Sharp LK Nerelius C Davis RL 2006 Neuroserpin binds Abeta and is a neuroprotective component of amyloid plaques in Alzheimer disease. J Biol Chem 281 29268 29277 [712] Nielsen HM Minthon L Londos E Blennow K Miranda E 2007 Plasma and CSF serpins in Alzheimer disease and dementia with Lewy bodies. Neurology 69 1569 1579 [713] Tabira T 2003 [Familial non-Alzheimer dementia]. Rinsho Shinkeigaku 43 775 778 [714] Yamasaki M Li W Johnson DJ Huntington JA 2008 Crystal structure of a stable dimer reveals the molecular basis of serpin polymerization. Nature 455 1255 1258 [715] Opii WO Joshi G Head E Milgram NW Muggenburg BA 2008 Proteomic identification of brain proteins in the canine model of human aging following a long-term treatment with antioxidants and a program of behavioral enrichment: relevance to Alzheimer's disease. Neurobiol Aging 29 51 70 [716] Poon HF Farr SA Thongboonkerd V Lynn BC Banks WA 2005 Proteomic analysis of specific brain proteins in aged SAMP8 mice treated with alpha-lipoic acid: implications for aging and age-related neurodegenerative disorders. Neurochem Int 46 159 168 [717] Somerville MJ Percy ME Bergeron C Yoong LK Grima EA 1991 Localization and quantitation of 68 kDa neurofilament and superoxide dismutase-1 mRNA in Alzheimer brains. Brain Res Mol Brain Res 9 1 8 [718] Wishart TM Paterson JM Short DM Meredith S Robertson KA 2007 Differential proteomics analysis of synaptic proteins identifies potential cellular targets and protein mediators of synaptic neuroprotection conferred by the slow Wallerian degeneration (Wlds) gene. Mol Cell Proteomics 6 1318 1330 [719] Shen Y Halperin JA Lee CM 1995 Complement-mediated neurotoxicity is regulated by homologous restriction. Brain Res 671 282 292 [720] Wallace MA 1994 Effects of Alzheimer's disease-related beta amyloid protein fragments on enzymes metabolizing phosphoinositides in brain. Biochim Biophys Acta 1227 183 187 [721] Shimohama S Matsushima H 1995 Signal transduction mechanisms in Alzheimer disease. Alzheimer Dis Assoc Disord 9 Suppl 2 15 22 [722] Sambamurti K Sevlever D Koothan T Refolo LM Pinnix I 1999 Glycosylphosphatidylinositol-anchored proteins play an important role in the biogenesis of the Alzheimer's amyloid beta-protein. J Biol Chem 274 26810 26814 [723] Strosznajder JB Zambrzycka A Kacprzak MD Strosznajder RP 1999 Amyloid beta peptide 25–35 modulates hydrolysis of phosphoinositides by membrane phospholipase(s) C of adult brain cortex. J Mol Neurosci 12 101 109 [724] Zambrzycka A Cakala M Kaminska M 2003 Transition metal ions significantly decrease phospholipase C activity degrading phosphatidylinositol-4,5-bisphosphate in the brain cortex. Pol J Pharmacol 55 915 917 [725] Merlos-Suarez A Ruiz-Paz S Baselga J Arribas J 2001 Metalloprotease-dependent protransforming growth factor-alpha ectodomain shedding in the absence of tumor necrosis factor-alpha-converting enzyme. J Biol Chem 276 48510 48517 [726] Gilmore GC Wenk HE Naylor LA Koss E 1994 Motion perception and Alzheimer's disease. J Gerontol 49 P52 57 [727] Hayes TL Lewis DA 1992 Nonphosphorylated neurofilament protein and calbindin immunoreactivity in layer III pyramidal neurons of human neocortex. Cereb Cortex 2 56 67 [728] Chin J Palop JJ Puolivali J Massaro C Bien-Ly N 2005 Fyn kinase induces synaptic and cognitive impairments in a transgenic mouse model of Alzheimer's disease. J Neurosci 25 9694 9703 [729] Falangola MF Dyakin VV Lee SP Bogart A Babb JS 2007 Quantitative MRI reveals aging-associated T2 changes in mouse models of Alzheimer's disease. NMR Biomed 20 343 351 [730] Helpern JA Lee SP Falangola MF Dyakin VV Bogart A 2004 MRI assessment of neuropathology in a transgenic mouse model of Alzheimer's disease. Magn Reson Med 51 794 798 [731] Lahiri DK Chen D Ge YW Farlow M Kotwal G 2003 Does nitric oxide synthase contribute to the pathogenesis of Alzheimer's disease?: effects of beta-amyloid deposition on NOS in transgenic mouse brain with AD pathology. Ann N Y Acad Sci 1010 639 642 [732] Levine S Saltzman A Levy E Ginsberg SD 2009 Systemic pathology in aged mouse models of Down's syndrome and Alzheimer's disease. Exp Mol Pathol 86 18 22 [733] Neiva TJ Fries DM Monteiro HP D'Amico EA Chamone DA 1997 Aluminum induces lipid peroxidation and aggregation of human blood platelets. Braz J Med Biol Res 30 599 604 [734] Parent A Linden DJ Sisodia SS Borchelt DR 1999 Synaptic transmission and hippocampal long-term potentiation in transgenic mice expressing FAD-linked presenilin 1. Neurobiol Dis 6 56 62 [735] Perez SE Lumayag S Kovacs B Mufson EJ Xu S 2009 Beta-amyloid deposition and functional impairment in the retina of the APPswe/PS1DeltaE9 transgenic mouse model of Alzheimer's disease. Invest Ophthalmol Vis Sci 50 793 800 [736] Sadowski M Pankiewicz J Scholtzova H Ji Y Quartermain D 2004 Amyloid-beta deposition is associated with decreased hippocampal glucose metabolism and spatial memory impairment in APP/PS1 mice. J Neuropathol Exp Neurol 63 418 428 [737] Sahara N Vega IE Ishizawa T Lewis J McGowan E 2004 Phosphorylated p38MAPK specific antibodies cross-react with sarkosyl-insoluble hyperphosphorylated tau proteins. J Neurochem 90 829 838 [738] Wang CY Shen YC Lo FY Su CH Lee SH 2007 Normal tension glaucoma is not associated with the interleukin -1alpha (-889) genetic polymorphism. J Glaucoma 16 230 233 [739] Wang CY Shen YC Su CH Lo FY Lee SH 2007 Investigation of the association between interleukin-1beta polymorphism and normal tension glaucoma. Mol Vis 13 719 723 [740] Wang X Su B Siedlak SL Moreira PI Fujioka H 2008 Amyloid-beta overproduction causes abnormal mitochondrial dynamics via differential modulation of mitochondrial fission/fusion proteins. Proc Natl Acad Sci U S A 105 19318 19323 [741] Yu WH Matsuoka Y Sziraki I Hashim A Lafrancois J 2008 Increased dopaminergic neuron sensitivity to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in transgenic mice expressing mutant A53T alpha-synuclein. Neurochem Res 33 902 911 [742] Zhuo JM Prakasam A Murray ME Zhang HY Baxter MG 2008 An increase in Abeta42 in the prefrontal cortex is associated with a reversal-learning impairment in Alzheimer's disease model Tg2576 APPsw mice. Curr Alzheimer Res 5 385 391 [743] Freude S Plum L Schnitker J Leeser U Udelhoven M 2005 Peripheral hyperinsulinemia promotes tau phosphorylation in vivo. Diabetes 54 3343 3348 [744] Lowe XR Lu X Marchetti F Wyrobek AJ 2007 The expression of Troponin T1 gene is induced by ketamine in adult mouse brain. Brain Res 1174 7 17 [745] Morris BJ 2005 A forkhead in the road to longevity: the molecular basis of lifespan becomes clearer. J Hypertens 23 1285 1309 [746] Nakagawa K Kitazume S Oka R Maruyama K Saido TC 2006 Sialylation enhances the secretion of neurotoxic amyloid-beta peptides. J Neurochem 96 924 933 [747] Lian Q Ladner CJ Magnuson D Lee JM 2001 Selective changes of calcineurin (protein phosphatase 2B) activity in Alzheimer's disease cerebral cortex. Exp Neurol 167 158 165 [748] Shibata N Kobayashi M 2008 [The role for oxidative stress in neurodegenerative diseases]. Brain Nerve 60 157 170 [749] Wang H Dong K Li G Peng X Zhu H 2009 [Effect of yizhi jiannao granules on the expression of Pin1 and HMGB1 mRNA in the hippocampus of SAMP8 mice.]. Zhong Nan Da Xue Xue Bao Yi Xue Ban 34 63 66 [750] Yang G Wang L Zhu M Xu D 2008 Identification of non-Alzheimer's disease tauopathies-related proteins by proteomic analysis. Neurol Res 30 613 622 [751] Desjardins P Ledoux S 1998 Expression of ced-3 and ced-9 homologs in Alzheimer's disease cerebral cortex. Neurosci Lett 244 69 72 [752] Akiyama H Nishimura T Kondo H Ikeda K Hayashi Y 1994 Expression of the receptor for macrophage colony stimulating factor by brain microglia and its upregulation in brains of patients with Alzheimer's disease and amyotrophic lateral sclerosis. Brain Res 639 171 174 [753] Boissonneault V Filali M Lessard M Relton J Wong G 2009 Powerful beneficial effects of macrophage colony-stimulating factor on {beta}-amyloid deposition and cognitive impairment in Alzheimer's disease. Brain [754] Du Yan S Zhu H Fu J Yan SF Roher A 1997 Amyloid-beta peptide-receptor for advanced glycation endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: a proinflammatory pathway in Alzheimer disease. Proc Natl Acad Sci U S A 94 5296 5301 [755] Ebadi M Bashir RM Heidrick ML Hamada FM Refaey HE 1997 Neurotrophins and their receptors in nerve injury and repair. Neurochem Int 30 347 374 [756] Flanagan AM Lader CS 1998 Update on the biologic effects of macrophage colony-stimulating factor. Curr Opin Hematol 5 181 185 [757] Georganopoulou DG Chang L Nam JM Thaxton CS Mufson EJ 2005 Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. Proc Natl Acad Sci U S A 102 2273 2276 [758] Hamilton JA Whitty G White AR Jobling MF Thompson A 2002 Alzheimer's disease amyloid beta and prion protein amyloidogenic peptides promote macrophage survival, DNA synthesis and enhanced proliferative response to CSF-1 (M-CSF). Brain Res 940 49 54 [759] Hasegawa Y Sawada M Ozaki N Inagaki T Suzumura A 2000 Increased soluble tumor necrosis factor receptor levels in the serum of elderly people. Gerontology 46 185 188 [760] Ito S Sawada M Haneda M Fujii S Oh-Hashi K 2005 Amyloid-beta peptides induce cell proliferation and macrophage colony-stimulating factor expression via the PI3-kinase/Akt pathway in cultured Ra2 microglial cells. FEBS Lett 579 1995 2000 [761] Kaku M Tsutsui K Motokawa M Kawata T Fujita T 2003 Amyloid beta protein deposition and neuron loss in osteopetrotic (op/op) mice. Brain Res Brain Res Protoc 12 104 108 [762] Kawata T Tsutsui K Kohno S Kaku M Fujita T 2005 Amyloid beta protein deposition in osteopetrotic (op/op) mice is reduced by injections of macrophage colony stimulating factor. J Int Med Res 33 654 660 [763] Kondo Y Lemere CA Seabrook TJ 2007 Osteopetrotic (op/op) mice have reduced microglia, no Abeta deposition, and no changes in dopaminergic neurons. J Neuroinflammation 4 31 [764] Kong QL Zhang JM Zhang ZX Ge PJ Xu YJ 2002 [Serum levels of macrophage colony stimulating factor in the patients with Alzheimer's disease]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 24 298 301 [765] Kumar AP Piedrafita FJ Reynolds WF 2004 Peroxisome proliferator-activated receptor gamma ligands regulate myeloperoxidase expression in macrophages by an estrogen-dependent mechanism involving the -463GA promoter polymorphism. J Biol Chem 279 8300 8315 [766] Lee SC Liu W Brosnan CF Dickson DW 1994 GM-CSF promotes proliferation of human fetal and adult microglia in primary cultures. Glia 12 309 318 [767] Li M Pisalyaput K Galvan M Tenner AJ 2004 Macrophage colony stimulatory factor and interferon-gamma trigger distinct mechanisms for augmentation of beta-amyloid-induced microglia-mediated neurotoxicity. J Neurochem 91 623 633 [768] Lue LF Rydel R Brigham EF Yang LB Hampel H 2001 Inflammatory repertoire of Alzheimer's disease and nondemented elderly microglia in vitro. Glia 35 72 79 [769] Lue LF Walker DG Brachova L Beach TG Rogers J 2001 Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer's disease: identification of a cellular activation mechanism. Exp Neurol 171 29 45 [770] Lue LF Walker DG Rogers J 2001 Modeling microglial activation in Alzheimer's disease with human postmortem microglial cultures. Neurobiol Aging 22 945 956 [771] Majumdar A Cruz D Asamoah N Buxbaum A Sohar I 2007 Activation of microglia acidifies lysosomes and leads to degradation of Alzheimer amyloid fibrils. Mol Biol Cell 18 1490 1496 [772] Mitrasinovic OM Grattan A Robinson CC Lapustea NB Poon C 2005 Microglia overexpressing the macrophage colony-stimulating factor receptor are neuroprotective in a microglial-hippocampal organotypic coculture system. J Neurosci 25 4442 4451 [773] Mitrasinovic OM Murphy GM Jr 2003 Microglial overexpression of the M-CSF receptor augments phagocytosis of opsonized Abeta. Neurobiol Aging 24 807 815 [774] Mitrasinovic OM Perez GV Zhao F Lee YL Poon C 2001 Overexpression of macrophage colony-stimulating factor receptor on microglial cells induces an inflammatory response. J Biol Chem 276 30142 30149 [775] Mitrasinovic OM Robinson CC Tenen DG Lee YL Poon C 2004 Biolistic expression of the macrophage colony stimulating factor receptor in organotypic cultures induces an inflammatory response. J Neurosci Res 77 420 429 [776] Mitrasinovic OM Vincent VA Simsek D Murphy GM Jr 2003 Macrophage colony stimulating factor promotes phagocytosis by murine microglia. Neurosci Lett 344 185 188 [777] Murphy GM Jr Zhao F Yang L Cordell B 2000 Expression of macrophage colony-stimulating factor receptor is increased in the AbetaPP(V717F) transgenic mouse model of Alzheimer's disease. Am J Pathol 157 895 904 [778] Vincent VA Robinson CC Simsek D Murphy GM 2002 Macrophage colony stimulating factor prevents NMDA-induced neuronal death in hippocampal organotypic cultures. J Neurochem 82 1388 1397 [779] Vincent VA Selwood SP Murphy GM Jr 2002 Proinflammatory effects of M-CSF and A beta in hippocampal organotypic cultures. Neurobiol Aging 23 349 362 [780] Wollmer MA Nitsch RM Hock C Papassotiropoulos A 2006 Genetic association study on colony-stimulating factor 1 in Alzheimer's disease. Neurodegener Dis 3 334 337 [781] Yan SD Stern D Kane MD Kuo YM Lampert HC 1998 RAGE-Abeta interactions in the pathophysiology of Alzheimer's disease. Restor Neurol Neurosci 12 167 173 [782] Zhang JM Kong QL Wang H Qin C He W 2004 [Expression of macrophage colony stimulating factor in brains of PDAPPV717I transgenic mice]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 26 62 65 [783] Marsagishvili LG Shpagina MD Emel'ianenko VI Podlubnaia ZA 2005 [Sarcomeric proteins of the titin family form amyloids]. Biofizika 50 803 809